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Abstract 
 Pancreaticobiliary tract diseases are common digestive disorders diagnosed by 
painful symptoms with minimal treatment options. Among these diagnoses, pancreatic 
ductal adenocarcinoma (PDA) is the third most common cause of cancer death in the 
United States with only a 10 percent 5-year survival rate. Pancreatic injury promotes 
acinar to ductal metaplasia (ADM), a wound healing process, which can be hijacked by 
mutant KRAS expression, leading to progressive dysplasia termed pancreatic 
intraepithelial neoplasia (PanIN), and carcinoma. Accompanying this process is a 
desmoplastic stromal response which aids progression through suppression of immune 
mediated cytotoxicity.   
 Formation of ADM and PanIN lesions promotes epithelial cell heterogeneity and 
metaplastic tuft cell (MTC) formation, a cell found only in the common bile duct in the 
normal pancreas. Tuft cell function regulates immune cell recruitment and activation in 
many organs by use of canonical gustatory signaling pathways. Initiation of tuft cell 
signaling through G-protein coupled receptor (GPCR) activation promotes alpha-
gustducin (GNAT3), the gustatory G alpha-protein, activation, ultimately leading to cell 
depolarization, through opening of TRPM5 cation channels, which releases signals to 
regulate immune function. MTC roles in the pancreaticobiliary tract remain unknown but 
expression of gustatory signaling and immune-regulatory proteins indicate a sensory 
role to also modify immune cell function. The aim of the research presented in this 
xviii 
 
dissertation is to understand the role of MTC gustatory signaling following biliary 
dysfunction and pancreatic neoplastic progression. 
  To explore the role of gustatory signaling in pancreatic neoplasia and 
progression, alpha-gustducin ablated (Gnat3-/-) mice were bred to models of pancreatic 
neoplasia. GNAT3 ablation in the neoplastic pancreas increased CXCL1 and CXCL2 
expression in the pancreatic epithelium, studied in 3D culture and animal models, and 
increased immunosuppressive myeloid-derived suppressor cells (MDSC) in the stromal 
compartment. Exploration of tumorigenesis finds GNAT3 ablation promotes advanced 
PDA tumorigenesis and metastasis. Preliminary data suggest MTC function requires the 
use of canonical gustatory signaling to promote multiple signaling molecules, including 
ATP, acetylcholine or CXCL1. Preliminary work also indicates a role for other immune 
populations and fibroblasts in contribution to MTC function in PDA. Overall, these data 
indicate a tumor suppressive role for MTC function in PDA progression. 
 The function of biliary MTCs gustatory signaling was studied in GNAT3 ablated 
biliary tract tissue expressing mutant KRAS. While expression of mutant KRAS 
promotes mild biliary dilation, additional loss of GNAT3 enhances immune cell 
presence, bile accumulation and biliary dilation with increased mortality of a small group 
of mice in a pilot study. No obvious histological blockages were found in the ampulla of 
Vater but the presence of apical vesicles suggests altered cholangiocyte secretion or 
absorption into the biliary tract. Advancement of this model with the addition of mutant 
TP53 did not progress to biliary cancer. These preliminary data suggest mutant KRAS 
expressing biliary tuft cells may play a role in the secretory function of cholangiocytes 
and bile homeostasis. 
xix 
 
 These data indicate organ specific functions for MTC during disease progression. 
In the neoplastic pancreas, MTCs regulate tumor suppressive immunity, slowing PDA 
progression, and in the biliary tract, MTCs aid in homeostasis. Though further work is 
required to fully analyze the differential mechanisms behind MTC function, these results 
demonstrate neoplastic epithelial cell signaling can play a multifaceted role in the 
development of pancreaticobiliary disease. 
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Chapter 1. Introduction 
1.1. Pancreatic Ductal Adenocarcinoma 
Cancer is a disease that has appeared in all species throughout recorded history. 
In humans, cancer is one of the world’s leading health problems with over 1.8 million 
new cases diagnosed each year in the United States alone1,2. Current advancements in 
cancer treatments have increased survival rates but still roughly 606,520 people will die 
in 2020 because of cancer and its associated complications1,3,4. The third leading cause 
of cancer death is pancreatic ductal adenocarcinoma (PDA) with only a 10% 5-year 
survival rate1. Worryingly, PDA incidence has been on the rise and is predicted to 
become the second leading cause of cancer death by 20301,5. The dismal prognosis of 
PDA is exacerbated by late detection of an advanced disease, primarily due to 
nonspecific symptoms including weight loss, abdominal discomfort and jaundice1,4. 
Leading risk factors include smoking, heavy alcohol consumption, type 2 diabetes, 
obesity or a high fat diet, family history and a history of chronic or acute pancreatitis1-3. 
One of the main features of PDA is its rapid metastasis, or spreading of the cancer 
beyond the primary site, which occurs in 89.2% of patients by the time of diagnosis6 
and, in combination with the non-specific symptoms and lack of clear imaging 
techniques, contributes to decreased patient treatment options and survival7,8. New 
screening options are needed for diagnosis of early stage disease to allow for effective 
resection, increasing survival of PDA patients9,10. However, novel screening options are 
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limited because of difficulties with early detection, including the relatively low incidence 
rates within the general population1, the rapid progression of early lesions to metastatic 
disease4,11,12 and the difficulties in pancreas location for imaging small lesions13. New 
developments in screening options, with low false positive and false negative rates, as 
well as new imaging modalities, will enhance the ability of PDA detection and patient 
survival. 
Treatment options for PDA include surgery, radiation and chemotherapy in 
patients. Surgery is the most effective option for lasting remission, however, only 20% of 
patients are candidates for surgical removal because of tumor location in proximity to 
critical blood vessels or metastatic spread7,8. Current standard-of-care chemotherapy for 
patients with advanced PDA are regimens of FOLFIRINOX, a therapy combining 5-
fluorouracil, leucovorin, irinotecan and oxaliplatin14, or gemcitabine plus nab-
paclitaxel15. Both chemotherapeutic treatment options extend survival but complete 
responses are extremely rare and most patients will continue to progress16. 
Advancements in targeted treatment options is informed by current research findings of 
basic molecular drivers to devise new drug targets that, in combination with current 
therapies, may provide lasting responses16. In addition, immunotherapy options have 
shown promise in other cancers by activating the anti-tumor immune response17 leading 
to several clinical trials in PDA. These initial trials met with minimal success, promoting 
the need for novel targets or combination therapies specific for PDA18. Further 
understanding the tumor intrinsic, immune targeted and desmoplastic processes that 
occur to advance the normal pancreas to PDA will provide novel molecular targets for 
early stage detection and treatment.  
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1.2. The Pancreas 
The pancreas is found behind the stomach adjacent to many organs and blood 
vessels in the upper abdomen19. It is classified into two major regions based on 
location, with the head of the pancreas near the duodenum and the tail proximal to the 
spleen (Figure 1.1A)19. The location of the pancreas is proximal to major blood vessels 
including the superior mesenteric artery, superior mesenteric-portal vein, inferior vena 
cava and aorta (Figure 1.1A), limiting surgical options for pancreatic removal 
(pancreatectomy) during disease19. The common bile duct passes from the liver, 
through the head of the pancreas, joining the main pancreatic duct to drain into the 
duodenum through the ampulla of Vader (Figure 1.1A)19,20. This connection allows the 
secretion of bile and digestive enzymes from liver and pancreas, respectively, into the 
duodenum to aid food break down and digestion19. The proximity to other organs and 
specific location make the pancreas difficult to image and resect following disease 
detection20. 
The role of the pancreas is comprised of both endocrine and exocrine functions. 
The endocrine role of the pancreas is performed by multiple cell types organized into 
functional units called islets of Langerhans (islets) to regulate hormone release, 
Figure 1.1 Pancreas 
Anatomy and 
Histology (A) Diagram of 
pancreatic anatomy. 
Pancreas labeled with head 
and tail orientation. Adapted 
from source18. (B) Histology 
of human or mouse pancreas. 
Islets, ducts and acini labeled. 
Scale bar = 50 µm. 
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including insulin, somatostatin and glucagon, into the bloodstream (Figure 1.1B)21. 
Acinar, centroacinar and ductal cells function as cells of the exocrine pancreas (Figure 
1.1B). Acinar cells are the largest proportion of the pancreas (~98%) with the islets 
composing only 1-2%21. The role of the acinar cells is to produce digestive enzymes, 
such as amylase, lipase and proteases, to be secreted into the duodenum to break 
down carbohydrates, fats and proteins, respectively, allowing for absorption of 
nutrients22. The secretion of digestive enzymes is primarily induced by food intake which 
activates endocrine, neuroendocrine and paracrine pathways to promote release of 
acinar digestive enzymes22. Regulators of secretion include cholecystokinin, 
acetylcholine and secretin which bind to receptors on the acinar cells to induce the 
luminal release of stored vesicles containing digestive enzymes22. These enzymes then 
travel through the ductal system, eventually merging into the main pancreatic duct and 
into the duodenum where food digestion can occur. Centroacinar cells, positioned at an 
interface between the acinar and ductal cells, and ductal cells aid in facilitating enzyme 
progress to the duodenum23. Though these functions are vital to survival, with current 
medical advances such as insulin monitoring and enzyme replacement, individuals can 
maintain reasonable living standards following complete pancreatectomy24.  
 
1.3. Pancreatic Development 
During development, progenitor cells activate distinct transcription factors to promote 
organogenesis19,21,25. In particular, the foregut progenitors require precise regulation of 
transcription to populate many organs including liver hepatocytes, intestinal epithelium, 
the common bile duct and the endocrine and exocrine pancreas (Figure 1.2)21,25. Two 
5 
 
critical transcription factors required for pancreatogenesis are pancreatic and duodenal 
homeobox 1 (Pdx1) and pancreas associated transcription factor 1a (Ptf1a). Pdx1 is 
active on day e8.5 (embryonic) in the dorsal and ventral pancreatic buds derived from 
the foregut endoderm, which will fuse around e12 to e13 to result in the formation of the 
main pancreatic duct spanning the composite organ19, and in progenitor cells that will 
populate the exocrine and endocrine pancreas, common bile duct and duodenum 
(Figure 1.2)26,27. However, in the adult pancreas, Pdx1 expression in acinar cells and 
ducts is low, with high expression only in the islets28,29. Interestingly, Pdx1 is also 
expressed in the suprabasal layers of the skin epidermis, potentially indicating a context 
specific role for this transcription factor30.  
Ptf1a expression is required in pancreatic progenitor cells at e9.5 and is co-
expressed with Pdx1 in the pancreatic anlagen, giving rise to exocrine and endocrine 
pancreas but, unlike Pdx1, excludes the cell lineage for the common bile duct and 
duodenum (Figure 1.2)21. In the adult, Ptf1a expression is confined to the acinar cells 
and is required to maintain acinar differentiation21. Ptf1a expression is also found in 
developing subpopulations of the nervous system, primarily in the inhibitory 
Figure 1.2 
Embryonic 
Development of the 
Pancreas Highly 
simplified diagram of 
pancreas development by 
embryonic (e) timepoint. 
Only Ventral pancreas 
transcriptional regulation 
pictured. Fusion with 
dorsal pancreas on e12.5. 
Adapted from 
sources24,33,34. 
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interneurons of the cerebellum, retina and spinal cord, but is absent in the adult31,32. The 
function of PTF1A relies on epigenetic modification of chromatin to restrict transcription 
factor binding in distinct progenitor cells33. While Ptf1a and Pdx1 both play critical roles 
in pancreatic development, other transcription factors including SRY-box transcription 
factor 9 (Sox9), critical for pancreatic progenitors and adult ductal cells, and SRY-box 
transcription factor 17 (Sox17), required for segregation of the biliary, liver and 
pancreatic lineages, are integral for pancreatogenesis (Figure 1.2)21,34,35.  
 
1.4. Adult Pancreas Plasticity and Regeneration 
The pancreas is a highly plastic organ well known for its ability to facilitate wound 
healing responses and restore homeostasis after injury. The pancreatic stem cell 
compartment that contributes to pancreatic repair is still incompletely defined but could 
be multipotent, meaning that the pancreatic progenitor cells could arise from 
differentiated cells repopulating the endocrine and exocrine compartments36,37. One 
hypothesis for pancreatic regeneration suggests that the pancreas is maintained by 
mature, terminally differentiated adult cells that are plastic in their ability to restore 
normal pancreatic function post injury36. There is evidence that centroacinar and ductal 
cells contribute to this differentiated progenitor cell pool in order to repopulate the 
endocrine and exocrine compartments23,38. However, acinar cells, in particular, have 
been most studied to understand their role as facultative progenitor cells participating in 
pancreatic restoration under conditions of injury and stress39-41. During states of injury, 
acinar cells undergo acinar-to-ductal metaplasia (ADM), a process of acinar 
dedifferentiation and loss of acinar genes, such as digestive enzymes, and acquisition 
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of ductal features, including cytokeratin 19, and a more progenitor-like state (Figure 
1.3)39,42,43. The process of ADM functions as part of a wound healing cycle to restore 
pancreatic function by acinar healing and repopulation following injury resolution43,44, 
but sustained ADM is closely associated with PDA genesis40,41.  
Multiple studies have pinpointed molecular markers to define populations with the 
stem-like capacity to achieve pancreatic repopulation. Nestin marks cells that contribute 
to acinar cell genesis during development45, progenitor cells to PDA formation46 and is 
found increased during injury in the surrounding supportive microenvironment, including 
in stellate cells and the endothelium47,48. Doublecortin like kinase 1 (DCLK1) has been 
implicated to mark a quiescent stem-like population of acinar and ductal cells 
contributing to pancreatic regeneration49,50 and as a marker of cancer stem cells in 
PDA51,52. Both nestin and DCLK1 require further study to understand their role in 
pancreatic wound healing. An eloquent study on acinar cell regeneration using linage 
tracing and single cell sequencing to track acinar cells in vivo, has found stathmin 1 
(STMN1) to be a marker of a regenerating acinar population53. STMN1 marks a subset 
of acinar cells which express proliferation markers and is expanded following injury to 
the pancreas53, making this population worth further functional study. Understanding the 
unique role injury-induced regenerative cells have in the normal pancreas can directly 
inform studies to aid healing damage and wounded states of the pancreas.  
 
1.5. Metaplasia Development 
During the progression of the normal pancreas to PDA, there arise distinct precursor 
lesions that mark the progression to carcinoma3,4,12. The three known morphologically 
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Figure 1.3 Diagram of the Histology of PDA Progression Acinar cell 
transdifferentiation to ductal metaplasia (ADM) with resolution of injury promoting re-differentiation. 
Progression from ADM to low grade PanIN, high grade PanIN and PDA with associated gene 
mutations at each histological stage. Progression is accompanied by a desmoplastic response of 
inflammation and activated fibroblasts. MDSC = myeloid-derived suppressor cells, ECM = 
extracellular matrix. Adapted from source2-4,12.  
 
distinct lesions that are found prior to invasive pancreatic cancer are mucinous cystic 
neoplasms (MCNs), intraductal papillary mucinous neoplasms (IPMNs) and pancreatic 
intraepithelial neoplasia (PanIN)54. The most well-known and well-studied precursor 
lesions to PDA are PanINs55. MCNs and IPMNs require careful monitoring and 
assessment to identify lesions that require surgical removal but have a lower risk of 
malignancy55,56. PanIN formation has been found to arise from ADM precursors that 
acquire further genetic mutations to promote progression from normal pancreatic tissue 
to PDA formation (Figure 1.3)3,40,41. Traditionally, PanIN states were characterized as a 
progressive tiered scheme from PanIN-1A/B, PanIN-2, and PanIN-3, dependent on the 
histological assessment of mucin presence (mucin 5AC (MUC5AC)), nuclear atypia and 
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ductal architecture57. However, this was recently revised to classify PanIN lesions into 
low-grade and high-grade structures, improving clinical reproducibility and relevance 
(Figure 1.3)57,58. Associated with and promoted by these lesions, is a corresponding 
desmoplastic reaction composed of a fibrotic stroma and immune cell influx that make 
up roughly 80% of the tumor volume (Figure 1.3)59. These features become more 
prominent as PanINs progress from low grade lesions to high grade lesions with further 
genetic mutations, extracellular matrix (ECM) deposition and immune influx (Figure 
1.3)60. Development of PDA is associated with a tumor-supportive immune response61, 
high interstitial pressures62 and a nutrient poor63, collagen rich microenvironment64 with 
metastatic spread (Figure 1.3)11,65. Assessment and understanding these differences in 
histology that are associated with PDA progression is critical for staging patient disease 
for targeted, effective treatment options.  
 
1.6. Molecular Drivers of Pancreatic Cancer 
One of the earliest and most commonly mutated genes, comprising over 95% of 
cases, and a key driver for PDA formation is KRAS (Figure 1.3)55,66,67. Activating 
mutations in KRAS drive multiple cellular pathways, including the MAPK and PI3K 
pathways, to promote cell growth, proliferation66, immune recruitment68 and fibrosis69. 
Analysis of mutant KRAS signaling using an inducible, pancreas-specific animal model 
found active KRAS signaling is required for the promotion of initial immune and fibrotic 
responses in the pancreas68,70 as well as advanced metastatic spread71. Both MAPK 
and PI3K pathways are critical for these early KRAS-induced responses and in 
progression of pancreatic neoplasia. Loss of signaling through epidermal growth factor 
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receptor (EGFR) (MAPK pathway)72 or the catalytic subunit of the PI3K pathway, p110α 
(Pik3ca)73, inhibits progression in a mouse model of pancreatic neoplasia and 
transformation, even with KRAS mutations present. Inhibition of these pathways, and 
the lack of initiation, show the critical need for KRAS induced signaling in early 
pancreatic transformation.  
KRAS mutations promote initiation of pancreatic neoplasia but continued 
accumulation of more mutations induces PanIN formation and progression. Acquisition 
of high-grade PanIN structures are correlated with mutations in tumor suppressor genes 
including cyclin dependent kinase inhibitor 2A (p16/CDKN2A), tumor protein p53 (TP53) 
and SMAD family member 4 (DPC4/SMAD4) (Figure 1.3)66,67. The normal function of 
each of these tumor suppressor genes is to restrict cell growth and proliferation, or 
promote DNA repair74-77. The expression of these genes can be lost by direct mutation 
of the alleles or through epigenetic silencing78. Epigenetic alterations can take a variety 
of forms including DNA methylation, chromatin remodeling, histone modifications and 
non-coding RNA expression and can be used to define malignant phenotypes78. Recent 
work has used epigenetic states as a way to define PDA subtypes and as possible 
avenues for treatment78. However, further study is required to understand the interaction 
of mutant KRAS signaling that is enhanced by tumor-suppressor loss and epigenetic 
modifications to promote PDA. 
 
1.7. Pancreatic Cancer Mouse Modeling 
Studies of pancreatic cancer utilize animal systems to recapitulate disease 
development and progression in the context of an intact tumor microenvironment79. The 
11 
 
most commonly used systems are genetically engineered mouse models (GEMMs) 
which have been developed to activate tumor promoting or inactivate tumor suppressive 
proteins in an organ specific manner, promoting the development of carcinoma79. PDA 
GEMMs utilize mutations found in human patients to recapitulate disease progression in 
the pancreas. The models discussed here are only a subset of these models utilized in 
PDA research but are ones which are used in this dissertation.  
All the PDA models used in this thesis are driven by the KrasLSL-G12D/+ allele to 
activate mutant KRAS in the pancreas under the control of a CRE recombinase driven 
system29,80. The research discussed in Chapter 2 and 3 use the Ptf1aCre/+ promoter 
driven system to generate KrasLSL-G12D/+;Ptf1aCre/+ (KC) animals. Ptf1a-driven CRE 
recombinase is a knock-in animal model, where CRE replaces one allele of the 
endogenous Ptf1a locus, promoting KrasLSL-G12D/+ recombination81 on embryonic day 9.5 
in the developing pancreatic epithelium21. Expression of mutant KRAS in the pancreatic 
epithelium recapitulates the main features of human PDA, including ADM and PanIN 
formation associated with a desmoplastic fibroinflammatory microenvironment29,80. This 
model is further accelerated by the Ptf1aCre/+ knock-in allele, as Ptf1a expression 
functions as a tumor suppressor in the pancreas82. The neoplastic KC model can also 
be bred to the dominant-negative mutant TP53R172H allele, generating the KrasLSL-
G12D/+;p53LSL-R127H/+;Ptf1aCre/+ (KPC) model83. The KPC model accelerates 
tumorigenesis83, with histological features progressing through PanIN states to PDA and 
metastasis rapidly, causing mortality within five months of age. However, the KPC 
model also induces expression of mutant KRAS and TP53 in a subset of nerves31,32, 
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causing paralysis due to spinal and brain tumors, requiring careful analysis of cause of 
death when performing these studies84.   
To more closely resemble the human model, a temporally controlled GEMM was 
developed to activate KRAS mutations in the adult mouse, recapitulating more similarly 
what occurs over time in human cancers and utilized primarily in Chapter 2, 3, 5 and 6 
of this thesis. The Ptf1aCreERT/+ allele bred to KrasLSL-G12D/+ generates the KrasLSL-G12D/+; 
Ptf1aCreERT/+ (KCERT) model of pancreatic tumorigenesis. The KCERT GEMM is similar to 
the KC model, where expression of mutant KRAS is induced by CRE recombinase 
expression from Ptf1a. However, KRASG12D expression is controlled temporally as well 
as spatially by the CREERT function, where CRE recombinase has been fused to a 
mutated version of the estrogen receptor (ER) hormone binding domain that is modified 
to detect only the drug tamoxifen85. Following drug binding, CREERT can translocate to 
the nucleus and perform its recombinase function85, allowing expression of mutant 
KRAS in an acinar specific manner, as Ptf1a in the adult mouse is only expressed in 
acinar cells86. This model has less off-target effects, compared to models with 
embryonic CRE expression, and is a slower model of pancreatic transformation. 
Another common promoter of CRE expression in the pancreas uses the gene Pdx1, 
generating the KrasLSL-G12D/+;Pdx1Cre/+ (Kras; Pdx1Cre) model when bred to mutant KRAS 
and used in Chapter 4 of this thesis. Embryonic expression of mutant KRAS is 
promoted by expression of Pdx1Cre in the pancreatic epithelium, biliary tract and 
segments of the duodenum and distal stomach because of the expression at e8.5 in the 
developing foregut progenitors26,87. This induces transformation and neoplasia in the 
pancreas, recapitulating histopathological features of human disease80. However, 
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expression of Pdx1 promotes recombination in many organs, such that results can be 
disrupted by confounding tumors in the digestive tract88. Similar to the KC model, the 
Kras; Pdx1Cre system can be bred to the dominant-negative TP53R172H allele generating 
KrasLSL-G12D/+;p53LSL-R127H/+;Pdx1Cre/+ (p53;Kras;Pdx1Cre) animals. As in the KPC model, 
expression of mutant KRAS and TP53 induces PDA formation and metastasis, 
recapitulating clinical histological features and causing mortality by five months of age83. 
Expression of these mutant genes are driven by Pdx1 expression in developmental 
progenitors which form daughter cells a variety of organs in which addition of tumor 
activating mutations can lead to skin tumors along with the presence of PDA, making 
careful use of controls vital in research studies30,83.  
 
1.8. Pancreatic Cancer: Cell of Origin 
Due to its morphological appearance, PDA has been hypothesized to arise from the 
pancreatic ducts. However, recent data, using genetically engineered mouse models 
(GEMMs), have revealed that acinar cells can be the cell of origin for PDA27. One of the 
initial abnormal events that occur during pancreatic injury is ADM (Figure 1.3)89. The 
function of ADM as a wound healing mechanism can be hijacked with genetic 
mutations, in particular oncogenic KRAS activation, to inhibit the return to acinar state 
and sustain ADM (Figure 1.3)42. Induction and progression of ADM in GEMMs requires 
only the mutation of KRAS to induce PDA in the acinar compartment using acinar 
promoters including basic helix-loop-helix family member A15 (Mist1), elastase (Elane) 
and Ptf1a2,90. These ADM lesions progress through PanIN54 stages, similar to that found 
in human PDA, express cytokeratin 19, a common marker of tumor cells, and 
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disseminate from lesions previously thought to be pre-invasive (Figure 1.3)11. Additional 
loss of tumor suppressors, such as TP5383 or INK4A/ARF36, in the acinar compartment 
induces rapid PDA development in mouse models. Observations from individuals with a 
familial history of pancreatic cancer also support the hypothesis that acinar cells, though 
ADM, are the cell of origin for PDA58.  
Though there is abundant evidence for acinar cells initiating PDA, more recent 
studies have found that ductal cells can also be a cell of origin90. However, mutations in 
KRAS, sufficient to drive ADM and PanIN formation in the acinar compartment, do not 
promote early lesions from the ductal lineage, as determined by lineage-specific drivers 
Sox9 and Ck192,90. Addition of homozygous TP53 loss-of-function mutations are 
sufficient to drive PDA formation in the ductal linage when combined with activating 
KRAS mutations91. Both acinar-derived and ductal-derived tumors have similar survival, 
but ductal-derived PDA had more disorganized collagen and epithelium with fewer 
PanIN lesions than acinar-derived tumors91. These results suggest that the cell of origin 
plays a role in tumor architecture and formation, which impacts treatment and disease 
outcomes2,91,92. The cell of origin, and its role in PDA progression, remain unknown in 
the context of human disease but may become important information for effective 
patient treatment.  
 
1.9. Heterogeneity of Metaplasia 
Cellular heterogeneity is found in pancreatic tissue from initiation of ADM through 
advanced stages of PDA, including metastasis. Terminally differentiated acinar cells in 
the pancreas are a plastic cell type that can undergo ADM11,93,94, promoting cellular 
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heterogeneity through acinar dedifferentiation. Acinar transdifferentiation promotes the 
re-expression of developmental transcription factors, Pdx1 and Sox17, in dual positive 
cells found in ADM (Figure 1.2)94. These transcription factors are markers of a 
pluripotent progenitor cell (Figure 1.2), which may be promoting the generation of cells 
not normally present in the exocrine lineage94. Expression of Sox17, a transcription 
factor important for the biliary transition (Figure 1.2), correlates with the presence of a 
unique cell population in ADM and PanIN lesions, the tuft cell2. Tuft cells are a 
chemosensory cell population normally found only in the common bile duct that passes 
through the head of the pancreas (Figure 1.1A, 1.4A)95. These unique cells persist in 
ADM and PanINs (Figure 1.4B) but are lost with the development of PDA94. Another 
distinct cell type present in early neoplasia, non-overlapping with tuft cells95, takes on 
the phenotype of neuroendocrine-like cells, reminiscent of developmental endocrine 
cells (Figure 1.4B)96. Data from our lab and others find neuroendocrine cells in early 
ADM and PanIN lesions communicate to nerves in the pancreas to promote PDA 
(Figure 1.4B)96. Furthermore, studies in advanced cancer find neuroendocrine cells 
more able to delaminate and invade outside the pancreas, contributing to the overall 
poor prognosis of PDA97. The role of cellular heterogeneity in early stage neoplasia may 
contribute to late stage disease and novel treatment options.  
Metastasis requires the adaptation of cells to invade and colonize unique 
microenvironments outside of the pancreas. Cellular dissemination and invasion is 
found early in low-grade to high-grade PanIN structures11, though few cells persist to 
form secondary metastasis, suggesting a threshold of alterations in the cell clones 
required for establishment67. Colonial, heterogenous cell populations form by the 
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presence of many factors, including restriction to nutrients and oxygen98, high interstitial 
pressures99 and a robust extracellular matrix, which exerts selection pressure on the 
tumor to select mutant clones that are more able to survive in harsh conditions67,100. 
Survival and establishment of metastasis also seems to be directly tied to clonal 
advancement of the primary tumor67,100, promoting a need for understanding the 
selection factors contributing to primary tumor cellular heterogeneity and metastasis. In 
addition, there are distinct cancer stem cells identified by expression of CD44, CD24, 
prominin 1 (CD133)101, epithelial cell adhesion molecule (ESA/EPCAM)102, aldehyde 
dehydrogenase 1 family member A1 (ALDH1)103, CXCR4101 and DCLK151, among 
others, that have increased proliferative capacity, promoting tumor advancment104,105. 
These cancer stem cells contribute to drug resistance and increase cancer survival by 
becoming quiescent, making them both difficult and critical to target for regression104. 
The contribution of cellular heterogeneity to primary and metastatic tumors indicates a 
broad treatment spectrum for effective targeting of many different cell types. 
 
 
 
Figure 1.4 Cellular 
Heterogeneity (A) Common bile 
duct with tuft cells marked by TRPM5-
GFP (green) and phalloidin (white) to 
mark the filamentous actin tufts. DAPI 
(blue) are nuclei. Scale bar = 20 µm. 
(B) Neuroendocrine cells marked by 
synaptophysin (red) and metaplastic 
tuft cells marked by TRPM5-GFP 
(green) in a 3-month Ptf1a induced 
embryonic mutant KRAS pancreas. 
DAPI (blue) is nuclei, phalloidin (white) 
is filamentous actin. Scale bar = 5 µm. 
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1.10. Bile Duct Development and Disorders 
The biliary tract functions as part of the digestive system which carries bile from the 
gall bladder to the intestine for aiding digestion and elimination of waste from the 
body19. During development, foregut progenitors split into two lineages: hepatoblasts, 
becoming the liver and intrahepatic biliary cells, and pancreato-biliary progenitors, 
resulting in the ventral pancreas and the hepatopancreatic ductal system (Figure 1.2)35. 
Specification of the hepatobiliary system in pancreato-biliary progenitors requires 
targeted expression of Sox17 and Pdx1 for the development of the hepatobiliary tract 
and pancreas, respectively (Figure 1.2)35. The hepatobiliary system is composed of 
cholangiocytes, blood vessels, smooth muscle cells, immune cells and nerves, which all 
contribute to proper biliary function106. Cholangiocytes are a heterogenous population of 
epithelial cells107,108 which play a critical role in bile composition and function including 
modification of bile salts, water and bicarbonate levels109, forming a barrier from 
damaging molecules and microorganisms and communication between immune and 
vascular systems110. This cellular heterogeneity includes the presence of unique cell 
types such as tuft cells (Figure 1.4A),95,111 and functional heterogeneity of 
cholangiocytes that secrete different substrates and modify bile composition107. 
Cholangiocytes also constitutively express Toll-like receptors (TLRs) which can function 
to detect pathogens to activate chemokine and cytokine release, promoting immune 
responses110,112. Alterations in this system through infectious, genetic or immune-
mediated diseases can cause impaired bile formation and promote inflammation and 
fibrosis110. Further, alterations of bile composition, through cholangiocyte dysregulation, 
can promote formation of gallstones or bile duct stones blocking bile secretion leading 
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to pain and inflammatory activation113-115. Sustained biliary inflammation can lead to 
jaundice, chronic bile duct inflammation (cholangitis) and biliary pancreatitis116, higher 
risk diseases associated with liver failure110,117,118. In many cholangiopathies the 
functional mechanisms altering secretion contributing to stone formation or inability to 
respond to pathogen detection remain to be clarified.  
Sustained inflammation in the biliary tract can lead to cholangiocarcinoma, or cancer 
of the biliary epithelium. Cholangiocarcinoma (CC) is a rare tumor comprising only 3% 
of all gastrointestinal tumors119 but a poor prognosis, with a median survival of only 24 
months120,121. CC can develop throughout the biliary tract and, as such is broken down 
to 3 subtypes based on location from liver to pancreas, labeled intrahepatic, perihilar 
and distal, respectively121. Perihilar CC and distal CC are associated with worse 
outcomes121, sharing distinct similarities with PDA, which is hypothesized to be due to 
their shared path of embryonic development122. Current detection and treatment options 
for CC are limited, similar to PDA, with current imaging modalities unable to detect early 
lesions, differentiating malignant CC and PDA lesions123 and challenging surgical 
removal as the only potentially curative treatment124. Histologically, neoplasia in the 
biliary tree and pancreas are both characterized by mucin overexpression125, KRAS and 
TP53 mutations, and tumor markers, such as cytokeratin 19123. Similarities in the 
immune and desmoplastic reaction126 require more in depth methods to identify 
differences and determine distinct profiles to differentiate these diseases for targeted 
therapy.  
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1.11. Tuft Cells  
Discovered in 1956127,128, tuft cells are a rare solitary chemosensory cell found in the 
mucosal epithelia of the body which only recently gained functional relevance129. 
Structurally, tuft cells are a unique cell which was observed in multiple studies and given 
a variety of names including “tuft”, “brush”, “caveolated”, “multivesicular”, 
“fibrillovesicular” and “solitary chemosensory” cells129. They have a prominent apical 
microvilli “tuft”, allowing for distinct identification in multiple organs including the nasal 
passage130, intestine131, common biliary duct95,111, stomach128, urethra132 and thymus133. 
The gene expression signature of tuft cells includes core machinery of the gustatory 
pathway129,134 and neural133 and immune regulatory proteins135, including enzymes 
required for the synthesis of acetylcholine95 and prostaglandins136. Tuft cells throughout 
the body, excluding type-II taste cells129, also express the neural microtubule kinase 
DCLK1137. Expression of the transcription factor POU2F3 (Skn1α) during development 
is required138 for genesis of taste signaling cells, including tuft cells, indicating the ability 
to sense and respond to luminal signals using components of the gustatory pathway.  
Gustatory signaling was first studied in the bitter, sweet and umami responsive type-
II taste cells on the tongue through activation of a canonical taste signaling pathway139. 
Figure 1.5 Canonical 
Gustatory Pathway  
Illustration of canonical gustatory 
signaling pathway. Activation through 
G-protein coupled receptor (GPCR) 
binding to promote cell depolarization. 
GαGus = α-gustducin (GNAT3), PLCβ = 
Phospholipase Cβ, inositol triphosphate 
= IP3, inositol triphosphate receptor = 
IP3R and transient receptor potential 
cation channel subfamily M member 5 
= TRPM5. 
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Binding of sweet/umami to T1R or bitter chemicals to T2R G-protein coupled receptor 
(GPCR) heterodimers converges signaling to coupled heterotrimeric G proteins that 
include an α, β and γ subunit, specifically Gβ3, Gγ13140, and Gαgus (alpha-
gustducin/GNAT3) (Figure 1.5)141,142. Following GPCR activation, Gβγ dimers induce 
endoplasmic reticulum (ER) dependent calcium release through stimulation of 
phospholipase Cβ2 mediated pathways (Figure 1.5)143. Elevated intracellular calcium 
induces opening of transient receptor potential cation channel subfamily M member 5 
(TRPM5) channels allowing cation influx, cell depolarization and downstream signaling 
(Figure 1.5)144,145. Depolarization in type-II taste cells promotes calcium homeostasis 
modulator 1 (CALHM1) channel opening releasing ATP to induce activation of P2X2 
and P2X3 nerve receptors to activate the chorda tympani and taste relaxation in the 
brain146. Analysis of gustatory pathway signaling and function in the tongue leads to 
questions of sensory function in tuft cells found in other organs. 
Gustatory signaling in tuft cells throughout the body do not elicit a classical ‘taste’ 
response but rather promote immune mediated activation. In the intestine, tuft cell 
detection of parasitic succinate activates the succinate receptor 1 (SUCNR1) receptor to 
drive release of interleukin-25 (IL-25) in tuft cells, promoting a type-2 immune response 
through recruitment of innate lymphoid cells type 2 (ILC2) expressing interleukin-13 (IL-
13), inducing tuft cell hyperplasia and parasite clearance135,147,148. Tuft cell loss or 
modification through ablation of POU2F3, ablation of IL-25 or loss of TRPM5 mediated 
gustatory signaling, all reduces parasite clearance135,147. These parasitic responses also 
seem to be parasite specific, suggesting intrinsic tuft cell heterogeneity, as GNAT3 
ablation, the Gα protein mediating taste response, inhibits tuft cell hyperplasia when 
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colonized with Tritrichomonas147 but has no effect with N. brasiliensis infections148. A 
type-II immune mediated response has also been found in the lung epithelium after flu 
infection and in the nasal cavity, where bitter substances can promote tuft cell mediated 
induction of plasma extravasation and the associated immune influx149-151. Though 
these immune cell responses are not a universal feature and evidence suggests tuft 
cells found in the gall bladder, common bile duct, cecum and colon have organ specific 
responses to tuft cell activation129. Surprisingly, tuft cells have also been found in the 
thymus, an organ outside of the hollow tissues, to regulate the development of TCRβint 
CD1d+ IL-4+ invariant natural killer T (NKT2) thymocytes152, though the exact 
mechanism of activation and regulation is still to be uncovered. Tuft cell function, and 
the role of gustatory signaling, remains a mystery in many organs, requiring further 
research to understand this unique cell type. 
   
1.12. Metaplastic Tuft Cells in Pancreas  
Tuft cells are not found associated with the normal acinar, ductal or endocrine cell 
populations of the pancreas but are only present in the common bile duct95. During 
chronic inflammation of the pancreas (pancreatitis), ADM and PanIN formation, 
metaplastic tuft cells can be found in the neoplastic lesions but are lost during 
progression to PDA94. Similar to other tuft cells in the body, metaplastic tuft cells in the 
pancreas express gustatory signaling proteins, (GNAT3, TRPM5), nerve signaling (β-
endorphin, choline acetyltransferase (ChAT)), immune signaling (vav guanine 
nucleotide exchange factor 1 (VAV1), cyclooxygenase 1 (COX1), cyclooxygenase 2 
(COX2), prostaglandin D synthase (HPDGS)) and structural (DCLK1, acetylated-α 
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tubulin, phalloidin tufts) components that help to define this unique population51,94. 
Acinar specific lineage tracing animal models found that de-differentiated acinar cells 
generate metaplastic tuft cells by maintenance of a progenitor-like state able to use 
biliary signaling proteins, an organ where tuft cells are normally present94. Electron 
microscopy of metaplastic tuft cells confirm the presence of actin rootlets and 
uncovered lipid droplets/vesicles found at the basolateral region of the cell, indicating 
the ability for controlled release of downstream signals153. Activation of tuft cell signaling 
promotes release of substances that directly bind and modulate function of blood 
vessels, nerves149 and immune cells135 in other organs. However, the exact role of tuft 
cells in the neoplastic pancreas remains unknown but communication with any of the 
cell types found previously is possible as blood vessels154, nerve communication155 and 
immune cell alterations156,157 all influence PDA progression.  
DCLK1 is a microtubule kinase found in tuft cells throughout the body, including 
metaplastic tuft cells in the pancreas129. DCLK1 was discovered in nervous tissue as a 
critical remodeler of dendritic synapse formation158 and only more recently associated 
with tuft cells. During pancreatic tumor formation DCLK1 expression is associated with 
injury-induced quiescent stem-like progenitor cells following pancreatic damage50 and 
an interleukin-17 (IL-17) induced cancer stem cell-like population in PDA51,159. 
Therefore, it has been hypothesized that tuft cells, present in ADM and PanIN lesions, 
are DCLK1+ injury-induced quiescent stem cells that contribute directly to tumor cell 
proliferation and expansion159,160. However, multiple studies in the pancreas94 and 
intestine161 have found that tuft cells rarely express markers of proliferation and function 
as a sensory cell population not as a stem cell162. Furthermore, DCLK1 is not 
23 
 
exclusively expressed in tuft cells but is also found in nerves158 and pancreatic non-tuft 
cell expressing acinar and ductal cells50, indicating a multifaceted role for DCLK1+ 
expression in different cell types. Ultimately, the role of the metaplastic tuft cell in the 
pancreas, whether quiescent stem cell or gustatory responsive cell, has not yet been 
elucidated. 
  
1.13. Acute and Chronic Pancreatitis 
Inflammation of the pancreas, known as pancreatitis, is a leading cause of digestive 
disorders manifesting in either acute or chronic forms163,164 and is one of the most 
commonly diagnosed gastrointestinal diseases165,166. Acute pancreatitis (AP) resolves 
over time with minimal treatment options that are usually palliative and non-specific 
including fasting, fluid therapy and pain management22,167,168. However, continued bouts 
of AP can lead to chronic pancreatitis (CP)169, where scarring of the pancreas becomes 
irreversible and leads to continual pain, impacting quality of life with difficult symptom 
management163,164. Common risk factors for both AP and CP include obstruction of 
pancreatic ducts116, alcohol abuse, smoking, pancreatic trauma and infections163. These 
initiating insults lead to release and activation of pancreatic enzymes to damage the 
pancreas and is sustained by acinar injury which promotes release of cytokines to 
recruit and maintain an inflammatory response22,170. Interestingly, CP is also a risk 
factor for developing PDA27,171,172, suggesting a connection between the two disorders. 
Pancreatitis, similar to PDA, is characterized by inflammation, fibrosis and loss of the 
acinar compartment through acinar cell death27 or transdifferentiation (ADM)173,174, as 
well as the presence of metaplastic tuft cells175. Several factors could play a role in 
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promoting CP to PDA, including increased proliferation in the epithelial compartment 
and/or inflammatory cell production of both ROS, to induce cell damage, and cytokines, 
to promote proliferation27, indicating a role for immune signaling and advancement of 
disease. 
Despite advances in understanding the development and progression of 
pancreatitis, no targeted treatments are available for CP or AP176. Further investigation 
is needed to find new therapies however, experimental models of both CP and AP do 
not fully mimic the human disease177, making translational studies difficult. AP models 
require pancreatic damage reflecting clinical physiology which will resolve over time, 
allowing the study of both damage initiation and acinar cell repopulation. The most high-
fidelity models require limiting blood supply to the pancreas178, blocking secretion to the 
duodenum179 or pancreato-biliary duct180-182, or infusion of damaging agents into the 
ductal system, all of which replicate clinical disease and pathophysiology. However, all 
of these models require invasive surgical procedures and, outside of pancreatic ductal 
ligation which can be performed in mice182, larger animals are required, including rats, 
rabbits, dogs and pigs183, increasing challenges of study due to risk and cost. Other AP 
inducers, including cerulein and L-arginine, are used less invasively in many animal 
models to generate features of human disease183.  
Cerulein is an orthologue for cholecystokinin, a regulator of pancreatic exocrine 
secretion following food consumption, which dysregulates production and secretion of 
digestive enzymes, promotes edema formation, acinar cell death and inflammatory cell 
infiltration when administered at supramaximal doses184. L-arginine treatment induces 
acinar cell necrosis which mimics human necrotizing AP185, though the mechanism of 
25 
 
action is still unknown170. Repeated clinical episodes of AP increases fibrosis and 
scarring and is a risk factor for developing CP163,164, providing a useful model of 
experimental pancreatitis through repeated dosing of AP inducers. Chronic L-arginine 
treatment replicates CP acinar dropout, fibrosis and adipose replacement186, but 
treatment effects vary depending on mouse strain and can lead to rapid mortality187. 
Chronic application of cerulein also mimics CP fibrosis and remodeling188, however, 
following cessation of cerulein, the pancreas will resolve the induced damage, unlike 
clinical cases of CP168,184. Additionally, there has been little evidence that CCK 
dysregulation or L-arginine elevation play a role in the clinical disease183, perhaps 
questioning the utility of these models. Further understanding of clinical cases of 
pancreatitis initiation progression may lead to novel models that can further develop our 
understanding of this disease increasing treatment options. 
  
1.14. Fibrosis in the Pancreas 
Acute pancreatitis (AP), chronic pancreatitis (CP) and pancreatic ductal 
adenocarcinoma (PDA) are all characterized by a fibrotic stromal compartment, 
composed of activated fibroblasts and a rich extracellular matrix189. Pancreatic stellate 
cells (PSC), found in the normal pancreas as resident non-immune cells190,191, attain an 
activated myofibroblast-like state during injury, contributing to the extracellular matrix 
(ECM)190,192 and the release of cytokines to activate proliferation and migration190,193. 
After tissue damage, neighboring cells and recruited immune cells release cytokines, 
such as tumor necrosis factor-alpha (TNF-α), interleukin-1 (IL-1) and interleukin-10 (IL-
10)194, and growth factors, including platelet derived growth factor (PDGF) and 
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transforming growth factor-beta 1 (TGF-β1)194,195, to activate PSCs. In CP and AP, 
release of cytokines by damaged acinar cells activates PSCs194, suggesting specific 
acinar roles in promoting fibrosis. Activated PSCs then release autocrine activation 
factors, PDGF196 and TGF-β1195, proinflammatory molecules (COX2)197, and 
chemokines (interleukin-8 (IL-8), monocyte chemoattractant protein-1 (MCP-1))198 to 
promote pancreatic fibrosis and immune cell recruitment192. Activation of PSCs by TGF-
β1 stimulation promotes ECM deposition by increased collagen synthesis and 
decreased matrix-metalloproteinase production193,195, with the function of PDGF also 
promoting ECM synthesis193 as well as contributing to proliferation199 and migration196. 
In addition to resident activated PSCs, bone-marrow derived stem cell populations 
infiltrate the pancreas during CP to differentiate into fibroblasts, contributing to the 
fibrotic reaction200. The function of fibrosis and immune cell recruitment and activation 
promote a the wound healing response that is cleared following AP resolution201. 
However, in CP, the stromal presence is retained with a gene signature that closely 
matches the stromal gene expression in PDA202. This indicates that stromal activation 
may play a role in the advancement of chronic inflammatory diseases and development 
of cancer in the pancreas203.   
As early neoplastic lesions progress to PDA there is an increase in deposition of 
collagen and fibroblasts that promote tumor cell survival and immune influx (Figure 1.3). 
The progressive fibrosis is mediated by a heterogenous population of cancer associated 
fibroblasts (CAF) composed of activated PSCs204, bone marrow-derived mesenchymal 
stem cells200,205 and resident fibroblasts in the pancreas206. CAFs also have distinct 
compartments in the tumor microenvironment (TME). Near the tumor, CAFs are 
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phenotypically myofibroblastic CAFs (myCAFs), expressing α-smooth muscle actin 
(αSMA) and communicating directly with the tumor compartment, while the distal stroma 
has inflammatory CAFs (iCAFs), expressing mainly inflammatory mediators including 
interleukin-6 (IL-6)207,208. The exact role of myCAFs and iCAFs is not known but suggest 
a spatial CAF heterogeneity that has not yet been appreciated or understood in the 
context of PDA development and treatment209. Initial fibrotic deposition is promoted by 
tumor cells that release paracrine factors, including TGF-β1 and fibroblast growth factor 
2 (FGF2)210, to activate PSC release of ECM proteins210 and cytokines that promote 
invasiveness and proliferation of the tumor211,212, forming a positive feedback loop. This 
includes the release of collagen by CAFs, forming the main stromal compartment that 
promotes PDA cell survival and proliferation213, and release of amino acids, to support 
tumor growth214.  
Immune cell recruitment and activation is also driven by CAF promoted cytokine 
release215,216 and, reciprocally, CAFs can also be activated by immune 
populations217,218. CAF signaling also enhances metastatic spread219 by inducing EMT 
in tumor cells220, production of matrix metalloproteinases219,221 and activation of 
fibroblasts in the metastatic site222. The intense stromal reaction in PDA induces the 
formation of a hypovascular tumor with high pressures62 that promote a hypoxic 
environment223, resulting in additive effects on CAF induced migration, collagen 
expression, cell proliferation and angiogenesis224,225. The role of CAFs in tumors 
suggests a more tumor supporting role, however the extreme heterogeneity found in 
recent studies indicate multiple roles for CAFs that can be tumor suppressive or 
promoting. Analysis of CAFs expressing fibroblast activating protein (FAP) finds they 
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promote an immune suppressed microenvironment which develops into a more 
aggressive tumor226,227. However, depletion of the dense stroma228 or myofibroblast 
specific loss229 lead to aggressive tumors and decreased overall survival229,230, showing 
the complexity and heterogeneity in this compartment that requires further 
understanding before attempts at therapy. 
  
1.15. Inflammation  
The inflammatory response evolved to identify and remove damaged tissue or 
foreign molecules then promote healing to restore tissue homeostasis. Initial injury 
responses after tissue damage promote innate immune responses and neutrophil 
extravasation into the damaged site231. Neutrophils are a granulocytic cell population 
known to directly destroy infectious threats232,233 and also promote wound healing, as 
mediated through direct interaction or activation of other immune populations234. 
Neutrophil activation drives recruitment and activation of antigen presenting cells, 
primarily dendritic cells (DC)235, to induce macrophage activation236, maturation of B-
cells237 and T-cell differentation238. Neutrophils can also participate in tissue 
revascularization239, debris clearance240, and the release of growth factors, chemo-
attractive cytokines and toxic molecules to control the immune response in the 
tissue241,242. In addition, other innate immune populations, including natural killer (NK) 
cells243, natural killer T-cells (NKT)244, eosinophils245, basophils246 and mast cells247, 
though fewer in number during the inflammatory response, also play critical roles in 
tissue restoration by release of local and systemic cytokines, targeting foreign 
pathogens and the promotion of inflammatory resolution leading to tissue restoration.  
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Successful inflammatory initiation and resolution requires the activities of monocytes 
and macrophages to guide progression and healing outcome. Monocytes are found in 
the bloodstream and extravasate into inflamed tissue following chemokine gradients248-
250 and differentiate into macrophages251 and DCs252, thus combining with the pool of 
resident macrophages primed for the inflammatory process253. Macrophages are a 
diverse, plastic cell type that can modulate inflammation through production of context-
dependent pro- and anti-inflammatory molecules254 as well as direct phagocytosis of 
debris255. Exposure to pro-inflammatory cytokines in the initial inflammatory response256 
promotes acquisition of a pro-inflammatory state in macrophages, termed M1 or 
“classically activated”257. M1 polarized macrophages are associated with high 
microbicidal activity258, which promote the inflammatory response through cytokine 
release259,260. Following the initial phase of inflammation, macrophages recruited to the 
tissue acquire an anti-inflammatory phenotype, termed M2 or “alternatively activated” 
state261, which induces production anti-inflammatory molecules, promotes angiogenesis 
and stimulates tissue repair262,263. This transition demonstrates the plasticity of 
macrophages to acquire specific functions as determined by signals from the 
extracellular environment264. Biologically, macrophage classification, into M1 and M2 
states, is an oversimplification and does not represent the true spectrum of macrophage 
states in the tissue265. Proper activation and timing of macrophages function is key for 
the initial and resolving wound response266,267 as well as proper immune response to 
pathogens268. This is most notable in chronic inflammatory diseases269,270 and in 
cancer271 where aberrant function of macrophages promote continued disease states. 
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Following activation of the innate immune response, cells in the adaptive immune 
response are activated as an antigen targeted system that identifies specific pathogens 
and maintains memory responses272. Two types of adaptive responses mediate 
inflammatory responses through T-cell mediated immunity and the humoral immune 
response controlled by B-cells272. T-cells are a heterogeneous, plastic population of 
adaptive immune cells that have dual roles of inhibition and promotion of disease 
pathogenesis273. In the context of wound healing, the role of T-cells stimulates pro-
inflammatory responses, contributing to pathogen clearance274, but in the late 
inflammatory phase275, contribute to wound healing276. T-cells are categorized in two 
broad populations to accomplish these opposing functions, with expression of either 
CD4 or CD8 antigens identifying the groups277.  
CD4+ T-cells have multiple subsets including: T helper cells to activate immune 
targeting of pathogens (Th1, Th2278, Th17279), T regulatory cells (Treg)280, and T 
follicular helper cells to aid in B-cell antibody production281. Though T helper cells 
activate pro-inflammatory responses and thus contribute to cytotoxic clearance278, T 
regulatory cells facilitate wound healing and maintain peripheral tolerance282 by 
suppressing pro-inflammatory mediators283,284, identifying opposing roles in 
inflammation and wound repair.  
CD8+ T-cells are a cytotoxic population that meditate lysis of target cells to clear 
pathogens or foreign cell bodies and maintain tissue homeostasis285, though do not 
directly participate in wound closure286. Activation of antigen specific maturation in T-
cells is mediated through antigen presenting cells that process and present the pieces 
of the foreign material for detection272. Mature DC are professional antigen presenting 
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cells recruited and activated in the inflammatory process272 that release cytokines to 
promote activation and differentiation of naïve T-cell responses272, mediating pathogen 
clearance. B-cell adaptive immune responses use targeted antibodies to drive 
clearance of antigen specific foreign bodies272. The role of B-cells during wound healing 
indicates that B-cells contribute to wound healing287 yet in chronic diseases is 
associated with a worse outcome, particularly in autoimmune diseases288. Activation of 
the adaptive immune response supports the innate immune cells in immunogenic 
clearance of foreign cells and tissue restoration during normal wound resolution and 
pathogen clearance.  
 
1.16. Inflammation in Pancreatitis 
Pancreatitis is characterized not only by loss of normal pancreatic tissue and 
increased fibrosis but also by a targeted inflammatory reponse289,290. Initial acinar cell 
damage promotes inflammatory influx to the pancreas through cytokine release291-293 to 
attract neutrophils and monocytes amplifying the wound response to heal and resolve 
the damage294,295. Multiple immune subsets have been found to contribute to the 
prolonged damage phase found during AP, including mast cells296, T-cells297-299 and 
macrophages300,301. Neutrophils in particular302,303, have been shown to be a critical 
mediator of the initial damage response, with depletion leading to a reduction in 
severity304,305. In AP, the damage will eventually resolve unlike CP, where pancreatic 
damage is irreversible and maintains a persistent fibro-inflammatory response306. As in 
AP, the immune cell populations in CP are similar but maintain a persistent presence in 
the damaged organ. Continued macrophage presence promotes activation of pancreatic 
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stellate cells to maintain the fibrosis in the pancreas270,307. In addition, T-cells are also 
increased, including active cytotoxic CD8+ T-cells308, whose activation may contribute to 
the damaged phenotype. Identification of immune cell targets have resulted in 
immunotherapy based clinical trials for AP, though with minimal success309-312. Further, 
there are no targeted treatments for CP289, inspiring a need for further understanding 
the role of immune targets in pancreatitis.  
 
1.17. Pancreatic Cancer Immune Microenvironment 
Pancreatic ductal adenocarcinoma (PDA) is defined by a landscape of progressive 
immune cell influx in combination with neoplastic formation and fibrotic response (Figure 
1.3)313. Following ADM and acquisition of KRAS mutations, cytokines are released from 
the transformed epithelium promoting immune influx314, similar to CP (Figure 1.3)315. 
During tumor progression, the immune phenotype shifts as inflammatory mediators315 
modulate the immune microenvironment to maintain immunosuppressive cell types316 
and tumor-supportive immune cells for continued neoplastic growth317. 
Immunosuppressive cells, including T regulatory cells (Treg), tumor-associated 
macrophages (TAM) and myeloid-derived suppressor cells (MDSC)318, suppress both 
innate and adaptive immunity inhibiting further immune responses and associated 
cytotoxic killing of neoplasia. The fibrotic microenvironment also contributes to the 
immunosuppressive phenotype though CAF directed cytokine release promoting TAM 
anti-inflammatory function319, recruitment of MDSCs215, and CD8+ T-cell apoptosis320 or 
loss of migration to the tumor epithelium321. Initiation of these immunosuppressive 
responses are found in early PanIN formation157, through activated CAFs194 and acinar 
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cell transdifferentiation322, and becomes more advanced following lesion progression, 
with reduced CD8+ cytotoxic T-cells and increased supportive cells323.  
T-cell response in the tumor microenvironment directly correlates with patient 
survival324,325. The presence of CD8+ cytotoxic T-cells and Tregs, both found in the 
normal inflammatory response, are found in a skewed ratio that favors a tumor 
supportive immune response324,326. Comparing T-cell levels from CP, there is an overall 
decrease of both CD8+ and CD4+ T-cells from patients with PDA323,327. Tumor 
expression of programmed cell death protein 1 (PD-1)328 represses CD8+ T-cell function 
and is correlated with worse prognosis329. The tumor microenvironment also promotes 
T-cell evasion330 in part due to Treg influence331 and restriction from the tumor by the 
physical barrier of the stroma332. Tregs promote immune tolerance333 though biding of 
cytotoxic T-lymphocyte-associated protein 4 (CTLA4) to suppress antigen presenting 
cells334, among other immunosuppressive roles335. Tregs are elevated in patients with 
PDA336, correlate with worse survival334 and repress proliferation and function of other 
CD4+ and CD8+ T-cells336. Influx of Tregs occur early in the immune response, driven by 
TGF-β1 elevation337,338, suggesting they are a part of the normal wound response but 
their function is maintained or elevated during tumor progression334,339. Other CD4+ T-
cells also contribute to the immunosuppressed microenvironment and are skewed 
toward a Th2 state340, associated with type-II immunity and associated with disease 
progression341,342, supporting tumor growth. 
Tumor associated macrophages (TAM) and myeloid-derived suppressor cells 
(MDSC) are tumor promoting innate immune cells present early in neoplastic 
development that increase during progression156,316,323. TAMs are a unique macrophage 
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population characterized by a mixed M1-M2 phenotype which support tumor growth343 
by maintaining growth factor signaling, as well as suppression of pro-inflammatory 
responses. In PDA, TAM presence is elevated early in neoplastic development with a 
mixed M1-M2 phenotype that is defined by a more M1, or antitumor response344-346. 
With continued disease progression, TAM function is associated with an anti-
inflammatory, or M2, phenotype344 and is correlated with poor patient prognosis347. 
Recruitment of TAMs is promoted by tumor specific release of CCL2, a chemoattractant 
for macrophages344, as well as signaling from the ECM348. TAM function in the tumor 
microenvironment advances tumor progression349, promotes metastasis350-352, ECM 
remodeling and decreases the host cytotoxic T-cell responses directly343,353,354 and by 
inducing Treg immunosuppression353.  
MDSCs are an immature355, heterogeneous population of immunosuppressive 
myeloid cells356,357 present in the tumor microenvironment, chronic infectious diseases 
and other pathological conditions358,359 but not found in the normal pancreas360. They 
are categorized into two subtypes of suppressor cells, monocytic MDSCs (mMDSC) and 
granulocytic MDSCs (gMDSCs)361, which can be identified through flow cytometry using 
the extracellular markers Ly6C and Ly6G362,363, respectively. However, both subtypes of 
MDSCs have immunosuppressive364 functions through inhibiting antigen specific T-cell 
responses365, induced by upregulation of PD-L1 to stimulate cell cycle arrest and self-
tolerant T-cells366 as well as expansion of Tregs367. MDSC development and presence 
is promoted by oncogenic KRAS induced tumor-specific granulocyte-macrophage 
colony-stimulating factor (GM-CSF)365,368 in the neoplastic tissue and is elevated 
through PDA progression156,323,369. PSCs also promote MDSC differentiation using a 
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signal transducer and activator of transcription 3 (STAT3) dependent mechanism368. 
Both TAMs370 and MDSCs371 induce T-cell immunosuppression through multiple ways 
including reactive oxygen species and arginase 1372 and have become promising 
targets for development of novel immune targeted therapies359.  
 
1.18. Key Questions and Summary 
 The function of tuft cells in the pancreaticobiliary system remains unknown in 
pancreatitis, PDA and in the bile duct. However, the presence of metaplastic tuft cells in 
chronic pancreatitis and in PDA suggests a role in the damaged pancreas94,175. 
Research in the intestine finds tuft cell signaling critical during parasitic infections to 
regulate type II immunity through gustatory signaling135,147. As inflammation plays a 
critical role in PDA, with many populations either promoting tumor cytotoxicity or 
enhancing immunosuppression, I tested the hypothesis that metaplastic tuft cells in the 
pancreas can regulate immunity during pancreatic transformation. In Chapter 2, I find 
that germline ablation of the gustatory protein, α-gustducin (GNAT3), present in tuft cells 
throughout the body94,129,373 and required for bitter, sweet and umami detection374, 
promotes PDA progression through increased CXCL1/CXCL2 expression in both ex 
vivo and in vivo systems. In addition, I find increased granulocytic myeloid-derived 
suppressor cells (gMDSC) in the pancreas, suggesting increased immunosuppression, 
and an increase in PDA progression. Additional pilot work with these data, presented in 
Chapter 6, analyze other immune populations and fibroblasts as possible contributors to 
the immunoregulatory role of metaplastic tuft cells. Overall, these data indicate that 
metaplastic tuft cells play a role in PDA progression by inducing immunosuppression. 
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Expansion of the hypothesis presented in Chapter 2 is presented in Chapter 3, 
where preliminary analysis of Gnat3 ablated experimental pancreatitis animals and KPC 
animals suggest differences in healing and progression, respectively. The germline 
ablated Trpm5 mouse model, a gustatory cation channel known to reduce detection of 
bitter, sweet and umami compounds in the tongue375 and abrogation of which 
diminishes parasite detection leading to loss of immune cell activation in the 
intestine147,376, is also utilized to further explore gustatory signaling function in PDA. 
Pilot studies of Trpm5 ablation animals finds only minimal differences in pancreatic 
transformation, requiring further study of the intact of gustatory pathway in the 
pancreas. Chapter 3 also provides preliminary data on the signaling mechanism of 
pancreatic metaplastic tuft cells by identifying possible targets which could be regulating 
immune cell function.  
 Tuft cells in the biliary tract are understudied in the context of their normal 
function and during disease. Biliary diseases are associated with pain, morbidity and 
economic costs; with minimal curative treatments, outside of surgery, for chronic 
conditions115,377. Gustatory signaling in tuft cells may play a role in the context of 
disease initiation and progression by modification of the immune compartment, as found 
during PDA. I hypothesize that ablation of gustatory signaling will alter biliary 
homeostasis in the context of oncogenic mutations. The role of gustatory signaling in 
the KRAS mutant expressing bile duct was studied in Chapter 4, using the Kras;Pdx1Cre 
model, where I found biliary dilation following gustatory ablation. Analysis indicates no 
obvious blockage in the Ampulla of Vater, but an increase in inflammatory cells 
compared to the normal bile duct. This phenotype is further exacerbated by addition of 
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mutant TP53, where a pilot animal study showed extreme bile retention and biliary 
dilation. These data indicate an overall modulatory role for tuft cells in the bile duct 
following acquisition of cancer initiating mutations. 
 Thorough analysis of these animal models finds a clear role for gustatory 
signaling in the pancreaticobiliary tract. The experiments presented here describe, in 
part, an immunomodulatory role for metaplastic tuft cells in the neoplastic pancreas and 
a role for tuft cell homeostasis in the bile duct. These analyses were evaluated with 
proper control animals, at times finding novel animal models which did not reflect 
published literature (Chapter 5). In total, the data in this thesis unveil new insights into 
tuft cell function, broadening the knowledge of tumor heterogeneity and cross-
communication in pancreaticobiliary disease.  
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Chapter 2. The Gustatory G-protein, GNAT3, Slows Pancreatic Cancer 
Progression in Mice1,2 
Introduction 
Pancreatic ductal adenocarcinoma (PDA) is predicted to become the second 
leading cause of cancer death by 2030 if no progress is made to improve its current 
10% 5-year survival rate1,5. Due to nonspecific symptoms, most patients are diagnosed 
at a late stage when treatments, including surgery and chemotherapy, are minimally 
effective7,8. The discovery of novel markers for early stage detection is likely to be 
guided by understanding alterations in the pancreas during PDA tumorigenesis.  
Early cellular transformation, a process called acinar-to-ductal metaplasia (ADM), 
can be induced by pancreatic injury173,378. ADM formation and the development of early 
pancreatic intraepithelial neoplasia (PanIN) are driven by oncogenic KRAS 
mutations72,379, found in >90% of PDA380,381. Additional mutations in tumor suppressor 
genes such as CDKN2A, TRP53 and SMAD4, drive neoplastic progression and 
eventually PDA382,383. Accompanying ADM is a coordinated immune influx that can 
 
1 The data presented in Chapter 2 has been submitted as a manuscript titled “The Gustatory Sensory G-Protein 
GNAT3 Suppresses Pancreatic Cancer Progression in Mice” to be reviewed in the journal Cellular and Molecular 
Gastroenterology and Hepatology fulfilling the requirements of first author publication determined by the Department 
of Molecular and Integrative Physiology at the University of Michigan. 
2 Author list for publication: Megan T. Hoffman1,2, Samantha B. Kemp1,3, Daniel J. Salas-Escabillas1,2, Yaqing 
Zhang1,4, Nina G. Steele1,4,5 Stephanie The6, Daniel Long1,2, Simone Benitz1,2, Wei Yan1,4, Robert F. Margolskee7, 
Filip Bednar1, 4, Marina Pasca di Magliano1,4,5, Hui-Ju Wen1,2 and Howard C. Crawford1,2 
1Rogel Comprehensive Cancer Center, Departments of 2Molecular and Integrative Physiology, 3Pathology, 4 Surgery, 
5Cell and Developmental Biology and 6Computational Medicine and Bioinformatics, University of Michigan, Ann 
Arbor, Michigan; 7Monell Chemical Senses Center, Philadelphia, PA 
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modify or sustain ADM and promote PanIN formation and progression295. This immune 
response is highly immunosuppressive, allowing immune evasion and promoting tumor 
growth384. Multiple immune populations contribute to this immunosuppressive 
microenvironment with the myeloid lineage, in particular, playing a critical role in this 
process384. Two major types of myeloid cells, tumor-associated macrophages (TAM) 
and myeloid-derived suppressor cells (MDSC), promote immune evasion by reducing 
the influx and function of cytotoxic T-cells through multiple mechanisms including 
expression of immune checkpoint ligands384. Both TAMs and MDSCs are present in 
early and late stages of pancreatic lesions and create a barrier for treatment of PDA by 
immune targeted or chemotherapeutic treatments102,323,384.  
ADM and PanIN lesions are composed of a heterogenous population of cell 
subtypes96,385,386, with one unique cell type identified in these lesions as the metaplastic 
tuft cell (MTC)94. Normal tuft cells are solitary chemosensory cells associated with 
sensing and responding to stimuli within the luminal spaces of many hollow organs 
throughout the body, including the bile duct and intestine387. In the intestine and nasal 
cavity, tuft cells can detect pathogens and subsequently signal to nearby cells to mount 
an immune response135,147,149. These sensory and immunomodulatory functions of tuft 
cells require functional gustatory signaling machinery, including transient receptor 
potential cation channel subfamily M member 5 (TRPM5), α-gustducin (GNAT3) and G-
protein coupled taste receptors, all components of the canonical taste sensory 
pathway129,387. The detection of sensory cues through the canonical gustatory pathway 
stimulates apical taste receptors activating GNAT3-dependant calcium efflux and 
subsequent activation of TRPM5 cation channels142. Cell depolarization, driven by 
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cation influx, promotes release of signaling molecules from intracellular stores to 
activate external cell responses, including nerve cell communication and immune cell 
activation129,142. In the normal mouse pancreas, tuft cells are only found in the common 
bile duct that passes through the head of the organ94. However, MTCs are a prominent 
cell type in ADM and PanINs and express TRPM5, GNAT3 and immunomodulatory 
molecules, suggesting they are fully functional and may influence the immune system 
during PDA progression94.  
In our current study, we compromised the chemosensory function of MTCs by 
ablating GNAT3 in complementary models of pancreatic transformation. Surprisingly, 
GNAT3 ablation increased the levels of different chemokines, including CXCL1 and 
CXCL2, in an ex vivo 3D organoid culture model. In vivo, GNAT3 loss in a KRAS-driven 
model of pancreatic neoplasia had no impact on initial transformation but showed 
increased infiltrating granulocytic MDSCs (gMDSC), a subtype of tumor promoting 
MDSC386. In addition, single-cell RNA sequencing revealed an enhanced 
immunosuppressive gene signature in the MDSC population. Increased CXCL1 and 
CXCL2 was found in the GNAT3-ablated neoplastic lesions while CXCR2, their cognate 
receptor, was found primarily expressed in MDSCs. The CXCL1/2-CXCR2 axis is 
known to promote PDA by altering MDSC and neutrophil recruitment and function388,389. 
Consistent with this, pancreatic neoplasia progressed more rapidly to metastatic cancer 
in GNAT3-ablated mice.  
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Results 
2.1. GNAT3 Ablation in KrasG12D-Expressing Epithelial Cells Increases CXCL1 and 
CXCL2 
Normal tuft cell chemosensory signaling drives alteration of the immune 
microenvironment during parasitic and bacterial infection135,147,149, leading us to 
hypothesize that MTCs play a similar immune modulatory role during PDA progression. 
Alpha-gustducin (encoded by the gene Gnat3) is a G protein critical for a gustatory 
response to bitter, sweet and umami stimuli in the taste bud, but is also critical for 
normal tuft cell function149,390. To test the contribution of MTC chemosensory function to 
pancreatic tumor progression, we used a GNAT3 knockout (Gnat3-/-) mouse to 
compromise MTC chemosensation in mouse models of pancreatic neoplasia374. The 
pancreata of Gnat3-/- mice showed no difference in pancreas histology and pancreas-to-
body weight ratios compared to wild type controls (Figure 2.1A). Furthermore, normal 
tuft cell presence in the common bile duct was not different in Gnat3-/- and wild type 
(WT) animals, as assessed by immunohistochemistry (IHC) staining for DCLK1 (double 
cortin-like kinase 1) (Figure 2.1B). Previous work in our lab has found that GNAT3-
expressing MTCs form within ADM and PanIN lesions in the KrasLSL-G12D/+;Ptf1aCre/+ 
(KC) model94. Therefore, in order to study the role of GNAT3 in MTCs in pancreatic 
neoplasia, we used the KC model crossed with Gnat3-/- mice to create the Gnat3-/-;KC 
model (Figure 2.1C).  
Primary acinar cell explants were isolated from 8- to 10-week old KC and Gnat3-/-
;KC mice, when the pancreas is still largely devoid of metaplasia and neoplasia, and 
cultured on a layer of Matrigel in Pancreatic Progenitor and Tumor Organoid Media 
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(PTOM), which is sufficient to drive ADM73,391. As expected, acinar cells underwent 
ADM within two days and could be propagated for several months. MTCs were stained 
in organoids and found after seven days of culture and persisted throughout culture 
duration. In Gnat3-/-;KC cultures we consistently found higher numbers of MTCs, as 
quantitated by Vav1 guanine nucleotide exchange factor (VAV1) staining73, suggesting 
possible compensatory tuft cell genesis when their sensory function is impaired (Figure 
2.1D). In order to assay differential signaling from the epithelial compartment, cytokine 
arrays were performed on 3 biological replicates of KC and Gnat3-/-;KC organoid 
conditioned media post-MTC generation (Figure 2.1E). Expecting that loss of the ability 
to respond to stimuli would lead to a reduction in cytokine release135, we were surprised 
to find that Gnat3-/-;KC media instead showed a consistent increase in 7 cytokines 
(Figure 2.1E). Interestingly, many of these cytokines, including amphiregulin392,393, 
chitinase3-like 1394, CXCL1386,389,395, CXCL2388, CXCL16396,397 and osteoprotegerin398, 
are associated with promoting PDA progression and decreased survival. These data 
suggest that altering the ability of MTCs to respond to environmental cues leads to 
dysregulated release of trophic signals and cytokines that will promote PDA 
progression.  
 
2.2. GNAT3 Ablation Does Not Affect Early Pancreatic Neoplastic Progression  
To explore how loss of MTC chemosensory function affects pancreatic tumor 
development, we crossed Gnat3-/- mice into the inducible KrasLSL-G12D/+;Ptf1aCreERT/+ 
(KCERT) model of pancreatic neoplasia. This model allows for the well-controlled acinar 
cell-specific expression of oncogenic KRAS after tamoxifen treatment in the adult 
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animal (Figure 2.2A)399. To accelerate transformation, we then induced acute 
pancreatitis with supramaximal doses of cerulein, as previously described (Figure 
2.2A)72. In order to determine the optimal timepoint to study the role of MTCs during 
disease progression, pancreata were harvested 1-week and 6-weeks post cerulein 
treatment (Figure 2.2B). While ADM lesions were present at both timepoints, we found 
few MTCs after 1-week of recovery but a large number after 6-weeks of recovery 
(Figure 2.2B). These data, similar to our acinar explants, suggests that generation of 
MTCs does not coincide with ADM itself but requires additional time (Figure 2.2B). 
Therefore, the 6-week timepoint was chosen for further analysis, as MTCs were present 
in the context of widespread transformation. We also characterized known MTC marker 
expression94 and found no differences in Gnat3-/-;KCERT MTCs, with the exception of 
GNAT3 itself (Figure 2.2C).  
Data from our organoid cultures suggested that GNAT3 loss promotes the 
release of pro-tumor cytokines. However, despite GNAT3 ablation, we found no 
apparent differences in early stage pancreatic neoplasia either by histology, pancreas-
to-body weight ratios (a measure of neoplastic burden) or amylase and cytokeratin 19 
(CK19) staining, measures of acinar cell dropout and ADM/PanIN genesis, respectively 
(Figure 2.3A). We found no difference in collagen deposition assessed by picrosirius red 
staining (Figure 2.3B, left). We also found no difference in proliferation by Ki67 staining 
but did observe an overall increase in epithelial cell apoptosis, measured by cleaved 
caspase 3 (CC3) IHC, indicating a difference in epithelial cell turnover (Figure 2.3B, 
middle). We also found an increase in MTC number, marked by DCLK1 staining, in the 
neoplastic lesions, similar to the ex vivo 3D culture model (Figure 2.3B, right). Overall, 
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we conclude that GNAT3 loss does not cause any profound changes in early KRAS-
induced pancreatic transformation. This may be expected from the delayed MTC 
genesis compared to ADM formation. However, MTC hypertrophy and increased 
epithelial cell turnover suggests subtle alterations that may have significant 
consequences later in progression.  
 
2.3. Myeloid-Derived Suppressor Cells are Increased in GNAT3-ablated Mice 
During Pancreatic Transformation 
The immune system plays a critical role in initiation and progression of pancreatic 
disease400. Results from our cytokine array indicate that loss of GNAT3 increases the 
release of cytokines, potentially affecting immune cell recruitment during pancreatic 
transformation. To examine this possibility, KCERT and Gnat3-/-;KCERT tissues were 
analyzed by mass cytometry to assay 16 different stromal and immune cell markers 
simultaneously, optimizing for characterization of immune cell populations401. We found 
no difference in cell number between KCERT and Gnat3-/-;KCERT samples in fibroblasts 
and overall immune cells (Figure 2.4A). We also found no difference in B-cells, total T-
cells or CD4+/CD8+ T-cell populations (Figure 2.4B and C). Macrophages, expressing 
both pro- and anti-inflammatory polarity markers402,403, were labeled tumor-associated 
macrophages (TAM) and were also unchanged (Figure 2.4D). In a previous study, 
compromising tuft cell function lead to a decrease of Natural Killer T-cells (NKT)152, but 
we found no difference in the NKT (NK1.1+CD3+) population between tissues (Figure 
2.4E). Natural killer (NK) cells, marked by NK1.1+CD3-, trended lower in Gnat3-/-;KCERT 
pancreata but this difference did not reach statistical significance (Figure 2.4E). 
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Likewise, overall numbers of non-TAM myeloid cells, including dendritic cells and 
myeloid-derived suppressor cells (MDSC), were not different than control in the GNAT3-
ablated neoplastic pancreas. However, there were significantly greater numbers of 
granulocytic MDSCs (gMDSC), a subset of MDSCs which are known to contribute to an 
immunosuppressive tumor microenvironment and promote PDA progression (Figure 
2.4F)404-406.  
 
2.4. GNAT3 Ablation Alters MDSC Gene Expression in Early Neoplasia 
Finding few differences in immune cell numbers, we then analyzed gene 
expression within the immune population using single-cell RNA sequencing on KCERT 
and Gnat3-/-;KCERT mice 6-weeks post cerulein treatment. We optimized tissue 
processing for recovering and profiling of the immune cell populations, leaving few 
epithelial cells and fibroblasts in the analysis. Using unsupervised clustering and 
Uniform Manifold Approximation and Projection (UMAP) visualization407, we identified 
many distinct cell populations, including multiple T-cell subsets (CD4+ T-cells, CD8+ T-
cells and T-regulatory cells) and fibroblast subsets (iCAF and myCAF), that have been 
previously identified in PDA (Figure 2.5A and B)207,385. Approximately the same number 
of the various cell populations were represented in the KCERT and Gnat3-/-;KCERT data 
sets (Figure 2.5A).  
By comparing gene expression profiles of independent cell populations between 
KCERT and Gnat3-/-;KCERT pancreata, we did not observe distinct expression profiles in 
the macrophage populations (Figure 2.5C). In contrast, MDSCs showed marked gene 
expression changes with 56 genes being significantly altered between KCERT and 
46 
 
Gnat3-/-;KCERT samples (Figure 2.5D). It was not possible to transcriptionally define 
gMDSCs and mMDSCs with the same markers used for mass cytometry, therefore 
gene expression comparisons were done between all tumor infiltrating MDSCs in KCERT 
and Gnat3-/-;KCERT pancreata. Of interest, expression of the C-type lectin receptors, 
Clec12a and Clec4a2 were decreased in the Gnat3-/-;KCERT animals (Figure 2.5E). 
Camp408, Ngp, and Ltf 409, all associated with mature neutrophils, were decreased as 
well as Pglyrp1410 and Lyz2411, known antimicrobial proteins, many associated with 
proinflammatory responses (Figure 2.5E). Furthermore, while Il1b412, a known pro-
inflammatory cytokine, was increased, many other immunomodulatory secreted proteins 
were decreased including Serpinb1a413, Anxa1414, and Anxa3415, suggesting an 
alteration in immune state and function (Figure 2.5E). Together with the previous mass 
cytometry data, single-cell RNA sequencing results suggest that GNAT3 ablation in 
early neoplastic lesions alters both the quantity and quality of the MDSC compartment. 
 
2.5. Epithelial Expression of CXCL1 and CXCL2 Increase Upon GNAT3 Loss 
We have found that ablation of GNAT3 alters MDSC immunomodulatory gene 
expression and increases gMDSC numbers in the neoplastic pancreas as well as 
upregulates CXCL1 and CXCL2, known regulators of MDSC recruitment and 
function386,416, in organoid cultures (Figure 2.1E). CXCL1 and CXCL2 primarily signal 
through CXCR2 on immune cell populations and tumor cells to alter chemokine 
production, survival and immune cell recruitment388,417. Our single-cell RNA sequencing 
data showed Cxcr2 expression localized in the MDSC population, indicating that MDSC 
function would be directly targeted by changes in CXCL1/2 expression (Figure 2.6A). 
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Epithelial expression of Cxcl1 and Cxcl2 in the single-cell sequencing data was not 
informative since the number of epithelial cells were too few to compare. In order to 
characterize CXCL1 and CXCL2 levels in Gnat3-/-;KCERT animals, we used IHC and in 
situ hybridization to examine CXCL1/2 expression in vivo.  
Our results showed that CXCL1 did not differ in stromal cells but was increased 
in neoplastic lesions in Gnat3-/-;KCERT mice, consistent with our ex vivo culture system 
(Figure 2.6B). We next evaluated CXCL2 protein levels in lysates from small fragments 
of pancreatic tissue by ELISA. We found a trend toward higher CXCL2 protein in Gnat3-
/-;KCERT animals (Figure 2.6C), which did not reach statistical significance. Lacking a 
CXCL2 antibody suitable for IHC, we used RNAscope in situ hybridization to detect 
Cxcl2 expression. Cxcl2 transcripts were expressed focally, with some areas showing 
many cells with robust expression and others having virtually none, potentially 
explaining the variability in our ELISA results (Figure 2.6D). Following quantitation of 
Cxcl2 puncta, we found that expression levels were higher in both the stroma and 
neoplastic compartment in Gnat3-/-;KCERT mice (Figure 2.6D). Taken together, our data 
show that tissues from Gnat3-/-;KCERT mice have increased levels of CXCL1 with a 
smaller, but still significant, change in CXCL2 expression, both of which can stimulate 
CXCR2 on MDSCs, consistent with an increase in infiltration of this population.  
 
2.6. GNAT3 Ablation Accelerates Progression to Metastatic Pancreatic Cancer 
Our data suggest that MTC chemosensory signaling does not play a substantial 
role during the onset of pancreatic tumorigenesis but does influences the immune-
suppressive microenvironment. Given the increased pro-tumor gMDSC population in 
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Gnat3-/-;KCERT pancreata through the CXCL1/2-CXCR2 axis, we hypothesized that 
overall tumor progression would be enhanced by GNAT3 ablation. To address the long-
term effects of GNAT3 ablation, we turned to the well-established KC model of 
pancreatic neoplasia. KC and Gnat3-/-;KC mice were aged until moribund with the 
experiment terminated at 52-weeks. Within this time frame, KC mice rarely progress to 
PDA, generally presenting with advanced PanIN lesions and a substantial 
fibroinflammatory stromal reaction80. Consistent with this, only one KC mouse in our 
cohort became moribund before the endpoint of the experiment. In contrast, 30% of 
Gnat3-/-;KC mice became moribund and required sacrifice prior to 52-weeks of age 
(Figure 2.7A). Assessment of pancreatic histology confirmed that 4/12 control KC mice 
had histopathologically detectable focal lesions of early stage adenocarcinoma, 
primarily moderately to well-differentiated with local stroma invasion; while 11/16 Gnat3-
/-;KC mice had progressed to aggressive PDA, with 5 having extensive primary tumor 
mass (Figure 2.7B). Tumor grading indicated that Gnat3-/-;KC animals had more high-
grade tumors, evident in sarcomatoid carcinoma and poorly-differentiated carcinoma in 
3 of the Gnat3-/-;KC mice (Figure 2.7C). Comparing CK19 IHC, a marker of ductal 
transformation, between KC and Gnat3-/-;KC tissue illustrated the difference in histology 
as well as a distinct sarcomatoid tumor in the Gnat3-/-;KC mice, noted by the absence of 
CK19 stain (Figure 2.7D). Finally, 4 Gnat3-/-;KC animals had frank macrometastasis to 
liver or lung upon dissection, marked by CK19 positivity, with none of the KC mice 
showing distant metastatic spread (Figure 2.7E). Analysis of CXCL1 IHC and CXCL2 in 
situ hybridization also showed a trend toward higher levels in Gnat3-/-;KC tissue, with 
staining being more prominent in areas that had progressed to carcinoma (Figure 2.7F 
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and G). Since progression to carcinoma was a more common outcome in the Gnat3-/-
;KC mice, the higher levels of CXCL1/2 may be a secondary effect of the accelerated 
tumor progression. In total, our data suggest that MTC chemosensation serves to limit 
the immune-suppressive microenvironment in part by tempering the expression of 
CXCL1/2, thus slowing PDA progression.  
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Discussion 
Metaplastic tuft cells (MTCs) are present in both human and mouse cancers and 
have been hypothesized to have multiple roles contributing to tumor progression, such 
as a quiescent stem-like population51,418,419 or an immune modulatory sensory cell129. 
Previous studies in our lab identified MTCs in the neoplastic pancreas that expressed 
components of the chemosensory signaling cascade73,94, suggesting that these cells 
can sense and respond to stimuli. In order to assess if MTC chemosensation can drive 
pancreatic tumor progression, we used a KRAS-initiated model of pancreatic neoplasia 
and ablated Gnat3, the gene that encodes α-gustducin, a gustatory pathway G-protein 
expressed specifically in normal tuft cells, MTCs and type II cells of taste buds. To our 
surprise, we found that GNAT3 functions to restrict rather than promote PDA 
progression. 
We found no difference in transformation upon ablation of GNAT3 but did find 
changes in MDSC immune regulatory gene expression as well as a specific increase in 
the infiltration of tumor-promoting gMDSCs386. Further, CXCL1 and CXCL2 expression 
was increased in epithelial cells both in vivo and ex vivo. Together, these data suggest 
that GNAT3, and by extension MTCs, limits the immunosuppressive microenvironment, 
thus slowing PDA progression. Indeed, we found that GNAT3-ablated KC mice 
progressed rapidly to metastatic PDA, indicating a pivotal role of MTC sensory function 
in suppressing PDA progression. 
Upregulation of CXCR2 ligands, such as CXCL1, CXCL2 and CXCL5, in human 
specimens and mouse models of PDA correlate with decreased survival and 
morbidity386,388,389. Functional studies of CXCL1/2 signaling to CXCR2 on MDSCs 
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increases gMDSCs that promote PDA progression by decreasing cytotoxic T-cell 
numbers in the tumor microenvironment386,388,389,395, further demonstrating the 
immunosuppressive role of CXCR2 signaling in MDSCs. Our data show GNAT3 
ablation increases expression of CXCL1/2 by epithelial cells and alters 
immunomodulatory gene expression in Cxcr2-expressing MDSCs, with increased 
infiltrating gMDSC numbers. We found no difference in number and only slight 
differences by gene expression in T-cell response with GNAT3 ablation, possibly 
because of the early stage of lesions analyzed. Our data also finds accelerated tumor 
progression, resulting in advanced tumor grade and metastasis with long term GNAT3 
loss in KC mice, consistent with tumor cell CXCL1/2 activating CXCR2 on MDSCs and 
neutrophils promoting metastatic PDA388,395.  
The ablation of gustatory signaling alters the ability of normal tuft cells to sense-
and-respond to luminal signals129. Loss of sensory signals diminishes secondary 
responses including lack of action potentials in secondary nerves from type II taste cells 
on the tongue30 as well as lack of acetylcholine signaling to promote immune responses 
in the nasal epithelium149,374,420. In the intestine, loss of gustatory signaling prevents 
small intestinal tuft cell hyperplasia and blocks release of IL25 after parasitic infection, 
inhibiting parasite expulsion135,147. Surprisingly, our data show that GNAT3 loss 
increases the release of specific cytokines by epithelial cells within the neoplastic 
pancreas. It is possible that the loss of MTC sensation, through GNAT3 ablation, may 
lead to uncontrolled release of intracellular cargo, directly explaining the increased 
cytokine presence421. However, it seems more likely that this is a secondary effect 
caused by the loss of MTC function acting on surrounding cells, a possibility supported 
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by our observation that CXCL1 and CXCL2 levels are higher in non-MTC epithelia and 
stromal cells in the GNAT3 null background (Figure 2.6B).   
In summary, our data support that MTCs use gustatory signaling to suppress 
PDA progression in part by suppressing the CXCL1/2-CXCR2 immunomodulatory 
signaling axis, though other cytokines may also play a role in this response. This 
suggests the intriguing possibility that stimulation of the bitter/umami taste sensory 
pathway may further suppress PDA progression. Were this stimulation to further limit 
the immune-suppressive microenvironment, it may be an effective method to enhance 
the responsiveness to immune therapies in the treatment of pancreatic cancer. 
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Materials and Methods 
Mice 
All animal procedures and experiments were conducted with approval of the 
Institutional Committee on Use and Care of Animals at the University of Michigan. 
The following mice strains were used: Ptf1aCre/+ and Ptf1aCreERT/+;422 KrasG12D/+ 
(gift of David Tuveson, Cold Spring Harbor Laboratory, NY); and Gnat3-/- (gift of Robert 
Margolskee, Monell Chemical Senses Center, PA).374 Mice were crossed on a mixed 
background to generate Gnat3-/-;KrasG12D/+;Ptf1aCre/+ and Gnat3-/-;KrasG12D/+;Ptf1aCreERT/+ 
mice. All analyses were performed using strain-controlled animals. Analysis of adult 
pancreata were performed using 8- to 52-week old wild type or Gnat3-/- mice. Aged 
KrasG12D/+;Ptf1aCre/+ and Gnat3-/-;KrasG12D/+;Ptf1aCre/+ mice were monitored and 
euthanized at moribund per animal care guidelines. 
Acinar specific KrasG12D/+ recombination was induced in 8- to 12-week old 
KrasG12D/+;Ptf1aCreERT/+ mice by oral gavage with 5 mg of tamoxifen (T5648; Millipore-
Sigma, St. Louis, MO) dissolved in corn oil for 5 days. After a 2-day rest post tamoxifen 
treatment, experimental pancreatitis was induced once a day by intraperitoneal injection 
with 250 µg/kg cerulein (46-1-50; American Peptide company. Inc, Sunnyvale, CA) for 5 
days. Pancreata were harvested either 1- or 6-weeks post cerulein treatment.  
 
Immunohistochemistry and Quantification 
Pancreata were collected, weighed and fixed in Z-fix (NC9050753; Anatech Ltd., 
Battle Creek, MI) overnight. Processing of tissues was performed using a Leica 
ASP300S tissue processor (Buffalo Grove, IL). Sections (4 µm) of paraffin-embedded 
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tissue were stained for target proteins using the Discovery Ultra XT autostainer 
(Ventana Medical Systems Inc., Tucson, AZ). Antibodies were stained as depicted in 
Table 2.1 followed by Mayer’s hematoxylin (NC9220898; Millipore-Sigma) counterstain. 
H&E staining was done using Mayer’s hematoxylin and eosin Y (HT110116; Fisher, 
Pittsburgh, PA). Histopathological quantification of H&E staining was performed by 
pathologists (YZ and WY) on de-identified images using an Olympus BX53F 
microscope (Olympus, Shinjuku City, Tokyo, Japan), as previously described423. 
Macrometastasis presence in the liver and lung was determined by visual inspection 
and confirmed by H&E. Picrosirius red staining was performed on sectioned paraffin-
embedded tissue per manufacturer instructions (Polysciences Inc., Warrington, PA). 
Immunohistochemistry slides were imaged and stitched together by a Pannoramic 
SCAN scanner (Perkin Elmer, Seattle, WA) using a 20x objective lens. Scanned images 
were quantified using Halo software (Indica Labs, Corrales, NM) algorithms to identify 
tissue architecture and separate stroma, neoplasia and acinar compartments for 
analysis. For all quantification, blood vessels, lymph nodes and adipose/connective 
tissue were excluded. 
 
Tissue Immunofluorescence 
Immunofluorescence staining was performed on frozen tissue sections, as 
described previously424. In sum, pancreata were collected and fixed in Z-fix for 2-3 
hours, followed by 30% sucrose in phosphate buffered saline (PBS) overnight. 
Pancreata were equilibrated in a 1:1 mixture of 30% sucrose/PBS and optimal cutting 
temperature embedding medium (OCT) for 30 minutes, embedded in OCT, frozen by 
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liquid nitrogen and stored at -80°C. Frozen tissue sections (10 µm) were acquired using 
a Leica CM1860 (Leica Biosystems, Buffalo Grove, IL) cryostat set at -20°C, 
permeabilized in 0.1% Triton X-100 (T9284; Millipore-Sigma) in PBS for 1 hour and 
blocked by using 5% donkey serum/1% bovine serum albumin (BSA) in PBS for 1 hour. 
Incubation with primary antibody (listed in Table 2.1) was performed overnight at room 
temperature in 0.1% Triton X-100/1% BSA in PBS, followed by 3 washes of 0.1% Triton 
X-100/PBS for a total of 45 minutes. Sections were incubated with Alexa Fluor-
conjugated secondary antibodies at 1:500 and phalloidin at 1:250 (both Invitrogen, 
Carlsbad, CA) for 1-hour room temperature followed by 3 washes as before. Finally, 
slides were rinsed in deionized water and mounted with Prolong Diamond antifade 
mountant (P36961; Fisher). Images were acquired on a LSM800 confocal microscope 
(Zeiss, Oberkochen, Germany) using a 63x objective.  
 
Table 2.1 Immunostaining Antibodies 
Antibody Company Catalog number Dilution Purpose 
DCLK1 Abcam ab37994 1:2000 IHC, IF 
VAV1 Cell Signaling 2502S 1:100 IF 
GNAT3 Abcam ab113664 1:250 IF 
COX1 Santa Cruz sc-1754 1:200 IF 
COX2 Santa Cruz sc-1747 1:200 IF 
Amylase Sigma-Aldrich A8273 1:1000 IHC 
Cytokeratin 19 Abcam ab133496 1:500 IHC 
Ki67 Abcam ab15580 1:1000 IHC 
Cleaved Caspase 3 Cell Signaling 9664L 1:100 IHC 
CXCL1 Abcam ab86436 1:100 IHC 
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Organoid Culture 
Acinar cell isolation from fresh pancreas was performed as previously 
described28. Briefly, pancreata from 8- to 10-week old mice were sterilely harvested, 
washed twice in Hank’s buffered salt solution (HBSS), minced and digested in 0.2 
mg/mL Collagenase P (11249002001; Millipore-Sigma) for 15 minutes at 37°C. Tissue 
was washed 3 times in 5% fetal bovine serum (FBS) in HBSS, centrifuged at 300xg for 
2 minutes, re-suspended in HBSS and filtered through 500 µm and 105 µm 
polypropylene mesh (888-13570 and 888-13597; Spectrum Laboratories, New 
Brunswick, NJ). Cell suspension was slowly added to a gradient consisting of 30% FBS 
in HBSS and centrifuged at 300xg for 2 minutes. Cells were resuspended in Pancreatic 
Progenitor and Tumor Organoid Media (PTOM), made as previously described with 100 
U/mL Pen Strep (15140122; Invitrogen), 1% B27 supplement (17504044; Invitrogen), 50 
µg/mL ascorbic acid (A4403; Millipore-Sigma), 0.4% bovine pituitary extract (13028-014; 
Thermo Fisher, Waltham, MA), 10 µg/mL insulin (I2643; Millipore-Sigma), 0.5 µg/mL 
hydrocortisone (H0888; Millipore-Sigma), 5 ng/mL FGF-2 (F0291; Millipore-Sigma), 10 
ng/mL FGF-10 (345-FG; R&D Systems, Minneapolis, MN), 25 nM retinoic acid (R2625, 
Millipore-Sigma) and 5 µM Y-27632 (50-175-996; Fisher) in DMEM:Glutamax (10564-
011; Thermo Fisher)391. Acinar cells were floated in a petri dish for 2 hours in PTOM 
then 10,000 to 12,500 cells were plated in a PTOM 5% Matrigel mixture on a bed of 
100% Matrigel in a 24-well plate. Media was changed to fresh PTOM every 4 days. 
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Organoid Culture Immunofluorescence and Counting 
Organoids were fixed and stained using a modified protocol from previously 
described425. In sum, following a PBS wash, the organoids were fixed in Z-fix for 15 
minutes, washed twice in PBS and permeabilized in 0.5% Triton X-100/PBS for 1 hour. 
Following a second wash, organoids were blocked in 10% FBS/1% BSA in PBS for 1 
hour and then incubated with the primary antibody (VAV1, as in Table 2.1) in 1% 
FBS/1% BSA in PBS overnight at 4°C. Organoids were washed 3 times in 1% FBS/1% 
BSA/PBS for a total of 45 minutes then incubated with an Alexa Flour-conjugated 
secondary antibody at 1:500 and phalloidin at 1:250 (both Invitrogen) in 1% FBS/1% 
BSA/PBS for 2 hours. Organoids were washed for 30 minutes in 3 changes of PBS, 
carefully removed intact from their 24 well plates and mounted on a slide with Prolong 
Diamond antifade mountant (P36961; Fisher). Finally, the slides were compressed 
overnight at room temperature. The number of organoids and number of tuft cells per 
organoid per well were counted per slide using an Olympus IX83 Inverted Microscope 
(Olympus). Each biological sample had between 3 and 6 wells counted, with a minimum 
of 77 and up to 165 organoids counted per sample. Organoid cultures were collected at 
35, 26 and 20 days post acinar plating.  
 
Cytokine Array 
Conditioned media were collected from KC and Gnat3-/-;KC organoid cultures, 
pooled from 6 wells, centrifuged at 5,000 RPM for 15 minutes to remove debris and 
stored at -80°C for later analysis using the Mouse XL Cytokine Array Kit (ARY028, R&D 
Systems, Minneapolis, MN) per manufacturer instructions. The biological triplicate data 
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in Figure 2.1E was carried out by using conditioned media collected at day 32 (for 2 
repeats) and day 20 (for 1 repeat). Briefly, membranes were washed with Array Buffer 6 
for 1 hour then 560 µl or 630 µl conditioned media was added, plus array buffer mix, to 
membranes and incubated overnight at 4°C. Membranes were washed 3 times for a 
total of 30 minutes in 1X Wash Buffer before adding Detection Antibody Cocktail in the 
array buffer mix for a one hour incubation. Washing was repeated then Streptavidin-
HRP was incubated for 30 minutes following by washing and incubation with the 
ChemiReagent Mix. The chemiluminescent signal on the membranes was detected and 
analyzed by the Bio-Rad ChemiDoc™ Imaging System and Bio-Rad image Lab™ 
software Version 6.0.1, respectively (Bio-Rad Laboratories, Hercules, California). The 
volume tool was used to make a 1.4 mm2 circle around each antibody detected spot to 
acquire the pixel density means of each dot, subtracted from a blank image area. The 
pixel density means were imported into Microsoft Excel 2016, subtracted from the blank 
signal and each duplicate spotted pair was averaged to get a final value. The 
corresponding signals were then obtained by normalizing the pixel density of Gnat3-/-
;KC with KC.  
 
Mass Cytometry Immune Phenotyping 
Mouse pancreata were collected, minced, washed in PBS then digested using 1 
mg/mL of collagenase type V (C9263; Millipore-Sigma) in Roswell Park Memorial 
Institute (RPMI) medium at 37°C with gentle shaking for 15 minutes. Samples were 
washed with 10% FBS/RPMI 3 times then filtered through 500 µm, 105 µm (888-13570 
and 888-13597; Spectrum Laboratories) and 40 µm filters (22-363-547; Fisher) to obtain 
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single cells. Isolated single cells were prepared for mass cytometry according to 
manufacturer’s instructions, as previously described426. Briefly, single cell suspensions 
were washed twice with MaxPar® PBS (201058; Fluidigm, San Francisco, CA) prior to 
Cell-IDTM Cisplatin Live/Dead staining (201194; Fluidigm). Cell-IDTM Cisplatin reagent 
(1.67µM) was incubated for 5 minutes and quenched by adding 4mL of MaxPar® Cell 
Staining Buffer (201068; Fluidigm) followed by centrifugation at 300xg for 5 minutes. 
Supernatant removal was followed by a 2 mL wash of MaxPar® Cell Staining Buffer. Up 
to 3 million cells per sample were stained with cell surface antibody cocktail (all 
antibodies from Fluidigm in Table 2.2) in 100 µl volume of MaxPar® Cell Staining Buffer 
for 30 minutes followed by 2 washes in MaxPar® Cell Staining Buffer. Cell fixation was 
achieved by addition of freshly prepared 1.6% methanol-free formaldehyde (28906; 
Thermo Fisher) in MaxPar® PBS for 10 minutes. After fixation, samples were washed 
once with MaxPar® Cell Staining Buffer, incubated with MaxPar® Nuclear Antigen 
Staining Buffer (201063; Fluidigm) for 15 minutes, washed twice with MaxPar® Nuclear 
Antigen Staining Perm (201063; Fluidigm) then an intracellular antibody (FoxP3, in 
Table 2.2) was added for a 30-minute incubation. After a wash in MaxPar® Nuclear 
Antigen Staining Perm and a wash in 2mL MaxPar® Cell Staining Buffer, cells were re-
suspended in 2mL of 125 nM Cell-ID™ Intercalator-Ir (201192B; Fluidigm) solution in 
MaxPar® Fix and Perm Buffer (201067; Fluidigm). Fixed and stained cells were run for 
data acquisition by the CyTOF2 Mass Cytometer at the Flow Cytometry Cores at the 
University of Rochester Medical Center or the Indiana University Simon Cancer.  
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Table 2.2 Mass Cytometry Antibodies 
 
Mass Cytometry Data Preprocessing and Analysis 
Data was obtained from 7 independent sample collections with each experiment 
performed using pancreata from Gnat3-/-;KCERT accompanied by KCERT for comparison. 
Analysis of normalized FCS files was performed using the Premium CytoBank Software 
(cytobank.org). Data were assessed for staining quality, normalized by internal bead 
standards and then live singlet cell events identified by the combination of Ir191 DNA 
Intercalator, Event Length, and Pt195 Cisplatin staining. Filtered live single cells were 
exported as new FCS files for further analysis using FCS express 7 cytometry software 
(De Novo Software, Pasadena, CA). In order to avoid batch effects within the data 
analysis, each batch of KCERT and Gnat3-/-;KCERT pancreata were analyzed separately, 
and then comparisons were done using cell frequencies.  
 
 
Antibody Label Dilution Clone 
CD140a 148Nd 1:100 APA5 
CD31 (PECAM-1) 165Ho 1:100 390 
CD45 089Y 1:200 30-F11 
CD19 149Sm 1:200 6D5 
CD161 (NK1.1) 170Er 1:100 PK136 
CD3e 152Sm 1:100 145-2C11 
CD4 145Nd 1:200 RM4-5 
CD8a 168Er 1:200 53-6.7 
FoxP3 158Gd 1:100 FJK-16s 
TCRγδ 159Tb 1:100 GL3 
CD11b (Mac-1) 143Nd 1:300 M1/70 
CD11c 209Bi 1:100 N418 
F4/80 146Nd 1:100 BM8 
CD206 (MMR) 169Tm 1:200 C068C2 
Ly-6G 141Pr 1:400 1A8 
Ly-6C 150Nd 1:400 HK1.4 
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Single-Cell RNA Sequencing and Analysis  
Single-cell RNA sequencing was performed in duplicate. Each experiment 
included KCERT and Gnat3-/-;KCERT pancreata. To obtain a single cell suspension, 
pancreas tissue was mechanically and chemically digested as detailed above for the 
mass cytometry analysis. Dead cells were excluded using MACS® Dead Cell Removal 
Kit (130-090-101; Miltenyi Biotec Inc., Bergisch Gladbach, Germany). The 10X 
Genomics Platform at the University of Michigan Advanced Genomics Core was used 
for single-cell cDNA library preparation and sequencing. Samples were sequenced 
using paired-end 50 cycle reads on HiSeq 4000 (first two samples) or the NovaSeq 
6000 (second two samples) (Illumina, San Diego, CA) to a depth of 100,000 reads. Raw 
data were then processed, aligned, and filtered using the default setting of Cellranger 
version 3.0 at the University of Michigan Advanced Genomics Core. R package, Seurat 
version 3.0 (http://www.satijalab.org/seurat) was used for analysis427. Downstream 
analysis was performed as previously described401. Briefly, data were filtered to include 
cells with at least 100 genes and genes identified in greater than 3 cells. Data were then 
normalized using the NormalizeData function with a scale factor of 10,000 and the 
LogNormalize normalization method. Variable genes in the data set were identified 
using FindVariableFeatures function then the data were then scaled and centered using 
linear regression on the counts. Principal Component Analysis (PCA) was run using 
RunPCA function on the variable genes identified. Batch correction was performed 
using the R package Harmony (https://github.com/immunogenomics/harmony)428. 
FindNeighbors and FindClusters at a resolution of 1.2-2.0 were used to identify cell 
clusters. Cell clusters were visualized using Uniform Manifold Approximation and 
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Projection (UMAP) algorithms. To define cell clusters, FindAllMarkers table was 
generated and user-defined criteria were used for final cell population definitions. 
Differentially expressed gene heatmaps were manually annotated to remove B-cell and 
acinar contamination. 
 
CXCL2 ELISA 
Tissues were collected fresh from the head, body and tail of the pancreas, 
immediately frozen in liquid nitrogen and stored at -80°C. To acquire lysate, tissue was 
added to a metal bead and was homogenized in RIPA lysis buffer supplemented with 
protease inhibitor cocktail (PIA32965; Thermo Fisher Scientific) and PhosSTOP 
phosphatase inhibitor cocktail (4906845001; Millipore-Sigma) by using the TissueLyser 
LT (Qiagen, Hilden, Germany) for 3 minutes at 50 oscillations per second. The 
homogenate was collected and samples were centrifuged at 12,700 RPM for 20 
minutes at 4°C to remove debris. Supernatant was transferred into a new tube and 
protein concentration was determined by BCA assay (23227; Thermo Fisher). 
Quantikine ELISA for CXCL2 (MM200; R&D Systems) was performed according to the 
manufacturers protocol. Briefly, 120 µg of protein per well were added in duplicate to the 
Quantikine ELISA, using Calibrator Diluent to standardize volume to 50 µl. Following 
washing, addition of CXCL2 detecting horseradish peroxidase conjugated secondary, 
washing and then reaction solution, samples were measured at 450 nm with a 
wavelength correction of 540 nm. A standard curve was used to determine the 
concentration of CXCL2 per protein lysate with duplicate samples levels averaged. 
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Head, body and tail samples from each pancreas were also averaged for the resulting 
CXCL2 levels per each mouse. 
 
In situ hybridization 
Pancreatic tissues were fixed overnight in Z-fix, embedded in paraffin and 
sectioned as detailed above. In situ hybridizations were performed with the colorimetric 
RNAScope® 2.5 HD Reagent Kit - RED (322350; Advanced Cell Diagnostics Inc. 
(ACD), Newark, CA) according to the manufacturer’s protocol for mCxcl2 (437581; 
ACD), Negative Control Probe DapB (310043; ACD), and Positive Control Probe Mm-
Ppib (313911; ACD). Briefly, paraffin embedded sections were baked for one hour at 
55°C prior to staining. Slides were then deparaffinized with Histoclear® and treated with 
hydrogen peroxide for 10 minutes at room temperature. Target retrieval was performed 
in a steamer for 15 minutes, and then the slides were treated with the ProteasePlus® 
solution for 15 minutes at 40°C. Following this, the probe hybridized for two hours at 
40°C and the signal was amplified using the AMP materials provided in the RNAScope® 
2.5 HD Reagent Kit - RED. The signal was developed using reagent A and reagent B at 
a 1:60 ratio. Once completed, the samples were counterstained with Mayer’s 
hematoxylin, dried for 15 minutes at 60°C and mounted with Cytoseal®. 
 
Statistics 
All statistics were analyzed using GraphPad Prism 8.4.0 (San Diego, CA). 
Statistics for comparing 2 groups was done by unpaired Student t tests, except for the 
mass cytometry data where the Mann Whitney test for non-parametric samples was 
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corrected for multiple comparisons by the Benjamini-Hochberg approach429. For all 
single-cell RNA sequencing data statistical significance was determined using the non-
parametric Wilcoxon rank sum test with Bonferroni corrected P values. Kaplan-meier 
curve statistics were calculated by the log-rank (Mantel-Cox) test. P < 0.05 and P adj. < 
0.05 were considered statistically significant. P values and P adj. values are listed for all 
with ns = no significance.  
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Figures 
Figure 2.1 
 
Figure 2.1: Gnat3 ablation increases epithelial cytokine release in an ex vivo organoid culture model. (A) 
Analysis of wild type (WT) or Gnat3-/- adult pancreata by H&E, including magnified inset from box, and pancreas to 
body weight ratios (n = 11; 18). Scale bar: 2000 µm, inset = 50 µm. (B) IHC for DCLK1 to mark metaplastic tuft cells 
(MTC) on WT or Gnat3-/- common biliary ducts. Magnified inset indicated in black box in bottom right. Scale bar: 50 
µm, inset = 10 µm. (C) Genetic strategy to generate KrasG12D/+;Ptf1aCre/+ (KC) mice with Gnat3 ablation (Gnat3-/-;KC). 
(D) 3D organoid culture analysis of KC and Gnat3-/-;KC transdifferentiated acinar cells. Phalloidin (red) highlights the 
structure of individual 3D organoids (white dotted outline) stained for VAV1 (green) to mark MTC and DAPI (blue) to 
mark nuclei. White box denotes inset image in bottom right of VAV1 positive MTC with tufts marked by phalloidin. 
MTC numbers were determined from an average of 130 organoids per sample (n = 4). Scale bar: 20 µm, inset = 5 
µm. (E) Cytokine proteomic analysis of conditioned media derived from KC and Gnat3-/-;KC organoids. 
Representative cytokine array blot (left) and quantitation (right) shows 7 differentially expressed proteins (numbered). 
Differential protein levels from Gnat3-/-;KC (blue bars) were normalized by KC (green line) (n = 3). R = Reference 
points, 1 = Amphiregulin, 2 = Chitinase 2-like 1, 3 = CXCL1, 4 = CXCL2, 5 = CXCL16, 6 = Osteoprotegerin, 7 = 
WISP1. Significance was calculated using an unpaired t test; P < 0.05 statistically significant.   
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Figure 2.2 
 
Figure 2.2: Metaplastic tuft cells are present 6 weeks post injury and Gnat3 ablated cells maintain tuft marker 
expression. (A) Genetic strategy to generate KrasG12D/+;Ptf1aCreERT/+ (KCERT) mice with Gnat3 ablation (Gnat3-/-
;KCERT). Schematic of tamoxifen (TMX) treatment to induce KrasG12D/+ expression in the acinar compartment, 
followed by cerulein (CER) to promote inflammation and harvest of pancreas at 1- or 6-weeks. (B) H&E and IHC for 
DCLK1 to mark MTC from pancreata harvested from KCERT mice 1- or 6-weeks post cerulein. Quantitation of DCLK1 
positive MTC from neoplastic area in 1- or 6-week tissue (n = 3; 8). Scale bar: 100 µm. (C) Staining from 6-week post 
injury KCERT and Gnat3-/-;KCERT pancreatic tissues for known MTC markers: GNAT3, DCLK1, COX1, COX2 and 
VAV1 (all green), counterstained by phalloidin (red) to mark the luminal tufts and DAPI (blue) to label nuclei. Scale 
bars: 5 µm. Significance was calculated using an unpaired t test; P < 0.05 statistically significant. 
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Figure 2.3 
 
Figure 2.3: Gnat3 ablation has no effect on pancreatic neoplasia formation. Analysis of tamoxifen and cerulein 
treated KCERT and Gnat3-/-;KCERT pancreata harvested 6-weeks post cerulein treatment. (A) H&E staining with 
pancreas-to-body weight ratios below (n = 27; 35). IHC for amylase (n = 10; 13) and cytokeratin 19 (CK19) (n = 10; 
12) quantified below by total positive area from total pancreas area. Scale bars: 1000 µm. (B) Staining for picrosirius 
red (n = 9; 17), Ki67 and cleaved caspase 3 (CC3) (n = 6; 8), and DCLK1 (n = 8) with quantification below for each. 
Scale bars: 100 µm. Significance was calculated using an unpaired t test; P < 0.05 statistically significant. 
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Figure 2.4 
 
Figure 2.4: GNAT3 loss increases gMDSC presence during pancreatic transformation. Manually gated mass 
cytometry data from tamoxifen and cerulein treated KCERT and Gnat3-/-;KCERT pancreata harvested 6-weeks post 
cerulein treatment (n = 10). (A) Percentage of fibroblasts (CD140a+) or total immune cells (CD45+) from total cell 
numbers. (B) T-Cells (CD45+CD3+) as a percentage of total immune cells. Percent of CD4+ T-cells 
(CD45+CD3+CD4+) and CD8+ T-cells (CD45+CD3+CD8+) from T-cells. (C) B-cells (CD45+CD19+) as a percent of total 
immune cells. (D) Percent of tumor-associated macrophages (TAM) (CD45+CD11b+F4/80+) from total immune cells. 
TAM phenotypes were characterized by anti-inflammatory TAM (CD45+CD11b+F4/80+CD206+) and pro-inflammatory 
TAM (CD45+CD11b+F4/80+CD11c+ or Ly6C+) as a percent of TAM. (E) Natural killer (NK) family (CD45+NK1.1+) split 
into NK T-cells (CD45+NK1.1+CD3+) and NK cells (CD45+NK1.1+CD3-) as a percent of total immune cells. (F) Non-
TAM myeloid cells (CD45+CD11b+F480-) were determined as a percent of total immune cells. Myeloid-derived 
suppressor cells (MDSC) were separated into monocytic (mMDSC) (CD45+CD11b+F4/80-Ly6G-Ly6C+) or granulocytic 
(gMDSC) (CD45+CD11b+F4/80-Ly6G+Ly6C+) populations as a percent of non-TAM myeloid cells. Significance was 
calculated using the Mann-Whitney non-parametric test with the Benjamini-Hochberg correction for multiple 
comparisons. P adj. < 0.05 statistically significant. 
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Figure 2.5 
 
Figure 2.5: Single-cell RNA transcriptomic analysis identifies altered MDSC gene expression in Gnat3 ablated 
neoplasia. Analysis of tamoxifen and cerulein treated KCERT and Gnat3-/-;KCERT single-cell RNA transcriptomes from 
pancreata collected 6-weeks post cerulein treatment. (A) Unbiased clustering of single cells driven by transcriptome 
differences and visualized by UMAP (n = 2; 2). (B) Dot plot of gene expression patterns used to identify cell 
populations from pooled KCERT and Gnat3-/-;KCERT cells. Percent of cells expressing each gene per cluster noted by 
dot size. Average gene expression is represented by color of dot. Abbreviations: T regulatory cells (T-reg), tumor-
associated macrophages (TAM), myeloid-derived suppressor cells (MDSC), inflammatory cancer associated 
fibroblasts (iCAF) and myofibroblastic cancer associated fibroblasts (myCAF). (C and D) Heatmap of single-cell RNA 
transcriptomes for TAMs (C) and MDSCs (D) displaying the statistically significant differentially expressed genes 
(rows). Selected genes identified on right of MDSC heatmap. (E) Violin plots displaying the frequency and expression 
levels of selected genes from cells in the MDSC cluster. Genes labeled by group: C-type lectin receptors (Clec12a, 
Clec4a2), neutrophil granule proteins (Camp, Ngp, Ltf), anti-microbial proteins (Pglyrp1, Lyz2) and secreted proteins 
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(Il1b, Serpinb1a, Anxa1, Anxa3). Significance was calculated using Bonferroni adjusted P values from the non-
parametric Wilcoxon rank sum test. P adj. < 0.05 statistically significant. 
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Figure 2.6 
 
Figure 2.6: Gnat3 ablation increases CXCL1 and CXCL2 expression in the neoplastic epithelial compartment. 
Analysis of tamoxifen and cerulein treated KCERT and Gnat3-/-;KCERT pancreata collected 6-weeks post cerulein 
treatment. (A) UMAP of Cxcr2 single-cell RNA transcriptome expression from KCERT and Gnat3-/-;KCERT cells. 
Myeloid-derived suppressor cell (MDSC) cluster circled. Color scale denotes expression level. (B) IHC for CXCL1 
quantified from positive area of stroma or neoplasia area (n = 4). Scale bar: 50 µm. (C) CXCL2 protein levels 
measured by ELISA from pancreas lysate (n = 3; 4). (D) In situ hybridization for Cxcl2 transcript quantified by positive 
puncta area (red) of stroma or neoplasia area (n = 3). Inset boxes are magnified area. Scale bar: 50 µm, inset = 5 
µm. Significance was calculated using an unpaired t test; P < 0.05 statistically significant.  
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Figure 2.7 
 
Figure 2.7: Ablation of Gnat3 increases PDA genesis, grade and metastasis. Analysis of KC and Gnat3-/-;KC 
mice aged to moribund or 52 weeks. (A) Kaplan-meier survival curve, with endpoint of study indicated by black line at 
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52 weeks (n = 12; 17). (B and C) H&E analysis of tissues to determine number of mice with carcinoma (n = 12; 16) 
(B) and grading of carcinoma samples (poor, moderate or well) (n = 4; 11) (C). (D) H&E and IHC for cytokeratin 19 
(CK19). Inset boxes are magnified area. Scale bar: full pancreas = 2000 µm, inset = 100 µm. (E) IHC for CK19 on KC 
or Gnat3-/-;KC lung and liver (black dashed line) and quantification of mice with macrometastasis (n = 12; 16). Scale 
bar: 2000 µm. (F) IHC for CXCL1 on KC or Gnat3-/-;KC pancreas quantified by positive stain from total pancreas area 
(n = 6; 7). Scale bar: 100 µm. (G) In situ hybridization for Cxcl2 transcript quantified by positive puncta area (red) of 
total pancreas area from KC or Gnat3-/-;KC pancreata (n = 7,7). Scale bar: 50 µm. Significance was calculated using 
the log-rank (Mantel-Cox) test and unpaired t tests; P < 0.05 statistically significant.  
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Chapter 3. Additional Data Exploring Tuft Cell Gustatory Signaling in 
the Pancreas 
Introduction 
Chronic pancreatitis (CP) and pancreatic ductal adenocarcinoma (PDA) are 
pancreatic disorders with poor prognosis and minimal treatment options1,18,165,176. 
Pancreatitis, both acute and chronic forms, is one of the most commonly diagnosed 
gastrointestinal diseases165, with more than 2 billion dollars spent annually on treatment 
options430. Pain associated with pancreatitis reduces quality of life with minimal 
treatments or symptom management163,164. CP is also a risk factor for PDA27,171,172, 
where survival rates are only 10% over 5 years1. Understanding the novel biology of 
both CP and PDA are critical for development of novel therapies to improve quality of 
life and extend survival. 
Establishment of CP and PDA is associated with loss of normal pancreas tissue27 
and presence of a desmoplastic reaction characterized by increased stromal 
deposition64 and immune influx22,61,170. The acinar population, following damage to the 
pancreas, will undergo acinar-to-ductal metaplasia (ADM) in a wound healing cycle to 
repopulate following injury resolution173,174. ADM is sustained in CP173,174 and during 
PDA genesis41,378 but with progression of disease, undergoes a transition to more 
disorganized structures, termed pancreatic intraepithelial neoplasia (PanIN), and 
carcinoma54. Advancement to PDA is also characterized by an increase in pancreatic 
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fibrosis64 and an immune suppressed microenvironment317. Immune cell signaling in 
PDA promotes immune suppression295, through modulation of immune cell populations, 
including T regulatory cells336, tumor-associated macrophages (TAM)349, and myeloid-
derived suppressor cells (MDSC)365, in the tumor microenvironment to sustain tumor 
immune evasion and growth by repressing the anti-tumor immune response317,318. 
Neoplastic lesion development in CP and PDA is composed of a heterogenous 
population of cells94,175,431. A unique chemosensory cell type found in multiple organs 
are tuft cells129. Tuft cells are not present in the normal pancreatic epithelium but are 
metaplastic tuft cells (MTC), derived from transdifferentiated acinar cells following injury 
in CP175 and PDA94. These sensory cells detect compounds on the luminal surface and 
transmit this information to downstream signaling pathways, including nerves146,149, 
muscle fibers432 and immune cells135,147, eliciting a host response. Interestingly, this 
detection relies on the gustatory signaling pathway, known to detect bitter, sweet, and 
umami molecules on the tongue143 or succinate in the intestine148. Canonical gustatory 
signaling initiates by compound detection through G-protein coupled receptors (GPCR) 
on the luminal surface which conformationally activate associated Gα-gustducin 
(Gnat3), Gβ and Gγ proteins in the cytoplasm140. G-protein activation stimulates 
phospholipase Cβ2 signaling to mobilize intracellular calcium, activating the transient 
receptor potential cation channel subfamily M member 5 (TRPM5) non-specific cation 
channels opening and cell depolarization, inducing signal molecule release140,142,143. 
Though tuft cells use a central signaling pathway for luminal sensing143, the 
signaling molecules differ depending on the function and organ. In the tongue, the main 
signaling molecule is ATP which is released through calcium homeostasis modulator 1 
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(CALHM1) channels activating associated nerve fibers that will transmit taste 
information to the brain146. However, tuft cell gustatory signaling in nose and trachea 
stimulates release of acetylcholine (ACh) to communicate with nerves149 or muscle 
fibers432 promoting immune influx or inducing breathing responses, respectively. 
Intestinal tuft cells are directly activated by parasitic succinate release binding to the 
succinate receptor 1 (SUCNR1), transmitting signals by the activation of TRPM5 cation 
channels and inducing the release of interleukin-25 (IL-25)135,147. IL-25 then promotes a 
type-2 immune response through recruitment of innate lymphoid cells type 2 (ILC2), 
expressing interleukin-13 (IL-13), inducing tuft cell hyperplasia and parasite 
clearance135,147. Expression of gustatory signaling molecules in MTCs in CP and PDA 
indicate use of canonical signaling during damage and neoplastic states94,175. However, 
it is still unknown what compounds are released and what cell type is being activated 
due to MTC signaling.  
Gustatory signaling in MTCs during PDA development was explored in Chapter 
2, where ablation of GNAT3 increased CXCL1 and CXCL2 expression, increased the 
number and polarization of MDSCs leading to advanced, metastatic carcinoma. In this 
chapter, continued analysis of MTC gustatory signaling through GNAT3 or TRPM5, the 
cation channel promoting MTC depolarization, ablation in the context of pancreatitis 
models and PDA was performed, the results of which will be described to supplement 
and expand upon the findings detailed in Chapter 2. Analysis of cerulein-induced 
damage with gustatory pathway ablation finds no difference in histology during damage 
recovery, though GNAT3 ablation may have more subtle differences to be explored. 
Analysis of GNAT3 or TRPM5 ablation in the context of neoplasia or rapid 
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tumorigenesis show interesting trends compared to control animals and suggests use of 
canonical gustatory signaling in the pancreas. Organoid culture was validated for MTC 
presence in both human and mouse culture and MTC signaling altered macrophage 
polarization found minimal differences with GNAT3 or TRPM5 loss, similar to the results 
from the single-cell RNA sequencing data (Figure 2.5C). Preliminary data analyzing 
MTC function, suggests potential roles for the direct release of ATP, ACh and CXCL1 in 
altering the tumor microenvironment. Analysis of Chapter 2 and the data presented 
here, indicate a role for canonical gustatory signaling promoting release of compounds, 
including CXCL1, directly participating in myeloid-derived suppressor cells (MDSC) 
immunosuppression and tumor progression. 
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Results 
3.1. Gustatory Ablation Does Not Alter Cerulein Associated Damage or Resolution 
Chronic pancreatitis (CP) is characterized by irreversible damage to the 
pancreas163,164 and is a risk factor for PDA27,171,172. Metaplastic tuft cells (MTC) are 
found derived from transdifferentiated acinar cells in the pancreas during pancreatitis 
but no clear indication as to their role in this disease175. In order to analyze MTC roles in 
pancreatitis, we verified the presence of tuft cells following experimental treatment with 
cerulein two times per day for either two or three weeks, as previously described (Figure 
3.1A)424. Analysis of these tissues showed increased numbers of tuft cells following 
longer cerulein treatment duration, in agreement with published data (Figure 3.1A)175. 
Gustatory signaling proteins, α-gustducin (GNAT3) or transient receptor potential cation 
channel subfamily M member 5 (TRPM5), are found in tuft cells throughout the body433 
and can be tracked with the use of transgenic reporter mice. Expression of enhanced 
green fluorescent protein (EGFP)140,434 is driven by bacterial artificial chromosome 
(BAC) derived promoter sequences for either Gnat3 or Trpm5 and inserted into animals 
generating Gnat3EGFP or Trpm5EGFP expressing mice, where Gnat3EGFP expression only 
marks a subset of tuft cells (Figure 3.1B)148. Therefore, gustatory ablation models of 
either GNAT3 ablation (Gnat3-/-) or TRPM5 ablation (Trpm5-/-) were used to analyze 
three weeks of cerulein induced damage and three different timepoints of recovery post 
pancreatitis treatment (Figure 3.1C). 
Histological analysis of GNAT3-ablated mice compared to controls found no 
noticeable difference in damage following cerulein cessation by either H&E, tuft cell 
presence by DCLK1 staining or pancreas-to-body weight ratios (Figure 3.1D). During 
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recovery, histologically there was no difference by H&E or tuft cell presence, but there 
was an increase in the pancreas-to-body weight ratio of Gnat3-/- pancreata seven days 
post cerulein treatment (Figure 3.1D). This suggests subtle differences in recovery post 
cerulein which require further analysis to understand. Ablation of TRPM5, though a 
more ubiquitous marker of tuft cells, showed no difference in histology or pancreas-to-
body weight ratios (Figure 3.1E), potentially indicating a difference in MTC gustatory 
signaling during pancreatitis. MTCs in pancreatitis appear over time in the metaplastic 
lesions1, indicating their role may require long-term treatment and establishment of MTC 
presence to understand gustatory function.  
 
3.2. Continued Analysis of GNAT3 ablation 
Analysis of gustatory function, described in Chapter 2, uncovered a tumor 
suppressive role for GNAT3 signaling to reduce CXCL1 expression and 
immunosuppression during tumorigenesis. Aging of the Gnat3-/-;KrasG12D/+;Ptf1aCre/+ 
(Gnat3-/-;KC) model of carcinogenesis found increased mortality and tumor progression 
between 40 and 52-weeks of age (Figure 2.7). Therefore, we analyzed earlier time 
points to explore histological changes and CXCL1 levels occurring before 
carcinogenesis. Analysis of 16- or 24-week aged KC or Gnat3-/-;KC animals uncovered 
no difference in histology, CXCL1 levels or pancreas-to-body weight ratios (Figure 
3.2A), suggesting subtle differences in GNAT3 ablation contributing to the long-term 
phenotype requiring quantitation and further analysis.  
Functional analysis of GNAT3 ablation during neoplastic formation in Chapter 2 
was performed in the acinar specific, tamoxifen inducible model of carcinogenesis. Use 
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of the KrasG12D/+;Ptf1aCreERT/+ (KCERT), tamoxifen- and cerulein-treated model only 
explored differences during neoplasia formation (Figure 2.3A) with long-term aging 
performed using the KC model of carcinogenesis (Figure 2.7). Therefore, KCERT and 
Gnat3-/-;KCERT mice were aged to 52 weeks post tamoxifen- and cerulein-treatment to 
analyze tumorigenesis. My analysis of pancreas-to-body weight ratios found no 
difference at any timepoint (Figure 3.2B), though trends of increased size of GNAT3-
ablated pancreata at 16- and 52-weeks suggest a potential increase in tumorigenesis, 
as found in aged KC animals. Survival of aged Gnat3-/-;KCERT agree with this hypothesis 
as GNAT3-ablated animals trend with higher rates of mortality compared to control mice 
(Figure 3.2C). These data indicate the functional utility of using KCERT mice to study 
neoplastic development and carcinogenesis, however, further analysis and higher 
power is required to elucidate differences.  
Carcinogenesis, through expression of mutant KRAS alone, requires extended 
time for development29,80 which can be accelerated by the additional mutation of the 
tumor suppressor TP5383. In order to analyze the role of gustatory signaling during rapid 
carcinogenesis, I bred Gnat3-/- animals to the KrasG12D/+;p53R172H/+;Ptf1aCre/+ (KPC) 
model of carcinogenesis. This model, unlike the KC model, develops carcinoma rapidly, 
between three and five months of age83, with MTCs found in early stage lesions but lost 
during the transition to carcinoma94. There was no difference in Gnat3-/-;KPC mice 
mortality compared to controls, indicating gustatory signaling does not alter PDA 
development in this model (Figure 3.2D). However, I found that histologically, GNAT3-
ablated animals had more poorly differentiated, sarcomatoid-like tumors compared to 
control KPC mice (Figure 3.2D), similar to results in aged Gnat3-/-;KC pancreata (Figure 
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2.7C). Minimal MTC presence94 and rapid carcinogenesis83 in the KPC model may 
explain the subtle phenotype of gustatory ablation in this model.  
 
3.3. Ablation of TRPM5 Requires Further Analysis of Phenotype 
Metaplastic tuft cells in the pancreas express markers of gustatory signaling and 
alteration of that signaling, through GNAT3 ablation, promotes rapid tumorigenesis. 
However, analysis of GNAT3 expression finds that only a subset of pancreatic MTCs 
produce this protein, in comparison with TRPM5, the cation channel which induces 
depolarization of sensory cells and is found in nearly every tuft cell94. Using the 
Gnat3EGFP;KC model, I confirmed the observed sporadic expression in MTCs, compared 
to the Trpm5EGFP;KC model, which was expressed in all phalloidin marked tuft 
containing cells identified (Figure 3.3A). Since TRPM5 is expressed ubiquitously in 
MTC, we hypothesized ablation would, similarly to GNAT3 ablation, accelerate 
carcinogenesis. Following generation of Trpm5-/-;KC animals, I confirmed expression of 
tuft cell markers, including DCLK and choline acetyltransferase, demonstrating that, 
similar to GNAT3 ablation (Figure 2.2C), MTC are present and expression of known 
markers remain unchanged (Figure 3.3B). To assess the role of TRPM5 in 
tumorigenesis, I collected Trpm5-/-;KC animals at 16- and 24-weeks of age. My 
comparison of Trpm5-/-;KC and KC pancreata found no obvious difference in histology 
or pancreas-to-body weight ratios, though there was a trend for higher pancreas-to-
body weight in 24-week animals (Figure 3.3C). These results are similar observations 
found in GNAT3-ablated tumorigenesis (Figure 3.3A) but require further analysis and 
aging to find if Trpm5-/-;KC mice also present with advanced carcinoma. Further data is 
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required to understand the role of TRPM5 in canonical gustatory signaling in pancreatic 
tumorigenesis. 
Next, I bred TRPM5 ablated animals to the KCERT model of neoplasia to probe 
similarities with the Gnat3-/-;KCERT animals used in Chapter 2. KCERT and Trpm5-/-;KCERT 
animals were treated with tamoxifen to induce pancreas specific mutant KRAS 
expression, followed by supramaximal doses of cerulein and then pancreata were 
collection at 6 weeks, as described in Chapter 2. By analysis of the overt histology of 
TRPM5 ablated animals, I found no difference in transformation but a decreased 
pancreas-to-body weight ratio (Figure 3.3D). Staining for MTCs, by DCLK1 IHC, I 
noticed a possible elevation of tuft cell numbers (Figure 3.3D), mirroring results from 
Gnat3-/-;KCERT model (Figure 2.3B). In order to appropriately compare Trpm5-/-;KCERT 
and Gnat3-/-;KCERT phenotypes, more data and analysis need to be performed. Gnat3-/-
;KCERT pancreas-to-body weight ratios have a wide range of results which trend 
downward (Figure 2.2A) and showcase the need for further samples of the Trpm5-/-
;KCERT model to perform a proper comparison. Continued analysis of TRPM5 ablation 
during neoplasic formation is required to confirm its similarities with GNAT3 ablation and 
its tumor suppressive function. 
 
3.4. Organoid Culture Systems Generate Tuft Cells and Can Alter Macrophage 
Polarization 
Development of 3D organoid culture provides a model system which can be used 
as a proxy for in vivo study of aspects of animal and human disease391,435. In order to 
probe MTC function, I adapted and validated a culture system generated from 
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pancreatic acinar cell isolation391. Acinar cell isolation was confirmed as the source of 
ductal lesions by use of tamoxifen treated non-KRASG12D expressing 
Ptf1aCreERT/+;ROSA26RLSL-EYFP/+ (CreERT;ROSA26REYFP) or mutant KRAS containing 
KrasG12D/+;Ptf1aCreERT/+;ROSA26RLSL-EYFP/+ (KCERT;ROSA26REYFP), using enhanced 
yellow fluorescent protein (EYFP) to exclusively mark Ptf1a expressing acinar cells prior 
to collection (Figure 3.4A). Plating of acinar cells in Matrigel alone induces acinar-to-
ductal metaplasia (ADM) on day 4 for the CreERT;ROSA26REYFP cultures or, slightly 
accelerated, on day 3 for the KCERT;ROSA26REYFP model (Figure 3.4A). Acinar-derived 
cultures maintained EYFP expression and could be cultured for months with re-plating 
as necessary (Figure 3.4A). Following organoid system establishment, I confirmed MTC 
presence by the use of the Trpm5EGFP reporter (Figure 3.1B and 3.3A) to track KC 
acinar-derived cultures in real-time, using the enhanced green fluorescent protein 
(EGFP) expression (Figure 3.4B). I also collected and stained organoid cultures for 
phalloidin to mark the tuft of tuft cells, confirming MTC presence in organoid culture 
(Figure 3.4C). My analysis of MTC presence in KC culture over time, by use of the 
Trpm5EGFP reporter, found that expression of Trpm5EGFP takes 7- to 14-days to appear 
in culture, where numbers remain steady, then drop when the cells become 
overconfluent and return following cell re-plating (Figure 3.4D). These data indicate this 
is a stable culture system for generating MTC derived from the acinar compartment and 
its use for understanding MTC function. 
MTC are not found in areas of de-differentiated carcinoma94, however organoid 
culture may promote cell reprogramming to a less aggressive state, and thereby 
generate MTC in 3D culture from human PDA cell lines436. In order to explore this 
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possibility, I was given human primary PDA cells collected by Dr. Diane Simeone’s Lab 
at the University of Michigan from Dr. Ethan Able. Following tumor collection, tumors 
were cultured in an animal PDX model for establishment then briefly in 2D culture for 
expansion by Dr. Able, before I plated them on a bed of Matrigel in PTOM (Figure 3.4E). 
Cells were cultured for up to 20 days, with ductal organoids appearing by day 10, before 
collection for staining (Figure 3.4E), as the cells would become overconfluent past this 
time (not pictured). With aid of Riley Bergman, serial sectioning and staining of 
organoids was performed to identify VAV1 and phalloidin stained MTC in human 
organoid culture (Figure 3.4F). These data showcase the utility and expand the 
applications of this model to understand both mouse and human MTC function.  
Establishment of an MTC-containing culture system can be used to explore 
gustatory function by direct assessment of media released signaling molecules, as in 
Chapter 2, and also by crosstalk with immune populations. Macrophages and 
macrophage function is known to play driving roles in PDA progression437 and can be 
studied using bone marrow derived macrophages (BMM) in culture424. GNAT3-ablated 
organoid cultures have increased cytokine expression in conditioned media (Figure 
2.1E) therefore, in order to understand the role of MTC signaling on macrophage 
polarization states, I collected BMM from wild type mice to culture in either KC or Gnat3-
/-;KC MTC containing organoid conditioned media (Figure 3.4G). Analysis was 
performed by macrophage RNA assessment of select polarization markers 48-hours 
post culture (Figure 3.4G). I found Gnat3-/-;KC conditioned media directly altered 
macrophage polarization by decreasing IL-6 and IL-1α, after normalization to KC 
conditioned media controls (Figure 3.4G). Both IL-6438 and IL-1α439 have roles in the 
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tumor microenvironment to modulate pro-inflammatory signaling and suggest a direct 
signaling role for MTC modulation of inflammation. In order to more accurately replicate 
in vivo cell communication, I co-cultured MTC containing organoids with BMM for 48 
hours before RNA collection, to measure macrophage polarization (Figure 3.4H). 
Interestingly, Gnat3-/-;KC co-cultured macrophages showed no difference in 
polarization, following normalization to KC controls (Figure 3.4H). This suggests critical 
crosstalk occurring between the two cell types which modulate polarization and 
replicates the minimal gene expression differences found in the single cell sequencing 
results from the TAM population collected in vivo (Figure 2.5C). 
 
3.5. Metaplastic Tuft Cell Signaling in the Neoplastic Pancreas 
Activation of tuft cell signaling throughout the body induces release of different 
signaling molecules including ATP146, IL-25135,147 and ACh149. In order to explore the 
mechanism of MTC signaling, I collected conditioned media from KC and Gnat3-/-;KC 
MTC containing cultures and boiled to denature the protein components in the media. 
My preliminary analysis of macrophage polarization, as a read-out of functional 
conditioned media, found macrophage expression of Arginase 2 (ARG2) and IL-6 
remained unchanged while IL-1β expression was restored to control levels when 
GNAT3 ablated media was boiled (Figure 3.5A), suggesting both protein independent 
and protein dependent functions of MTCs on macrophage gene expression (Figure 
3.5A). Interestingly, boiling KC conditioned media eliminated the induction of IL-6 
expression in macrophages to a level comparable to macrophages treated with unboiled 
or boiled Gnat3-/-;KC conditioned media (Figure 3.5A). This suggests that a protein 
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responsible for inducing IL-6 expression by KC cells is not expressed upon the ablation 
of GNAT3 (Figure 3.5A). These data require further replicates and analysis but suggest 
a multifaceted signaling response following activation of gustatory signaling.  
In the tongue, type-II taste cells use gustatory signaling to activate ATP release 
through CALHM1 channels in the basal surface of the cell, activating taste sensory 
nerves146. Staining for CALHM1 in pancreatic neoplasia finds heterogenous MTC 
expression, indicating ATP as a signaling mechanism for MTC (Figure 3.5B). Utilizing 
our 3D organoid culture system and the help of David Bushhouse, conditioned media 
was collected from KC and Gnat3-/-;KC MTC containing organoid cultures and assessed 
for ATP levels. Preliminary results show ATP levels remained low in both conditioned 
media samples, but trended lower in GNAT3-ablated conditioned media (Figure 3.5B), 
suggesting gustatory signaling induced ATP release as a potential mechanism for 
modulation of the tumor microenvironment.  
Tuft cell expression of choline acetyltransferase (ChAT), a key enzyme for 
production of ACh, and production of ACh is a driving mechanism in nasal 
inflammation149 and muscle contraction in the trachea432. Assessment of ChAT 
expression, though use of ChATEGFP;KC animals, finds that a subset of pancreatic MTC 
express ChAT (Figure 3.5C). In order to probe MTC-specific ACh signaling function in 
the pancreas with the help of Daniel Salas-Escabillas, I treated tamoxifen and cerulein 
Gnat3-/-;KCERT and control KCERT mice with bethanechol, a broad muscarinic agonist440, 
for 6-weeks to replace any loss in ACh due to gustatory ablation (Figure 3.5D). My 
observations of control KCERT pancreata, following 6-weeks of bethanechol treatment, 
had no difference in pancreas-to-body weight ratios but seemed to retain more normal 
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acinar area, as has been reported in prior literature (Figure 3.5D)440. However I 
observed no difference in pancreas-to-body weight ratios or histology of Gnat3-/-;KCERT 
animals. Further analysis of this model is required to fully understand the impact of MTC 
derived ACh on the tumor microenvironment.  
Ablation of GNAT3 increases CXCL1 and CXCL2 in the conditioned media of 3D 
organoid culture samples and in the neoplastic epithelial compartment (Figure 2.1E, 
2.6B-D). Expression of CXCL1 is found in PDA cells but has not been evaluated in 
earlier stages of neoplasia386,441. Staining in KCERT and Gnat3-/-;KCERT tissues found 
CXCL1 expression higher in acinar cells, neoplastic lesions (Figure 3.5E, purple arrows) 
and at similar levels in MTCs (Figure 3.5E, yellow arrows), marked by colocalization 
with the MTC marker COX. Both KCERT and Gnat3-/-;KCERT tissues show MTC 
expression of CXCL1, suggesting that signaling could be driven from tuft cells directly. 
Although, a majority of signaling in the GNAT3-ablated animals seem to have higher 
levels of CXCL1 stain in the neoplastic lesions as compared to the stroma in KCERT 
pancreata (Figure 3.5E, white arrow). Further analysis of MTC CXCL1 expression is 
required but these data indicate a potential novel tuft cell signaling mechanism to 
directly regulate immune cell signaling and activation during pancreatic tumorigenesis.  
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Discussion 
Metaplastic tuft cells (MTC) use gustatory signaling to modulate the immune 
microenvironment to slow PDA progression. Ablation of canonical gustatory signaling 
proteins, GNAT3 and TRPM5, have similar histological outcomes during pancreatitis 
and tumorigenesis. MTC directed signaling alters macrophage polarization but these 
changes are no longer apparent following epithelia-macrophage crosstalk, suggesting a 
more complicated role in neoplastic modulation of polarization outside of gustatory 
signaling. It is still unknown the stimulus for MTC gustatory activation but, following 
stimulation, my preliminary data indicate release of multiple signaling molecules, 
including ATP, acetylcholine (ACh) and CXCL1, to modulate the tumor 
microenvironment and which are altered following GNAT3 ablation. Functional gustatory 
signaling has an overarching role in pancreatic tumorigenesis through modulation of the 
tumor microenvironment resulting in decreased PDA progression.  
Tuft cell activation and signaling leads to many downstream effects in different 
organs including taste detection146, muscle contraction432, immune recruitment149 and 
parasite expulsion135,147. The tuft cell-specific signals mediating these functions result 
from vesicle fusion or channel opening promoting the release of ATP146, ACh133,149 or 
interleukin-25 (IL-25)135,147 in different organs. The exact signals released by pancreatic 
MTCs remain unknown, but preliminary data presented here suggests a combination of 
MTC directed signaling mechanisms. In the tongue, depolarization of type-II taste cells 
promotes the opening of CALHM1 channels and ATP efflux to stimulate afferent taste 
sensory nerves146. Ablation of GNAT3 blocks bitter and sweet taste detection in type-II 
taste cells374, indicating ablation of CALHM1 directed ATP release. Preliminary data in 
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the pancreas show tuft cell-specific CALHM1 expression and evaluation of GNAT3-
ablated 3D organoid culture trend toward decreased ATP release. Pancreatic MTC also 
express choline acetyltransferase (ChAT), an enzyme key for ACh synthesis, which is 
known to promote tuft cell-specific immune responses in the nose149. Functional data of 
MTC-specific ACh release is still lacking as initial results using bethanechol treatment to 
replace muscarinic signaling in GNAT3-ablated mice finds few differences in phenotype. 
Staining for CXCL1 also finds some expression in MTC in pancreatic neoplasia. CXCL1 
MTC expression, along with the elevated CXCL1 found in GNAT3-ablated systems, 
indicate a potential novel signaling mechanism of MTC to directly regulate immune cell 
function and tumor progression386. 
Organoid culture is an ex vivo model which recapitulates the 3D cell 
microenvironment to study PDA outside of the more complicated in vivo setting391,435. 
Organoid models have been used to successfully generate patient-derived cultures391 to 
explore mechanisms of drug resistance435,442-444, but analysis of the cellular 
heterogeneity acquired via cell reprogramming to a less aggressive state in culture was 
not performed435,436. Here I find, using an adapted model of organoid culture391, that 
mouse acinar cells or human primary PDA cell lines can generate MTC in 3D culture. 
These results provide a useful system for probing compounds promoting MTC 
activation, downstream signal release and pathways critical to this process. 
Furthermore, direct co-culture or transwell systems allow the study of MTC gustatory 
roles beyond macrophage polarization, providing a system for coculture of immature 
monocytes, to assess MDSC polarization, nerves or fibroblast activation states. 
Development and characterization of MTC in 3D culture provides a new avenue for 
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understanding tuft cell directed signaling influencing distinct cells of the 
microenvironment in both mouse and human PDA.   
Ablation of gustatory signaling accelerates PDA tumor formation and metastasis. 
However, initial analysis of GNAT ablation using the KrasG12D/+;p53R172H/+;Ptf1aCre/+ 
(KPC) model of carcinogenesis finds no difference in survival with loss of gustatory 
signaling. Though these data require higher power to accurately make reliable 
conclusions, I hypothesize that the rate of carcinogenesis may be one factor which 
diminishes the effect of MTC signaling. Tuft cells are not found in the normal pancreas, 
outside of the common bile duct95,111, but appear following ADM and PanIN formation94. 
PanIN progression to PDA is associated with loss of cell structure and organization445 
and the progressive loss of MTC within the carcinoma94. The rapid progression of the 
KPC model, where animals succumb to disease at five months of age83, show loss of 
tuft cell presence within dysplastic areas early in disease formation, though they remain 
present around the tumor area in PanIN structures (data not shown). However, analysis 
of mice with mutant KRAS alone, KrasG12D/+;Ptf1aCre/+ (KC), finds substantial MTC 
presence starting in early neoplastic lesions at 8- to 12-weeks and continually 
throughout the transformed pancreas for past 52-weeks (data not shown). Alternatively, 
the carcinogenesis found following GNAT3 ablation in KC mice may require functional 
TP53 signaling. Mutation of TP53 is known to alter signaling and metastasis, potentially 
hiding GNAT3 dependent effects446. Though further analysis will need to be performed 
on GNAT3-ablated KPC tissue, as presence of more advanced sarcomatoid-like 
tumors, similarly to aged KC mice, indicate a universal role for gustatory signaling in 
altering the microenvironment and PDA development.  
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Analysis of these data indicate a role for canonical gustatory signaling in 
modulating the tumor microenvironment in PDA. Further work is required to assess 
activation, propagation and downstream signaling of MTC in the pancreas as well as the 
influence these signals have on cells in the stromal compartment. Understanding the 
signals driving MTC activation and the downstream mediators may be critical for 
developing targeted sustained therapies to modulate the microenvironment to support 
chemotherapeutic responses.  
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Future Directions 
The data presented in this chapter gives a preliminary understanding of 
metaplastic tuft cell (MTC) signaling in pancreatic neoplasia but also brings up many 
further questions about the function of gustatory signaling. Continuing data collection 
and analysis of GNAT3 and TRPM5 ablated animals will add further insight to the steps 
altered during neoplastic formation. Exploring the immune cell microenvironment of 
aged Gnat3-/-;KC and Trpm5-/-;KC mice, as well as CXCL1 and CXCL2 expression, will 
provide a comparison of function between the two models and to the data collected in 
Chapter 2. Expanding this model further, I want to explore possible genetic changes 
occurring in aged carcinoma bearing Gnat3-/-;KC mice (Figure 2.7). GNAT3 ablation 
results in more rapid PDA development, with metastasis and sarcomatoid-like tumors, 
not present in control KC mice and typically not found in this model80. Animal models of 
metastatic PDA are usually promoted by loss of tumor suppressor function447-450, along 
with mutant KRAS activation, and is aided by interactions with the tumor 
microenvironment451. Presence of advanced metastatic disease in GNAT3-ablated 
animals indicate the possibility of further acquired genetic mutations, along with an 
immune suppressed microenvironment. The acquisition of tumor promoting genetic 
mutations would make this a unique model to study the influence of tumor intrinsic or 
microenvironmental signaling altered by MTC to promote genetic mutations in PDA. 
Where absence of further genetic mutations indicates an extremely tumor-supportive 
microenvironment that, with further study, may present novel targets for therapy.  
 Use of GNAT3 or TRPM5 ablation animal models induces germline loss of 
function, ablating gustatory signaling in sensory cells throughout the body. Based on 
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analysis with both Gnat3EGFP and Trpm5EGFP expression in the neoplastic pancreas, 
both gustatory proteins are only found in tuft cells within the epithelium (data not 
shown). However, expression is found throughout the body to impact sensory directed 
immune signaling147,149, most interestingly in the thymus where ablation of tuft cells 
reduces a subset of invariant natural killer T-cells152. Germline ablation of gustatory 
signaling may impact development of immune cells in other organs, contributing to the 
advancement of carcinoma following GNAT3 ablation. The cleanest way to clarify this 
issue is to generate CRE inducible GNAT3-ablated animals, where a genetically 
engineered construct consisting of loxP flanked exons of Gnat3 can be knocked into the 
animals model. These animals can be bred to the KC model of tumorigenesis, removing 
any confounding effects that GNAT3 ablation may have outside the pancreas and to 
specifically address MTC signaling and PDA progression. However, novel animal model 
generation is a time-consuming process, requiring years of effort and substantial cost. 
Therefore, to study the impact of the tumor microenvironment of GNAT3-ablated 
animals on PDA tumor progression, I generated a pure strain of C57BL/6J animals for 
orthotopic experiments452. Orthotopic implantation of PDA tumor cells can be evaluated 
in wild type or GNAT3-ablated mice for survival and histology. If no difference in PDA 
progression is found, this would suggest that differences due to GNAT3 ablation in the 
tumor microenvironment are not the driving role for PDA progression and be a faster, 
more cost-effective way of analyzing germline loss of gustatory signaling. 
Preliminary analysis of MTC gustatory signaling requires higher power and data 
to find the functional signaling molecules released from MTC. One way to analyze MTC 
signaling in 3D organoid culture is to ablate all tuft cells following organoid generation. 
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Our lab has generated a novel model for study of tumorigenesis that allows for a dual 
recombinase system where FLPO recombinase is driven by Ptf1a, allowing pancreas 
specific recombination by recognition of FRT sequences, and leaving CRE 
recombination open for other drivers424. Generation of the KrasFSF-G12D/+;Ptf1aFlpO/+ (KF), 
similar to the KC model of tumorigenesis80, promotes pancreatic neoplasia through 
expression of mutant KRAS in the epithelium (data not shown). I then generated KF 
animals bred to the tuft cell-specific driver POU2F3CreERT (Skn1αCreERT), generously 
shared by Dr. Ichiro Matsumoto at the Monell Chemical Senses Center, PA, and CRE 
specific diphtheria toxin A expression from the ROSA26R locus (ROSA26RDTA)453. This 
KF;Skn1αCreERT;ROSA26RDTA model induces pancreatic neoplasia then allows the 
targeted ablation of tuft cells under the control of tamoxifen treatment. A caveat of this 
system is that tuft cell ablation occurs in POU2F3 expressing tuft cells throughout the 
body138, which may impact immune cell signaling152. However, collection and culture of 
acinar cells from the KF;Skn1αCreERT;ROSA26RDTA allows analysis of ATP, ChA and 
CXCL1 levels prior to and after MTC ablation. This model can also be used for co-
culture with other cell types, probing gene expression differences following tuft cell 
ablation to understand the cell-to-cell crosstalk occurring the tumor microenvironment. 
This novel system provides a robust way of probing tuft cell-specific signaling in 3D 
organoid culture. 
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Materials and Methods 
Mice 
All animal procedures and experiments were conducted with approval of the 
Institutional Committee on Use and Care of Animals at the University of Michigan. 
The following mice strains were used: Ptf1aCre/+ and Ptf1aCreERT/+;422 KrasG12D/+ and 
p53R172H/+ (gift of David Tuveson, Cold Spring Harbor Laboratory, NY); Gnat3-/-, Trpm5-/-
, Gnat3EGFP and Trpm5EGFP (gifts of Robert Margolskee, Monell Chemical Senses 
Center, PA)140,374,375,434 and ChATEGFP and ROSA26REYFP/+ (from the Jaxson 
Laboratory). Mice were crossed on a mixed background to generate Gnat3-/-
;KrasG12D/+;Ptf1aCre/+// Gnat3-/-;KrasG12D/+;Ptf1aCreERT/+// Gnat3-/-
;KrasG12D/+;p53R172H/+;Ptf1aCre/+// Trpm5-/-;KrasG12D/+;Ptf1aCre/+// Trpm5-/-
;KrasG12D/+;Ptf1aCreERT/+// Trpm5EGFP;KrasG12D/+;Ptf1aCre/+// Gnat3EGFP;KrasG12D/+;Ptf1aCre/+ 
and ChATEGFP;KrasG12D/+;Ptf1aCre/+ mice. All analyses were performed using strain-
controlled animals. Aged KrasG12D/+;Ptf1aCre/+ and KrasG12D/+;p53R172H/+;Ptf1aCre/+ mice 
were monitored and euthanized at moribund per animal care guidelines. Cerulein-
induced experimental pancreatitis was induced by 25 µg/kg cerulein (46-1-50; American 
Peptide Company. Inc, Sunnyvale, CA) intraperitoneal injections twice daily for 2- or 3-
weeks in 8-week old mice, as described previously168. 
Acinar specific KrasG12D/+ recombination was induced in 8- to 12-week old 
Ptf1aCreERT/+;ROSA26REYFP or KrasG12D/+;Ptf1aCreERT/+;ROSA26REYFP mice by oral 
gavage with 5 mg of tamoxifen (T5648; Millipore-Sigma, St. Louis, MO) dissolved in 
corn oil for 5 days. After a 2-day rest post tamoxifen treatment, experimental 
pancreatitis was induced once a day by intraperitoneal injection with 250 µg/kg cerulein 
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(46-1-50; American Peptide Company) for 5 days. Pancreata were harvested either 1-, 
6-, 16- or 52-weeks post cerulein treatment. Bethanechol (C5259; Milipore-Sigma, St. 
Louis, MO) was administered at 400 µL/mL in drinking water in KCERT mice after 
tamoxifen- and cerulein treatment and changed every 4 days for 6 weeks before 
collection, as based on prior literature440. 
 
Immunohistochemistry 
Pancreata were collected, weighed and fixed in Z-fix (NC9050753; Anatech Ltd., 
Battle Creek, MI) overnight. Processing of tissues was performed using a Leica 
ASP300S tissue processor (Buffalo Grove, IL). Sections (4 µm) of paraffin-embedded 
tissue were stained for target proteins using the Discovery Ultra XT autostainer 
(Ventana Medical Systems Inc., Tucson, AZ). Antibodies were stained as listed in Table 
3.1 followed by Mayer’s hematoxylin (NC9220898; Millipore-Sigma) counterstain. H&E 
staining was done using Mayer’s hematoxylin and eosin Y (HT110116; Fisher, 
Pittsburgh, PA). Immunohistochemistry slides were imaged and stitched together by a 
Pannoramic SCAN scanner (Perkin Elmer, Seattle, WA) using a 20x objective lens.  
 
Immunofluorescence 
Immunofluorescence staining was performed on frozen tissue sections, as 
described previously424. In sum, pancreata were collected and fixed in Z-fix for 2-3 
hours, followed by 30% sucrose in phosphate buffered saline (PBS) overnight. 
Pancreata were equilibrated in a 1:1 mixture of 30% sucrose/PBS and optimal cutting 
temperature embedding medium (OCT) for 30 minutes, embedded in OCT, frozen by 
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liquid nitrogen and stored at -80°C. Frozen tissue sections (10 µm) were acquired using 
a Leica CM1860 (Leica Biosystems, Buffalo Grove, IL) cryostat set at -20°C, 
permeabilized in 0.1% Triton X-100 (T9284; Millipore-Sigma) in PBS for 1 hour and 
blocked by using 5% donkey serum/1% bovine serum albumin (BSA) in PBS for 1 hour. 
Incubation with primary antibody (listed in Table 3.1) was performed overnight at room 
temperature in 0.1% Triton X-100/1% BSA in PBS, followed by 3 washes of 0.1% Triton 
X-100/PBS for a total of 45 minutes. Sections were incubated with Alexa Fluor-
conjugated secondary antibodies at 1:500 and phalloidin at 1:250 (both Invitrogen, 
Carlsbad, CA) for 1-hour room temperature followed by 3 washes as before. Finally, 
slides were rinsed in deionized water and mounted with Prolong Diamond antifade 
mountant (P36961; Fisher). Images were acquired on a LSM800 confocal microscope 
(Zeiss, Oberkochen, Germany) using a 63x objective or with an Olympus BX53F 
microscope (Olympus, Shinjuku City, Tokyo, Japan) using a 20x objective. Endogenous 
signaling was used for all EGFP and EYFP imaging (ROSA26REYFP, Gnat3EGFP, 
Trpm5EGFP, and ChATEGFP). 
 
Table 3.1 Immunostaining Antibodies 
Antibody Company Catalog number Dilution Purpose 
DCLK1 Abcam ab37994 1:2000 IHC, IF 
VAV1 Cell Signaling 2502S 1:100 IF 
ChAT Millipore-Sigma AB144P 1:200 IF 
TRPM5 Novus Biologicals NBP1-44059 1:500 IF 
COX2 Santa Cruz sc-1747 1:200 IF 
CALHM1 Millipore-Sigma AB2268 1:50 IF 
CXCL1 Abcam ab86436 1:100 IHC, IF 
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Organoid Culture 
Either mouse acinar cells or primary human cell lines were used for 3D organoid 
culture. The primary human cell line, UM5, was derived from a human pancreatic 
cancer by Dr. Diane Simeone’s lab at the University of Michigan following IRB protocols 
as described102,454. In sum, establishment of tumor cells was performed through mouse 
PDX four times, then cells were frozen down for storage, passaged twice on 2D culture 
before plating in organoid samples, detailed below. Acinar cell isolation from fresh 
pancreas was performed as previously described28. Briefly, pancreata from 8- to 10-
week old mice were sterilely harvested, washed twice in Hank’s buffered salt solution 
(HBSS), minced and digested in 0.2 mg/mL Collagenase P (11249002001; Millipore-
Sigma) for 15 minutes at 37°C. Tissue was washed 3 times in 5% fetal bovine serum 
(FBS) in HBSS, centrifuged at 300xg for 2 minutes, re-suspended in HBSS and filtered 
through 500 µm and 105 µm polypropylene mesh (888-13570 and 888-13597; 
Spectrum Laboratories, New Brunswick, NJ). Cell suspension was slowly added to a 
gradient consisting of 30% FBS in HBSS and centrifuged at 300xg for 2 minutes.  
Isolated acinar cells or UM5 human PDA cells were resuspended in Pancreatic 
Progenitor and Tumor Organoid Media (PTOM), made as previously described with 100 
U/mL Pen Strep (15140122; Invitrogen), 1% B27 supplement (17504044; Invitrogen), 50 
µg/mL ascorbic acid (A4403; Millipore-Sigma), 0.4% bovine pituitary extract (13028-014; 
Thermo Fisher, Waltham, MA), 10 µg/mL insulin (I2643; Millipore-Sigma), 0.5 µg/mL 
hydrocortisone (H0888; Millipore-Sigma), 5 ng/mL FGF-2 (F0291; Millipore-Sigma), 10 
ng/mL FGF-10 (345-FG; R&D Systems, Minneapolis, MN), 25 nM retinoic acid (R2625, 
Millipore-Sigma) and 5 µM Y-27632 (50-175-996; Fisher) in DMEM:Glutamax (10564-
99 
 
011; Thermo Fisher).391 Acinar cells were floated in a petri dish for 2 hours in PTOM 
then 10,000 to 12,500 cells were plated in a PTOM 5% Matrigel mixture on a bed of 
100% Matrigel in a 24-well plate. Media was changed to fresh PTOM every 4 days. 
Waymouth media (W1625; Millipore-Sigma) was used for establishment of acinar 
derived culture in place of PTOM (Figure 3.4A). 
Live imaging of lineage traced CreERT;ROSA26REYFP and KCERT;ROSA26REYFP 
was performed using an Olympus CKX41 light microscope (Olympus) or, for imaging 
Trpm5EGFP positive tuft cells, on a LSM800 confocal microscope (Zeiss). Trpm5EGFP 
cell number was counted every 2 to 4 days for one 24 well containing 
KrasG12D/+;Ptf1aCre/+ derived organoids using an Olympus CKX41 light microscope 
(Olympus).   
 
Organoid Staining 
Organoids were fixed and stained using a modified protocol from previously 
described425. In sum, following a PBS wash, the mouse or human derived organoids 
were fixed in Z-fix for 15 minutes, washed twice in PBS and left overnight in a 30% 
sucrose/PBS mix. Organoids were carefully removed intact from their 24 well plates, 
embedded in OCT then frozen by liquid nitrogen and stored at -80°C. Frozen tissue 
sections (50 µm) were acquired using a Leica CM1860 (Leica Biosystems) cryostat set 
at -20°C and allowed to warm to room temperature. Slides were washed in PBS 3 times 
for 15 minutes, permeabilized in 0.5% Triton X-100/PBS for 1 hour, a second PBS 
wash, then blocked in 10% FBS/1% BSA in PBS for 1 hour and incubated with the 
primary antibody (VAV1, as in Table 3.1) or no antibody (for Trpm5EGFP cultures) in 1% 
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FBS/1% BSA in PBS overnight at 4°C. Organoid slides were washed 3 times in 1% 
FBS/1% BSA/PBS for a total of 45 minutes, then incubated with an Alexa Flour-
conjugated secondary antibody at 1:500 (for VAV1 staining) and phalloidin at 1:250 
(both Invitrogen) in 1% FBS/1% BSA/PBS for 2 hours. Organoids were washed for 30 
minutes in 3 changes of PBS and mounted on a slide with Prolong Diamond antifade 
mountant (P36961; Fisher). Finally, the slides were compressed overnight at room 
temperature and imaged using a 63x objection on a LSM800 confocal microscope 
(Zeiss). 
 
Bone Marrow Derived Macrophage Isolation, Culture and Co-Culture 
As described previously424, bone marrow cells were collected from femurs of 8- 
to 12- week old mice and cultured in Dulbecco’s modified eagle media (DMEM) 
supplemented with 20% fetal bovine serum (FBS), 30% L929 conditioned medium, 
1mmol/L sodium pyruvate and 2.5% penicillin/streptomycin for 5 days.  
Bone marrow derived macrophages (BMM) were then re-plated at a density of 3 
million cells per mL for co-culture or conditioned media culture in 12-well plates and 
allowed to settle overnight. For co-culture of 3D organoids, organoids from 
KrasG12D/+;Ptf1aCre/+ or Gnat3-/-;KrasG12D/+;Ptf1aCre/+ pancreata plated in the top of a 12 
well transwell, were added with fresh PTOM on BMM, washed once with PBS. For 
conditioned media culture, conditioned media from KrasG12D/+;Ptf1aCre/+ or Gnat3-/-
;KrasG12D/+;Ptf1aCre/+ was thawed and added to BMM culture, after a wash of PBS. 
Preparation of boiled conditioned media was performed by thawing conditioned media, 
splitting it into two fractions then boiling one half for 15 minutes and after 20 minutes of 
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cooling adding the different medias to different wells of BMM. Following 48-hour culture 
with BMM for each of the conditions, macrophages were washed twice in PBS then RLT 
Buffer Plus (QIA1053393; Qiagen, Hilden, Germany) mixed with β-mercaptoethanol 
(M6250; Millipore-Sigma) was added to each well, scraped and frozen at -80°C. 
 
RNA Isolation and Quantitative PCR 
RNA was isolated using the RNeasy Micro kit (QIA74004; Qiagen) then as 
described previously424. Briefly, complementary DNA was synthesized with an iScript 
synthesis kit (BIO1718891; Bio-Rad, Hercules, CA), followed by quantitative PCR with 
use of the Fast SYBR Green (4385612; Fisher) master mix on a Viia7 thermocycler (Life 
Technologies, Grand Island, NY). Primer sets as published168,424. Threshold cycle (Ct) 
obtained from the fluorescence readings were used to find a mean Ct value. Relative 
amounts of messenger RNA were then calculated as 2-ΔCt, where ΔCt is the mean Ct 
minus the Ct of the housekeeping gene, Hprt1. 
 
ATP Assay 
Conditioned media was collected fresh from KrasG12D/+;Ptf1aCre/+ or Gnat3-/-
;KrasG12D/+;Ptf1aCre/+ acinar derived organoid wells on day 10 post plating. The 
Invitrogen Molecular Probes ATP Determination Kit (A22066; Fisher) was used, per 
manufacturers protocol, to measure ATP levels per well. In sum, Luciferin/Luciferase 
mastermix was made, along with ATP standards, and added to a white 96 well plate. 10 
ul of media were then added in duplicate per each well then light absorption was 
measured, corrected with blank subtracted readings and ATP levels calculated based 
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on standards light emission. Analysis presented in Figure 3.5B is the average ATP 
levels of 3 wells for each point with the top points in the graph from media collected 
from macrophage co-culture with organoids and the bottom points are organoids alone. 
Further work with this system is required for optimization, as ATP levels decreased 
rapidly, causing issues with repeated detection. Use of stabilization agents were also 
unsuccessful, as found by secondary tests which found no ATP present in either 
KrasG12D/+;Ptf1aCre/+ or Gnat3-/-;KrasG12D/+;Ptf1aCre/+ media (data not shown).   
 
Statistics  
All statistics were analyzed using GraphPad Prism 8.4.0 (San Diego, CA). 
Statistics for comparing 2 groups was done by unpaired Student t tests. Kaplan-meier 
curve statistics were calculated by the log-rank (Mantel-Cox) test. P < 0.05 were 
considered statistically significant. P values are listed for all with ns = no significance. 
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Figures 
Figure 3.1 
 
Figure 3.1: Ablation of gustatory signaling does not alter recovery post cerulein treatment. (A) Staining for 
DCLK1 on animals treated with cerulein for either two or three weeks followed by 1-day recovery before collection. 
Scale bar: 20 µm. (B) Expression of Gnat3EGFP or TRPM5EGFP (green) in biliary tuft cells. DAPI (blue) = nuclei, 
phalloidin (white) = filamentous actin rich tufts. Scale bar: 20 µm. (C) Schematic of cerulein treatment twice a day for 
3 weeks followed by collection at 1-, 7- or 14-days post treatment. (D) H&E, pancreas-to-body weight ratios and 
staining for DCLK1 to identify tuft cell genesis through pancreatic recovery post cerulein treatment between wild type 
and Gnat3-/- pancreata. Scale bar: 50 µm. (E) H&E and pancreas-to-body weight ratios of different time points post 
cerulein treatment for wild type or Trpm5-/- animals. Scale bar: 50 µm. Significance was calculated using an unpaired 
t test; P < 0.05 statistically significant. 
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Figure 3.2 
 
Figure 3.2: Continued analysis of GNAT3-ablated pancreata during tumorigenesis. (A) Pancreas-to-body weight 
ratios for tamoxifen- and cerulein-treated KrasG12D;Ptf1aCreERT (KCERT) and Gnat3-/- KCERT mice collected at 1-, 6-, 16- 
and 52-weeks post cerulein treatment (n = 1 week = 6, 6; 6 weeks = 27, 35; 16 weeks = 3, 4; 52 weeks = 3, 3). (B) 
Kaplan-meier survival of tamoxifen- and cerulein-treated KCERT and Gnat3-/- KCERT mice aged to morbidity or 52-
weeks (n = 4). (C) H&E of full pancreas, pancreas-to-body weight ratios and staining of CXCL1 on KrasG12D;Ptf1aCre 
(KC) and Gnat3-/- KC animals at 16 or 24 weeks of age (n = 16 weeks = 10, 10; 24 weeks = 8, 6). Scale bar: H&E = 
1000 µm, CXCL1 = 100 µm. (D) H&E of full pancreas from KrasG12D;p53R172H;Ptf1aCre (KPC) and Gnat3-/- KPC with 
inset noted by black box. Kaplan-meier survival of KPC animals, excluding mice euthanized due to paralysis (n = 4, 
6). Scale bar: 2000 µm, inset = 200 µm. Significance was calculated using the log-rank (Mantel-Cox) test and 
unpaired t tests; P < 0.05 statistically significant. 
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Figure 3.3 
 
Figure 3.3: Ablation of TRPM5 requires further analysis to determine role in pancreatic neoplasia. (A) 
Immunofluorescence of 12-week old KrasG12D;Ptf1aCre (KC) mice expressing the transgene for Gnat3EGFP or 
Trpm5EGFP (green). Counterstained for nuclei (DAPI, blue) and filamentous actin (phalloidin, white). Scale bar: 10 µm. 
(B) Analysis of tuft cell marker expression in KC and Trpm5-/- KC pancreata aged to 16-weeks. Staining for tuft cell 
markers TRPM5 (green), DCLK1 (green) and ChAT (red) along with phalloidin (white) to mark the tufts and 
counterstained with DAPI (blue) for nuclei. Scale bars: 20 µm. (C) H&E of 16-week or 24-week KC and Trpm5-/- KC 
pancreata and pancreas-to-body weight ratios (n = 16 week = 7; 24 week = 6). Scale bar: 2000 µm. (D) H&E of 
tamoxifen- and cerulein-treated KrasG12D;Ptf1aCreERT (KCERT) and Trpm5-/- KCERT pancreas collected 6-weeks post 
cerulein treatment. Inset indicated by black box. DCLK1 staining to show tuft cell presence and pancreas-to-body 
weight ratios (n = 4, 3). Scale bar: 1000 µm, inset and DCLK1 = 50 µm. Significance was calculated using an 
unpaired t test; P < 0.05 statistically significant. 
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Figure 3.4 
 
Figure 3.4: 3D Organoid culture generates tuft cells with gustatory signaling able to influence macrophage 
polarization. (A) Tamoxifen- treated 8 week old Ptf1aCreERT/+;Rosa26REYFP/+ (CreERT;ROSA26REYFP) or 
KrasG12D/+;Ptf1aCreERT/+;Rosa26REYFP/+ (KCERT;ROSA26REYFP) pancreata were collected, extracted for acinar cells and 
plated on a bed of Matrigel in Waymouth media. Enhanced yellow fluorescent protein (EYFP) marked acinar cells and 
acinar derived ductal metaplasia in 3D culture which persisted past 83 days in culture. Scale bar: 50 µm. (B) 
Metaplastic tuft cells (MTC) can be identified in live culture using Trpm5EGFP (green) expression. Image is from 
Trpm5EGFP;KrasG12D/+;Ptf1aCre/+ (KC) acinar derived culture on day 22 post plating in Matrigel with pancreatic 
progenitor and tumor organoid media (PTOM)1. Scale bar: 20 µm. (C) Organoid derived MTC verified by phalloidin 
(white) marking filamentous actin tufts (yellow arrows) in Trpm5EGFP (green) animal. Counterstained by DAPI (blue) to 
mark nuclei. Scale bar: 20 µm. (D) MTC numbers were counted from acinar derived KC culture plated in a 24 well 
plate through the expression of TRPM5EGFP. MTCs formation requires time to initiate, are lost when cultures become 
overconfluent and are restored following re-plating. (E) The primary human cell line, UM5, was plated on a bed of 
Matrigel in PTOM. Cells were tracked over time, where they appeared as 3D organoids before becoming 
overconfluent (not pictured). Scale bar: 100 µm. (F) MTC identification from the UM5 human PDA cell line organoid 
culture collected at day 20 post plating. VAV1 staining (green) and phalloidin (white) mark MTC and counterstained 
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with DAPI (blue) to mark nuclei. Scale bar: 5 µm. (G) Conditioned media (CM) from MTC containing organoids 
cultured with bone marrow derived macrophages (BMM). BMM were collected after 48 hours in either Gnat3-/-;KC CM 
or control KC CM and assessed for differences in RNA expression of seven macrophage polarization markers. Gnat3-
/-;KC CM BMM polarization (blue bars) was normalized by KC control CM BMM RNA polarization (green line) (n = 5, 
5). Arginase 1 = ARG1, Arginase 2 = ARG2, interleukin-1α = IL-1α, interleukin-1β = IL-1β, interleukin-6 = IL-6, 
transforming growth factor beta 1 = TGF-β1, resistin-like molecule alpha = FIZZ1. Significance was calculated using 
an unpaired t test; P < 0.05 statistically significant.  
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Figure 3.5 
 
Figure 3.5: Metaplastic tuft cell signaling in the neoplastic pancreas. (A) Conditioned media was collected from 
KrasG12D/+;Ptf1aCre/+ (KC) or Gnat3-/-;KC metaplastic tuft cell (MTC) containing 3D organoid cultures, separated into 
two groups and either boiled or left un-boiled, then added to bone marrow derived macrophage (BMM) culture for 48 
hours before collection of BMM RNA. BMM RNA was evaluated for expression of polarization markers. Trends 
comparing boiled or un-boiled conditioned media indicated by black lines. (n = 1) (B) Staining for CALHM1 (green), 
an ATP release channel in MTC marked by phalloidin (white) and counterstained by DAPI (blue) for nuclei. ATP 
levels measured from conditioned media in MTC containing KC or Gnat3-/-;KC organoids (n = 2). Proper experimental 
comparisons indicated by black lines. Scale bar: 20 µm. (C) Choline acetyltransferaseEGFP (ChAT) (green) expression 
in a subset of tuft cells marked by DCLK1 (red) and phalloidin (white) to mark filamentous actin. DAPI (blue) marks 
nuclei. Scale bar: 10 µm. (D) KCERT or Gnat3-/-;KCERT mice were treated with tamoxifen and cerulein then divided to 
water or bethanechol treated cohorts for 6-weeks before collection. Analysis of full pancreas H&E and pancreas-to-
body weight ratios (n = water = 7, 6; bethanechol = 10, 8). Scale bar: 1000 µm. (E) Co-immunofluorescence for 
CXCL1 (red) and the tuft cell marker COX1 (white) in tamoxifen and cerulein treated KCERT;ROSA26LSL-EYFP and 
Gnat3-/-;KCERT;ROSA26LSL-EYFP pancreata. In KCERT;ROSA26LSL-EYFP pancreata a high level CXCL1 expression (red) 
is found primarily in non-epithelial cells (YFP-, white arrows). In Gnat3-/-;KCERT;ROSA26LSL-EYFP , non-tuft cell epithelia 
(YFP+, COX1-, purple arrows) express high levels of CXCL1, including relatively low expression in tuft cells 
(YFP+,COX1+, yellow arrows), and in stromal cells. Counterstained by DAPI to indicate nuclei. Scale bar: 20 µm.  
Significance was calculated using an unpaired t test; P < 0.05 statistically significant. 
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Chapter 4. Tuft Cell Alteration Induces Biliary Dilation 
Introduction 
Biliary tract diseases are common gastrointestinal malignancies that cause pain, 
morbidity and cost to patients and the economic system115. Gallstone disease, or biliary 
tract obstruction, is a leading cause of hospital admissions for gastrointestinal problems 
in the United states455, and constitutes indirect costs of approximately $6.2 billion 
annually456. Detectable gallstone disease is associated with pain and inflammation of 
surrounding organs110 that can escalate into sustained inflammation with worse disease 
outcomes116,117. One risk factor of chronic biliary inflammation is biliary carcinoma 
(cholangiocarcinoma)457, a cancer with dismal 5-year survival rates of 30%121. 
Continued understanding the molecular mechanisms contributing to advancement of 
these disease states will reduce their economic and social impact with effective 
treatments. 
The common bile duct originates in the liver, passes through the head of the 
pancreas, ultimately connecting with the duodenum to aid in digestion of fats and waste 
expulsion. Bile is composed, in part, of water, cholesterols, phospholipids and bile 
salts115 used to break down ingested fat. Blockage of bile excretion, through gallstones 
obstructing the gall bladder or biliary tract, form through imbalances in cholesterol 
solubility458 and is regulated by the secretion and absorption of solutes from the 
cholangiocyte population459. Imbalances of in the secretory patterns in the liver or 
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cholangiocyte populations alters bile composition contributing to gallstones and biliary 
obstruction113,114. Complications of biliary obstruction can lead to jaundice, bile duct 
inflammation (cholangitis) and biliary pancreatitis116, which are higher risk 
diseases117,118 and increase likelihood of developing cholangiocarcinoma (CC)460.  
Cholangiocytes are cells that line the biliary tree, a system of interconnected 
tubular conduits originating in the liver, passing through the head of the pancreas and 
connecting with the duodenum461. The cholangiocyte population is composed of a 
heterogeneous population of cells that regulate bile formation by absorption and 
secretion of solutes in the bile109, mediated by neuropeptide462, immune signaling463 and 
hormone release464. Cholangiocytes also regulate immune recruitment, fibrotic 
deposition and angiogenesis465,466 in disease states, that can aid in injury resolution or 
result in persistent damage via pro-inflammatory immune cell signaling regulation of 
secretory patterns467. Tuft cells are present in the biliary tract95,111, along with a 
heterogeneous population of cholangiocytes107, but their exact function remains 
unknown. Biliary tuft cells express markers of gustatory signaling, TRPM5 and GNAT3 
(Figure 3.1, B)373, and nerve signaling (acetylcholine transferase (ACh), DCLK1 (Figure 
2.1, B))95 and are known to regulate immunity135 and nerve signaling149 in other organs. 
These features suggest a functional gustatory system that may communicate with 
nerves, immune populations or alter cholangiocyte secretion through paracrine 
signaling.  
Cholangiocarcinoma (CC) develops from cholangiocytes into malignant neoplasms 
of the biliary ductal system. Development of CC is broken down into three subtypes by 
location from liver to pancreas labeled as intrahepatic, perihilar and distal, 
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respectively121. These classifications are becoming increasingly important as each 
subtype have different survival rates. Perihilar CC and distal CC and share distinct 
similarities with pancreatic ductal adenocarcinoma (PDA)468, as may be due to shared 
embryonic origin122, and are associated with a worse clinical outcome121. Similarly to 
PDA, CC is characterized by mucin overexpression125, typically absent in normal 
tissues, KRAS and TP53 mutations469, and tumor markers, such as cytokeratin 19123. 
CC altered signaling activates cancer associated fibroblast (CAF) to promote a 
desmoplastic reaction470,471 and release of immune cell modulators, including tumor 
necrosis factor-alpha (TNF-α)472 and interleukin-6 (IL6)473, promote a pro-inflammatory 
state466. Analysis of the signaling between CC cells and the reactive stroma will further 
our understanding of the molecular mechanisms and may uncover new treatment 
options to extend patient survival.  
In this study, tuft cell function was altered by ablation of gustatory signaling to 
determine its role in neoplastic biliary development. Prior analysis of DCLK1 epithelial 
specific ablation, a microtubule kinase in tuft and nerve cells, found indications of 
dilation in the common bile duct with the presence of mutant KRAS. In the context of 
cholangiocyte expression of oncogenic KRAS, GNAT3 heterozygous or homozygous 
ablated animals had visibly dilated common bile ducts associated with decreased 
epithelial organization and immune influx. Obstruction of the ampulla of Vader, blocking 
passage of bile to the duodenum, was not found with GNAT3 ablation but an increase in 
vesicles present on the apical region of cholangiocytes suggest alterations in 
cholangiocyte secretion. Induction of carcinoma, with the further addition of dominant 
negative p53 expression, in GNAT3-ablated animals induced PDA as expected and 
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massive biliary dilation but did not have the histopathological features of CC. These 
data present an insight into tuft cell function in the biliary tract as modulators of bile 
composition and secretion.  
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Results 
4.1. GNAT3 Ablation Promotes Biliary Dilation and Immune Influx 
Development of the pancreas requires Pdx1 signaling in early pancreatic 
progenitors of the biliary tree, duodenum and endocrine and exocrine pancreas26,27. 
Ptf1a, also required for pancreatogenesis, is expressed later in development promoting 
only the development of pancreatic epithelium26,27. Therefore, use Pdx1Cre/+ expressing 
animals results in recombination that is maintained in the common bile duct as indicated 
by GFP IHC marking Pdx1Cre/+ driven ROSA26RLSL-EYFP recombined cells (Figure 4.1A). 
Prior work in our lab explored the phenotype of doublecortin like kinase 1 (DCLK1), a 
tuft and nerve cell marker also expressed in PDA stem cells, and its ablation in 
pancreatic neoplasia. While it has been published that DCLK1 pancreas specific 
ablation decreases PDA progression51, prior work in the lab performed by Shan Gao 
found no difference in transformation in the context of Pdx1Cre/+ or Ptf1aCre/+ driven 
mutant KRAS (data not shown). However, Ms. Gao’s analysis 
Dclk1Δ/Δ;KrasG12D/+;Pdx1Cre/+ phenotype identified biliary dilation at 16-weeks of age with 
vacuole presence on the apical side of the cholangiocytes (Figure 4.1B), suggesting 
alteration of secretory patterns. Since DCLK1 is expressed in biliary tuft cells (Figure 
2.1B), I hypothesized that compromising tuft cell function leads to biliary dilatation. To 
test the role of metaplastic tuft cell (MTC) gustatory signaling in the common bile duct, I 
bred TRPM5- or GNAT3-ablated animals to the KrasG12D/+;Pdx1Cre/+ (Kras;Pdx1Cre) 
model.  
Analysis of gross histology identified marginal biliary dilation in control 
KrasG12D/+;Pdx1Cre/+ (Kras;Pdx1Cre) animals at 14- to 16-weeks of age, indicating mutant 
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KRAS alone can alter biliary homeostasis (Figure 4.1C). However, biliary dilatation of 
Gnat3-/-;Kras;Pdx1Cre was noticeably greater than control Kras;Pdx1Cre animals and 
identified with gross histology at 6 to 8-weeks of age, becoming more severe over time 
(Figure 4.1C). This phenotype also resulted in mortality at 16 weeks of age of one 
animal out of a small cohort of four animals, possibly due to biliary rupture. Biliary 
dilation was also found in Gnat3-/+;Kras;Pdx1Cre animals, indicating GNAT3 expression 
requires a minimal threshold to maintain homeostasis (Figure 4.1D). Interestingly, 
ablation of TRPM5, another protein in the gustatory pathway and ubiquitously 
expressed in tuft cells134, together with KRASG12D expression showed bile duct 
enlargement comparable to KRASG12D controls (Figure 4.1E). Histological analysis 
found increased stromal deposition and cell influx in both homozygous and 
heterozygous GNAT3-ablated animals (Figure 4.1F). Furthermore, the epithelial border 
was disrupted with apical vesicles present in Gnat3-/-;Kras;Pdx1Cre animals (Figure 
4.1F). Analysis of both the Dclk1Δ/Δ;Kras;Pdx1Cre model, by Ms. Gao, and Gnat3-/-
;Kras;Pdx1Cre model, by myself, find biliary dilation and vesicle presence in the epithelial 
layer suggesting tuft cell control of cholangiocyte secretion or absorption.  
GNAT3-ablated bile ducts where characterized for tuft and immune cell 
presence. By staining for DCLK1, tuft cells were found in non-disrupted epithelium of 
Gnat3-/-;Kras;Pdx1Cre common bile ducts (Figure 4.2A, 1) but were absent in the 
disrupted epithelium (Figure 4.2A, 2), indicating the need for intact epithelium to 
maintain tuft presence. Biliary proliferation was increased in both the epithelium and 
stroma of Gnat3-/-;Kras;Pdx1Cre animals as measured by Ki67 staining (Figure 4.2B). 
Insights into immune cell influx was analyzed by staining for macrophage subsets and 
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T-cells. Macrophages, stained by F4/80, were present in both wild type and Gnat3-/-
;Kras;Pdx1Cre common bile ducts (Figure 4.2B). However chitinase-like 3 (CHIL3), a 
marker of anti-inflammatory macrophages, was increased in stroma as well as the 
epithelium potentially contributing to epithelial cell to survival and proliferation (Figure 
4.2B)474. Macrophage function was further analyzed by immunofluorescence staining for 
FIZZ1 and Arginase 1 (ARG1), also markers of anti-inflammatory macrophages. This 
analysis found minimal levels of FIZZ1 or ARG1 in the stroma, but high levels of 
macrophage and non-macrophage stromal CHIL3, in agreement with the IHC staining 
(Figure 4.2C). T-cell presence, as determined by CD3 staining, was increased as well 
as presence of CD8 cytotoxic T-cell subsets, not found in the wild type pancreas (Figure 
4.2B). Increased immune influx suggest dysregulation of immune signaling that may be 
induced by disordered epithelial cell secretion and signaling. However, further 
comparisons with Kras;Pdx1Cre controls will be needed to confirm and analyze 
differences induced by mutant KRAS expression alone.  
 
4.2. No Obstruction of the Ampulla of Vater Evident by Histology in GNAT3-
ablated Animals 
Dilation of the common bile duct occurs through many mechanisms including 
altered regulation of bile composition creating cholesterol stones475 or obstruction of the 
connection to the duodenum, the ampulla of Vater. Analysis of the ampulla of Vater for 
polyp formation or histological blockages was performed by Riley Bergman for Gnat3-
/+;Kras;Pdx1Cre and Gnat3-/-;Kras;Pdx1Cre animals. Crosswise sections of the ampulla of 
Vater connection to the duodenum did not indicate polyp formation but did demonstrate 
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presence of vacuoles in the epithelial compartment in GNAT3 altered animals (Figure 
4.3A). Further assessment, performed by lengthwise sectioning, indicated no obvious 
polyp formation or histological obstructions present. Extensive vacuole presence in 
GNAT3-ablated animals, along with intact ampulla of Vater connection, suggest 
secretory dysregulation leads to biliary dilation.  
 
4.3. GNAT3 Ablation Does Not Progress to Cholangiocarcinoma  
Expression of mutant KRAS signaling in the biliary tract leads to dilation of the 
common bile duct, which is exacerbated by compromising tuft cell function. In order to 
determine the function of GNAT3 in CC, we generated animals with 
p53R172H/+;KrasG12D/+;Pdx1Cre/+ (p53;Kras;Pdx1Cre), which rapidly forms PDA83 leading to 
animal morbidity but can form CC, because of biliary recombination476. Initial control 
p53;Kras;Pdx1Cre animals were aged to morbidity due to PDA, with minimal biliary 
dilation or expansion, indicating a lack of CC (Figure 4.4A). Analysis of Gnat3-/-
;p53;Kras;Pdx1Cre animals found increased dilation of the bile duct at 8-weeks that 
increased in 14-week PDA tumor bearing mice, suggesting loss of p53 may contribute 
to biliary dysregulation. Histologically, the common bile duct does not have the features 
of cholangiocarcinoma and with only dilation comparable Kras;Pdx1Cre samples. 
However, the sample size for each group is too low for a proper comparison analysis to 
be performed at this time. Collection of more samples and time points will help 
characterize gustatory ablation and its role in biliary dilation and CC.   
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Discussion 
Obstruction of the biliary duct leads to pain, inflammation and complications of 
other organs, including liver and pancreas. Cholangiopathies, or chronic diseases of the 
biliary tree, affect cholangiocyte regulation and signaling leading to organ dysregulation. 
In this work we found that tuft cell signaling in the biliary tract influences secretory 
function of cholangiocytes. Tuft cell alteration, by ablation of DCLK1 or GNAT3 with the 
addition of mutant KRAS, induced dilation of the common bile duct and presence of 
apical vesicles on the cholangiocytes. This phenotype was most noticeable in GNAT3 
altered Kras;Pdx1Cre mice, with increased desmoplasia, CHIL3 macrophage presence, 
T-cell cell influx and disruption of the epithelial layer. Obstruction of the connection to 
the duodenum, the ampulla of Vater, was not found histologically in GNAT3-ablated 
animals, suggesting alternate mechanisms of bile retainment. Analysis of GNAT3-
ablated p53;Kras;Pdx1Cre animals found biliary dilation but no histological evidence of 
CC. These data indicate a tuft cell role for bile modulation in the biliary tract through 
direct influence on cholangiocytes or immune populations. 
Tuft cells in the bile duct were found nearly 40 years ago but their exact function 
is still unknown111. Tuft cells in other organs communicate with nerves, blood vessels 
and immune cell populations in order to modulate immunity129. These data suggest 
biliary tuft cells may have another role in regulating bile function. The composition of bile 
is regulated through activation of cholangiocyte secretion by neuropeptides477 and 
hormones461,478 controlling bicarbonate, water and bile salt levels479,480. Stimulation of 
cholangiocyte secretion is further regulated by acetylcholine (ACh)481-483 and adrenergic 
agonists484 secreted by nerves around the bile duct to potentiate bicarbonate presence 
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in the bile. Interestingly, biliary tuft cells are marked by choline acetyltransferase95, a 
key enzyme in the production of ACh, suggesting paracrine regulation of cholangiocyte 
secretion through binding to muscarinic receptors482. Indeed, inhibition of ACh signaling 
reduces the contraction rate of both the gallbladder485 and the sphincter of Oddi486, 
minimizing the capacity for biliary flow to the duodenum. Furthermore, tuft cells can 
communicate directly with nerves and immune cells, both populations dysregulated in 
biliary obstruction461. Alteration of tuft cell gustatory function would then directly or 
indirectly alter homeostasis of bile composition through cholangiocyte regulation.   
Addition of mutant KRAS into the cholangiocyte population alters homeostasis of 
the common biliary duct, irrespective of tuft cell gustatory signaling. Analysis of 
Kras;Pdx1Cre gross histology demonstrated a mild biliary dilation through aging that was 
further advanced with the alteration of tuft cell signaling. However, GNAT3-ablated bile 
ducts with normal KRAS presence did not show any features of biliary obstruction or 
dilation (data not shown), suggesting a unique role of mutant KRAS signaling to 
propagate these effects. Clinically, this phenotype presents similarly to choledochal 
cysts487, a rare cystic dilatation of the biliary tree, which currently has no known etiology 
or treatment beyond surgery488, potentially suggesting a role for KRAS mutations in this 
disease. In fact, intraductal papillary neoplasms of the bile duct are characterized by 
dilated intrahepatic ducts and are characterized by mutations in KRAS489. Expression of 
KRASG12D by Pdx1Cre induces recombination in the extrahepatic ducts, extending the 
role of KRAS in controlling secretion throughout the biliary tree. How tuft cell gustatory 
signaling is altered by the presence of mutant KRAS is still unknown but suggests 
crosstalk between gustatory and KRAS pathways.  
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This chapter finds tuft cell gustatory signaling directly or indirectly alters the 
homeostasis of the biliary tract. Dilation of the bile duct may be influenced by alterations 
in bile composition contributing to bile stone development or altered signaling to nerves 
or immune cells influencing secretion. Understanding the role of tuft cell gustatory 
signaling in the extrahepatic bile duct will continue to broaden our knowledge of 
cholangiocyte signaling and lead the way for novel treatment options. 
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Future Directions 
The mechanism of biliary dilation following tuft cell alteration is still not fully 
elucidated with the data presented in this chapter and require further analysis to explore 
this phenotype more in-depth. Survival analysis of both the Kras;Pdx1Cre and 
p53;Kras;Pdx1Cre models following GNAT3 ablation will inform survival benefits of tuft 
cell gustatory signaling. In addition, analysis of the biliary tract, before dilation, for 
immune and nerve presence will need to be performed by IHC or flow cytometry in 
order determine the role of gustatory signaling in immune influx prior to phenotypic 
disease. Presence of mutant KRAS alone causes mild bile duct enlargement, 
suggesting alteration in secretion or signaling to surrounding cell types. Understanding 
the role of KRASG12D by cytokine release or alteration in signaling can be measured 
through flow cytometry or cytokine arrays of the biliary tract.  
The biliary tract gross histology suggest alterations in the extrahepatic bile duct 
that can also be analyzed by presence of liver enzymes in the blood490, indicating biliary 
tract alterations influence liver function. Serum was collected from one Kras;Pdx1Cre and 
3 Gnat3-/-;Kras;Pdx1Cre to be analyzed for liver enzyme presence. Assessment of liver 
histology will also need to be performed to analyze intrahepatic biliary structures and 
hepatocyte presence. Furthermore, continued analysis and collection of Gnat3-/-
;p53;Kras;Pdx1Cre animals will be critical to understanding gustatory signaling with liver 
bile secretion and CC development. 
Analysis of the ampulla of Vater does not show histological obstruction of bile 
into the duodenum yet did show vacuole presence in the cholangiocyte population, 
suggesting alteration in secretion. Biliary blockages can occur due to gall or biliary 
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stones which inhibit bile flow115. Analysis of the bile will give insight to secretory function 
and obstruction and, as bile was collected from five Gnat3-/-;Kras;Pdx1Cre animals with 
dilated bile ducts, can be performed at a rapid pace. Measurement of cholesterol, 
bicarbonate and bile salt levels will give insight into the composition of bile, presence of 
gall stones and cholangiocyte secretory alteration due to gustatory signaling ablation. 
These analyses will also be aided in understanding tuft cell mediated signaling 
controlling secretory patterns. ACh is known to alter secretion and is found in biliary tuft 
cells, therefore, tuft cell-specific ablation of acetylcholine transferase and presence of 
mutant KRAS would be an informative experiment to investigate the role of tuft cell 
driven muscarinic signaling. 
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Materials and Methods 
Mice 
All animal procedures and experiments were conducted with approval of the 
Institutional Committee on Use and Care of Animals at the University of Michigan.  
The following mice strains were used: Pdx1Cre/+, KrasG12D/+ and p53R172H/+ (gift of 
David Tuveson, Cold Spring Harbor Laboratory, NY); and Gnat3-/- (gift of Robert 
Margolskee, Monell Chemical Senses Center, PA). Mice were crossed on mixed 
background to generate Gnat3-/-;KrasG12D/+;Pdx1Cre/+ and Gnat3-/-
;p53R172H/+;KrasG12D/+;Pdx1Cre/+ mice. Mice were aged and euthanized at specified time 
points or at moribundity. All analyses were performed using strain-controlled animals. 
 
Immunohistochemistry 
Following mouse euthanization, gross histology was photographed then bile duct, 
pancreas and spleen were collected and fixed in Z-fix (NC9050753; Anatech Ltd., Battle 
Creek, MI) overnight. Tissues were processed with a Leica ASP300S tissue processor 
(Buffalo Grove, IL). Paraffin-embedded tissues were sectioned at 4 µm per slide and 
stained for target proteins using the Discovery Ultra XT autostainer (Ventana Medical 
Systems Inc., Tucson, AZ). Antibodies were stained, as outlined in Table 4.1, followed 
by Mayer’s hematoxylin (NC9220898; Millipore-Sigma) counterstain. H&E staining was 
performed using Mayer’s hematoxylin and eosin Y (HT110116; Fisher, Pittsburgh, PA). 
Immunohistochemistry slides were imaged and stitched together by a Pannoramic 
SCAN scanner (Perkin Elmer, Seattle, WA) using a 20x objective lens.  
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Table 4.1 Immunostaining Antibodies 
Antibody Company Catalog number Dilution Purpose 
DCLK1 Abcam ab37994 1:2000 IHC 
Ki67 Abcam ab15580 1:1000 IHC 
F4/80 Cell Signaling 70076 1:250 IHC, IF 
CHIL3 Abcam ab113664 1:250, 1:800 IHC, IF 
CD3 Abcam ab5690 1:200 IHC 
CD8 Cell Signaling 98941S 1:100 IHC 
FIZZ1 Abcam ab39626 1:500 IF 
ARG1 Proteintech 16001-1-AP 1:500 IF 
 
Immunofluorescence 
Immunofluorescence staining was performed on frozen tissue sections, as 
described previously424. In sum, pancreata were fixed in Z-fix for 2-3 hours, 30% 
sucrose in phosphate buffered saline (PBS) overnight, equilibrated in a 1:1 mixture of 
30% sucrose/PBS and optimal cutting temperature embedding medium (OCT) for 30 
minutes, embedded in OCT, frozen by liquid nitrogen and stored at -80°C. Frozen tissue 
sections (7 µm) were acquired using a Leica CM1860 (Leica Biosystems, Buffalo Grove, 
IL) cryostat set at -20°C and permeabilized in 0.1% Triton X-100 (T9284; Millipore-
Sigma) in PBS (1 hour). H&E was performed to section through lengthwise ampulla of 
Vater following washing as detailed for paraffin sections.  
Immunofluorescence was performed by blocking with 5% donkey serum/1% 
bovine serum albumin (BSA) in PBS (1 hour), primary antibodies (listed in Table 4.1) 
overnight at room temperature in 0.1% Triton X-100/1% BSA in PBS, followed by 3 
washes of 0.1% Triton X-100/PBS for a total of 45 minutes. Sections were incubated 
with Alexa Fluor-conjugated secondary antibodies at 1:500 and phalloidin at 1:250 (both 
Invitrogen, Carlsbad, CA) (1-hour) then 3 washes as before, rinsed in deionized water 
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and mounted with Prolong Diamond antifade mountant (P36961; Fisher). Images were 
acquired on using an Olympus IX83 Inverted Microscope (Olympus).  
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Figures 
Figure 4.1 
 
Figure 4.1: Dilation of the bile duct with activating KRAS mutations and enhanced by tuft cell gustatory 
ablation. (A) GFP staining marking recombined cells on Dclk1Δ/Δ;KrasG12D/+, Pdx1Cre/+;ROSA26RLSL-YFP common bile 
duct. Scale bar: 50 µm. (B) H&E of 16-week KrasG12D;Pdx1Cre or two different Dclk1Δ/Δ;KrasG12D/+;Pdx1Cre/+ biliary 
ducts. Inset indicated by box and magnified below. Scale bars: 100 µm, far right = 200 µm, inset all = 50 µm. (C - E) 
Gross histology of common bile ducts. Bile duct is outlined in black, pancreas is outlined by dashed line. S = spleen, 
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L = liver, St = stomach and T = tweezers. (C) Aged KrasG12D;Pdx1Cre or Gnat3-/-;Kras;Pdx1Cre collected at 6 or 8, 12 
and 14 or 16 weeks old. (D) Gnat3-/+;Kras;Pdx1Cre sample at 14 weeks of age. (E) Trpm5-/-;Kras;Pdx1Cre bile duct 
aged to 26-weeks. (F) Histology of full pancreas and common bile duct. Insets indicated by black box and magnified 
below. Scale bar: full pancreas = 1000 µm, second row = 100 µm, final row = 50 µm.  
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Figure 4.2 
 
Figure 4.2: GNAT3-ablated extrahepatic biliary duct has reduced tuft cells and increased inflammation. (A) 
DCLK1 stain on Gnat3-/-;Kras;Pdx1Cre common bile duct. Tuft cells are found on the normal epithelium (1) but are lost 
in the vacuole-filled, disrupted epithelium. Scale bar: Top = 500 µm, bottom insets = 50 µm. (B) Staining of wild type 
or Gnat3-/-;Kras;Pdx1Cre common bile duct for proliferation (Ki67), immune infiltrate of macrophages (F4/80), 
macrophage anti-inflammatory polarization (CHIL1), T-cells (CD3) and cytotoxic T-cells (CD8). Scale bar: Ki67, F4/80 
= 100 µm, YM1, CD3, CD8 = 50 µm. (C) Immunofluorescent staining for macrophages (F4/80, green) with anti-
inflammatory markers: CHIL3 (white), FIZZ1 (red, top) or Arginase 1 (ARG1, red, bottom). Scale bar: 20 µm. 
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Figure 4.3 
 
Figure 4.3: Vacuoles found but no obstructions in GNAT3-ablated ampulla of Vater. (A) H&E of cross sectioned 
ampulla of Vater, the connection from the common biliary duct to the duodenum, surrounded by the intestinal 
epithelium. Magnified inset below from box. Scale bar: top = 100 µm, inset = 50 µm. (B) H&E of lengthwise ampulla of 
Vater sectioned through for one Gnat3-/-;Kras;Pdx1Cre to histologically assess for obstruction. Duodenum connection 
on top, pancreaticobiliary connection on bottom. Each section is 7 µm of tissue. Dark areas are folded tissue on 
section 10 and 50. Scale bars: 100 µm.  
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Figure 4.4
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Figure 4.4: GNAT3 ablation does not lead to cholangiocarcinoma. Analysis of p53LSL-R172H/+;KrasLSL-
G12D/+;Pdx1Cre/+ mice bred to Gnat3-/- animals. (A) Gross histology of 8-week animals or those that reached morbidity 
at 14-weeks. Bile duct is outlined in black, pancreas/tumor is outlined by dashed line. S = spleen, L = liver, St = 
stomach, GB = gall bladder and T = tweezers.  (B) H&E of two p53;Kras;Pdx1Cre pancreata, left, full carcinoma and 
right, prior to carcinoma, and a Gnat3-/-;p53;Kras;Pdx1Cre pancreas. First inset, unlabeled box on full pancreas and 
second inset of bile duct in box labeled BD. Scale bars: top = 1000 µm, inset = 100 µm. 
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Chapter 5. The Pitfalls of Genetically Engineered Mouse Models  
Introduction 
Advancements in cancer therapies and increased patient survival have been 
supported by development of animal models which recapitulate disease onset and 
progression. Common methods of studying these diseases in animals are cancer cell 
transplantation models, cancer-inducing genetic modifications and spontaneous cancer 
development491 using a variety of animal species, including mice, rats, cats and dogs492. 
In pancreatic ductal adenocarcinoma (PDA), use of genetically engineered mouse 
models (GEMMs) has become an important research tool for pre-clinical study and drug 
development493,494. The most common mouse models of PDA utilize the pancreas 
specific expression of mutant in KRAS80, found in over 90% of pancreatic patients55,66,67, 
withc disease further accelerated by mutations in TP5383 or other tumor suppressor 
proteins. These models recapitulate the histologic features of human PDA80,83 allowing 
in depth study of the changes that occur following acquisition of cancer mutations as 
well as studies with novel therapeutic compounds before treatment in human 
patients493,494. GEMMs are continually evolving with novel genetic engineering 
possibilities being developed. Recent dual recombinase models, those that use CRE 
and FLPO driver systems, are at the forefront of this technology as they can promote 
PDA while allowing the ability to alter other compartments in order to study their 
contribution to cancer development495-497. However, the development of novel models 
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for cancer research also comes with the risk of issues with these models to arise and 
must, therefore, be analyzed carefully in order to translate these results to patient 
treatments. 
Although PDA mouse models recapitulate disease outcomes in humans in some 
experiments498, other research has shown that treatment outcomes are disparate in 
mouse and human studies499,500. One pivotal study demonstrating this difference 
focused on inhibition of the hedgehog pathway, where in PDA bearing mice blockade of 
hedgehog signaling provided a survival benefit499. However in humans, the clinical trial 
was canceled as patients had a worse outcome compared to the placebo group501. 
Other studies expanding in more depth on these results found ablation of hedgehog 
signaling to increase PDA progression and metastasis, contradicting initial results, and 
suggesting, instead of a dissimilar model, that a more in depth analysis of the mouse 
model was required502. These results demonstrate that careful study of novel animal 
models must be thoroughly performed in the research space to lead to advancements in 
human health and survival. Understanding and acknowledging the shortcomings with 
GEMMs can lead to more carefully designed clinical trials to advance treatment 
outcomes. 
Many GEMM studies have issues with reproducibility following publication, but 
new data suggest this may be due to reporting bias and improper data analysis503, 
indicating a critical need for thorough evaluation of novel animal models. During my 
graduate career, I was made clearly aware by multiple examples, that animal models 
have pitfalls which can completely alter the results of any study. Initial studies to 
validate two tuft cell reporters, Dclk1Cre/+ and Dclk1CreERT/+, found a staining pattern in 
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compartments outside tuft cells, indicating lineage tracing experiments to track tuft cell 
specific progeny would be impossible with these models. In addition, I found the 
Dclk1CreERT/+ was active prior to tamoxifen treatment, reducing the temporal control of 
this model. I also analyzed two lineage reporter alleles, the Dual and mTmG reporters, 
for their effectiveness in two different models of pancreatic transformation. Analysis of 
the Dual reporter found cystic lesions in the pancreas during transformation as well as a 
low recombination frequency of targeted cells. The mTmG reporter also altered 
transformation in models of cerulein-induced pancreatitis and in two models of KRAS 
induced pancreatic neoplasia. In the cerulein-induced pancreatitis or 
KrasG12D/+;Ptf1aCreERT/+ induced neoplasia there was a lack of transformation, yet in the 
KrasG12D/+;Ptf1aCre/+ model, transformation was rapidly accelerated. My analysis of these 
different models indicates the need for careful evaluation of GEMMs before use in novel 
experimental systems as the results collected may be driven by unexpected sources.  
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Results 
5.1. Dclk1 Recombinase Expression is Not Tuft Cell Specific 
My research focused on understanding the function of metaplastic tuft cells 
(MTCs) in the pancreas. In order to analyze tuft cell specific function, I worked to 
optimize a tuft cell specific recombinase which would allow for MTC lineage tracing and 
gene ablation as needed for downstream experiments. One potential genetic driver I 
tested was Dclk1. DCLK1 is a robust marker for tuft cells throughout the body in 
intestine, trachea, lung and bile duct and is also found in pancreatic MTCs94,95,111,131. 
Therefore, I tested two Dclk1 promoter driven CRE recombinase artificial chromosome 
systems generously given to the lab by Dr. Timothy Wang, the Dclk1Cre/+ and 
Dclk1CreERT/+ models50, to analyze for tuft cell specific recombination. The Dclk1Cre/+ 
system functions to express CRE recombinase from an embryonic timepoint in all cells 
expressing Dclk1. The Dclk1 expressing cells, and all daughter cells, can be visualized 
by identifying expression of the ROSA26REYFP  or ROSA26RtdTomato lineage tracing 
alleles. Initial results using the Dclk1Cre/+ system found pancreatic YFP expression in 
normal ducts, acinar cells and, following cerulein-induced pancreatitis, in the stromal 
compartment, as stained for by a GFP antibody (Figure 5.1A). Additionally, analysis of 
intestine, lymph nodes, spleen and blood vessels found many cells from the Dclk1 
lineage which do not morphologically resemble tuft cells (Figure 5.1B). Interpreting the 
YFP expression indicates that, while tuft cells are recombined as found morphologically 
in the intestine (Figure 5.1B), the Dclk1Cre/+ expressing cells were not specific to tuft 
cells, as the location and histology of much of the YFP expression does not match what 
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is known of tuft cells throughout the body, making this system unable to accurately track 
and trace tuft cell specific progeny.  
I then tested the Dclk1CreERT/+ model for tuft cell specific recombination, as this 
model maintains temporal control through administration of tamoxifen to activate 
CREERT function, which may alleviate much of the non-tuft cell specific recombination of 
those cells only expressing Dclk1 during development. In order to validate the 
effectiveness of the Dclk1CreERT/+, I first collected and analyzed corn oil treated control 
tissue. Surprisingly, I found with either YFP or tdTomato lineage tracing, clear 
recombination of cells in the bile duct, following cerulein-induced pancreatitis or in the 
lymph nodes and spleen following corn oil treatment (Figure 5.1C and D), indicating a 
concerning leakiness to this CRE driver system. Administration of tamoxifen to activate 
Cre function did find excellent tuft cell recombination in the bile duct, as marked by 
serial sections of DCLK1, to mark tuft cells, and YFP expression, marked by a GFP 
antibody (Figure 5.1C). However, similar to the Dclk1Cre/+ model, tdTomato 
recombination was found in acinar and ductal cells following cerulein-induced 
pancreatitis with tamoxifen treatment and collection three days post treatment (Figure 
5.1D). Recombination was also found in the lymph node and spleen by tdTomato 
expression and indicates that Dclk1 expressing cells are found in the adult animal and 
present in these organs (Figure 5.1C and D). In my studies of both the Dclk1Cre/+ and 
Dclk1CreERT/+ models, I found a lack of specificity to tuft cell recombination in these CRE 
driven systems and, therefore, switched to a novel recombinase model driven by Skn1α, 
a gene specific to gustatory sensing cells and tuft cells504.  
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Similar to the Dclk1 model systems, recombination by the Skn1αCreERT/+ system 
finds DCLK1 marked tuft cells expressing specific tdTomato recombination in the bile 
duct (Figure 5.1C) but, in contrast, found no extraneous recombination in the acinar and 
ductal cells of the cerulein damaged pancreas, lymph node or spleen (Figure 5.1D). The 
difference between the Dclk1CreERT and Skn1αCreERT/+ models was further illustrated 
through use of a 3D organoid culture system, where hydroxytamoxifen addition to the 
culture activates the CREERT promoting tdTomato expression to track cells over time. 
Analysis of corn oil treated Dclk1CreERT and Skn1αCreERT/+ cells corroborates findings in 
vivo, where the Dclk1 system has tdTomato expression prior to hydroxytamoxifen 
treatment, unlike the Skn1α system. Following hydroxytamoxifen addition to the culture 
system, the Dclk1 model finds increasing numbers of tdTomato positive cells with 
continual culture (Figure 5.1E). In comparison, the Skn1α recombinase recombines in 
distinct cells in the organoids which have very little expansion over time (Figure 5.1E), 
showing a clear and dramatic difference in results. These data showcase the need for 
accurate evaluation of model systems, even those that have been published, prior to 
use for interpretation of the correct results and implications in disease outcomes. 
 
5.2. The Dual Lineage Reporter Recombines Ineffectively and Alters Pancreatic 
Transformation 
Following the verification of the Skn1αCreERT/+ tuft cell specific reporter allele, I 
then generated a lineage tracing system able to track tuft cells in vivo during 
experimental pancreatitis and PDA progression. This novel model requires the use of a 
dual recombinase system where Ptf1aFlpO/+ drives expression of KrasFSF-G12D/+ (KF) 
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expression in the pancreas, promoting transformation and neoplasia while Skn1αCreERT/+ 
can be used to track MTCs present during progression (Figure 5.2A). Evaluation of this 
system tested two lineage reporter models to track MTCs presence, the Dual 
reporter495, generously given by Dr. Dieter Saur, or the tdTomato reporter allele. Both of 
these genetic modifications are inserted in the ROSA26R allele but, where the 
tdTomato gene is a simple CRE activated system, the Dual reporter is a larger construct 
able to track FLPO induced recombination by GFP and CRE recombination by 
membrane tdTomato expression (Figure 5.2B). Initial analysis of these recombinase 
systems, using cerulein-induced pancreatitis treated Skn1αCreERT/+ animals, found a 
distinct lack of Dual reporter recombination in comparison to the tdTomato reporter 
when evaluating the bile duct and damaged pancreas (Figure 5.2C). This was 
concerning as the goal of the project was to track and trace MTCs and a faulty lineage 
tracing system could directly influence results, however, I continued to test these 
reporters in the experimental KF Skn1αCreERT/+ model.  
Utilizing the KF Skn1αCreERT/+ system, I again found a lack of recombination in the 
Dual animals compared to the tdTomato lineage reporter (Figure 5.2D). From my 
analysis, I determined approximately a 10% recombination rate of MTCs following the 
standard protocol in the lab of five tamoxifen treatments or a 40% recombination rate 
with three weeks of tamoxifen chow of Dual reporter tracking tuft cells in KF 
Skn1αCreERT/+ animals. In contrast, the tdTomato reporter had a nearly 100% 
recombination rate following five tamoxifen treatments in the KF Skn1αCreERT/+ animals, 
providing a far more useful system for MTC tracking. Additionally, the presence of the 
Dual reporter altered the phenotype of the pancreas, promoting more cystic lesions in 
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comparison to the tdTomato system, which was indistinguishable to the base KF model 
progression (Figure 5.2E). The cause of these differences in recombination and 
phenotype are unknown but may be due to the size of the reporter insert, the membrane 
tdTomato or the insertion process of the different alleles in the ROSA26R locus. Further 
studies will have to be performed to fully understand how lineage tracers can impact 
phenotype and recombination efficiency in this model. However, these analyses clearly 
show the need for proper experimentation and controls prior to the use of a novel 
GEMM system. 
 
5.3. The mTmG Reporter Allele Alters Pancreatic Transformation 
While generating Gnat3-/-;KrasLSL-G12D;Ptf1aCreERT model system for the results 
detailed in Chapter 2, I utilized the mTmG reporter allele to evaluate the effectiveness of 
tamoxifen induced recombination and downstream proliferation of acinar-derived 
daughter cells29. The mTmG reporter is a lineage tracing system which expresses 
membrane tdTomato in all cells of the animal that will be excised and replaced with 
membrane GFP following CRE activation505 (Figure 5.3A-C, left). However, initial 
evaluation of this otherwise useful model system finds that, regardless of Gnat3 status, 
mTmG presence profoundly affected the phenotype of the pancreas in cerulein-induced 
pancreatitis as well as KrasG12D/+;Ptf1aCreERT/+ (KCERT) and KrasG12D/+;Ptf1aCre/+ (KC) 
transformation. 
Analysis of the cerulein-induced pancreatitis model utilized the Ptf1aCreERT/+ 
(CreERT) system, where animals were either treated with tamoxifen, to induce mTmG 
recombination, or corn oil, as controls for tamoxifen treatment, then treated with cerulein 
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twice per day for two weeks followed by collection one day post treatment (Figure 5.3, 
left). Analysis of corn oil treated animals found little difference with mTmG presence in 
the pancreatic histology and transformation following cerulein-induced pancreatitis 
(Figure 5.3, right). However, activation of the mTmG system by tamoxifen administration 
prior to experimental pancreatitis treatment, finds a distinct lack of pancreatic acinar-to-
ductal metaplasia (ADM) and transformation in mTmG harboring pancreata. These 
results suggest activation of this model may influence pancreatic damage or healing 
responses with cerulein-induced pancreatic damage. I therefore went on to study KCERT 
animals which had not been treated with cerulein. 
With the help of Dr. Kenneth Takeuchi, I evaluated KCERT animals either with no 
transgene or harboring the mTmG allele treated with tamoxifen, to activate mutant 
KRAS, and collected six weeks post treatment (Figure 5.3B). Analysis of the histology 
found a similar result as the experimental pancreatitis animals, where the pancreas had 
reduced transformation with the mTmG allele (Figure 5.3B, right). In order to accelerate 
the pancreatic damage and evaluate this phenotype further, I treated KCERT animals 
with cerulein following tamoxifen treatment and collected pancreata after six weeks 
(Figure 5.3B, left). Similarly, I found a distinct lack of pancreatic transformation in this 
model, where strain and littermate control animals were noticeably more damaged than 
mTmG harboring siblings (Figure 5.3B, right). These results make this model system 
difficult to use in the context of experimental studies and clear interpretation of results. 
However, these results may be influenced by use of the Ptf1aCreERT/+ allele requiring 
tamoxifen treatment to activate mTmG recombination so I worked to test the KC model 
of pancreatic transformation. 
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Analysis of KC mice found a dramatic, yet opposite, difference in phenotype with 
presence of the mTmG allele, compared to the KCERT model. KC animals were aged for 
16 weeks prior to collection of animals with no transgene or mTmG harboring mice 
(Figure 5.3C, left). In comparison to the Ptf1aCreERT/+ models, the KC mTmG pancreata 
had a dramatic increase in pancreatic transformation and fibrosis, as depicted by the 
picrosirius red staining (Figure 5.3C, right). This advanced acceleration was found at 
even 8 weeks of age (data not shown) suggesting a rapid increase in pancreatic 
transformation with mTmG allele activation. Although the exact mechanism of mTmG 
function which alters pancreatic transformation is not known, these results demonstrate 
the crucial need for evaluation of lineage reporters and alteration of phenotypes to more 
directly translate research results to clinical treatments. 
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Discussion 
 During my graduate research my experiments uncovered potential vulnerabilities 
in recombinase driven systems and lineage reporters which would have dramatically 
impacted future experiments. Work in characterizing a tuft cell specific recombinase 
found that Dclk1 is expressed in multiple cell types and that the Dclk1CreERT/+ system has 
inherent leaky CRE activation, confounding results. This is in comparison to the 
Skn1αCreERT/+ model, which recombines with high fidelity for tuft cells and only after 
tamoxifen administration. Additionally, my data uncovers issues in the Dual and mTmG 
lineage tracing alleles in my animal models. The Dual recombinase demonstrates 
inefficient recombination frequency, with alterations in pancreatic transformation 
promoting cystic pancreatic lesions. Analysis of the mTmG model finds activation in 
Ptf1aCreERT/+ systems to suppress pancreatic transformation while in Ptf1aCre/+ models it 
accelerates neoplastic formation. By performing these control experiments I was able to 
accurately evaluate these systems and switch to the more effective and unobtrusive 
GEMM models. My data collected here emphasize the need for proper experimental 
controls and data analysis prior to use of GEMM model systems to effectively translate 
these results to human health.  
My evaluation of the Dclk1Cre/+ and Dclk1CreERT/+ model system finds expression 
of Dclk1 in a variety of organs which do not show tuft cell specificity. This makes it 
difficult to reasonably conclude the specificity of acinar specific Dclk1 expressing cells 
within the pancreatic milieu. However results published using the Dclk1CreERT/+ model 
suggest that DCLK1 expressing progenitor cells form a quiescent stem cell population 
within the pancreas50. This model would need to be supplemented with more careful 
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analysis showing the Dclk1 progenitor cells were pancreas-derived or characterization 
of the cell populations that were lost throughout the body which may be contributing to 
this phenotype, in order to clearly interpret the results and impact to biological 
outcomes50. In addition, I found the Dclk1CreERT/+ model to show leaky CRE expression, 
which is found in many CreERT models506 but use of these models require the proper 
controls to evaluate lineage tracing and ablation experiments. Though the results 
presented here may differ from the published results, as these models were bred into 
different lineage reporter systems which alters the background mouse strain, including 
the epigenetics507, which may influence recombination efficiency. However, to truly 
evaluate this system, a more thorough analysis would need to have been requested 
prior to publication in order to accurately interpret these results. 
Lineage tracing in GEMMs is a feature that has been used in scientific research 
to evaluate gene expression and proliferation within organisms. Many of these models, 
such as the mTmG reporter508, have been used for years while novel systems, such as 
the Dual reporter495, have been developed more recently. However, my results show 
that no matter what model is being generated, careful evaluation is required before use 
in experiments. Published results using the Dual reporter show efficient recombination 
and make no mention of any alterations in pancreatic phenotype495, while my results 
have a different outcome. However, there are many factors which may influence these 
differences including the use of different FLPO driven systems of Pdx1FlpO or Ptf1aFlpO, 
which impact the genome and recombination lineage as well as rate of transformation. 
Similarity, my results using the mTmG reporter model have not been noted in other 
papers using the same reporter in the pancreas51,509, though, again, this may be due to 
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different CRE genetic drivers altering results. Though lineage tracers have been 
established in the research field for many years, generation of novel mouse systems 
continues to require careful controls to evaluate functional differences.  
While a greater sample size is required to validate these results, these data 
provide a framework for future scientific endeavors. The presentation of these data calls 
into question prior results using these models and stresses informed discussions of the 
critical nature necessary for animal modeling. There are many differences between 
animal models and human disease but minimizing these differences starts with careful 
analysis of novel systems to maintain fidelity of model systems, even with the difficulties 
inherent in control studies, such as time and cost500. Issues with reproducibility in 
GEMM research influence drug therapies and clinical outcomes which can be minimized 
by careful data collection and analysis to increase the transparency and relevance of 
scientific results to human health.  
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Materials and Methods 
Mice 
All animal procedures and experiments were conducted with approval of the 
Institutional Committee on Use and Care of Animals at the University of Michigan. 
The following mice strains were used: Ptf1aFlpO/+, Ptf1aCre/+ and Ptf1aCreERT/+;422 
KrasG12D/+ (gift of David Tuveson, Cold Spring Harbor Laboratory, NY); KrasFSF-G12D/+ 
(gift of Chris Wright, Vanderbilt University, TN); Dclk1Cre/+ and Dclk1CreERT/+ (gift of 
Timothy Wang, Columbia University Medical Center, NY); Skn1αCreERT/+ (gift of  Ichiro 
Matsumoto, Monell Chemical Senses Center, PA); ROSA26RDual/+ (gift of Dieter Saur, 
Technical University of Munich, Germany); ROSA26RmTmG/+, ROSA26RtdTomato/+ and 
ROSA26REYFP/+ (from the Jaxson Laboratory). Mice were crossed on a mixed 
background to generate experimental animals. All analyses were performed using 
strain-controlled animals. Cerulein-induced experimental pancreatitis was induced by 25 
µg/kg cerulein (46-1-50; American Peptide Company. Inc, Sunnyvale, CA) 
intraperitoneal injections twice daily for 2- or 3-weeks in 8-week old mice, as described 
previously168. Dclk1CreERT/+ or Skn1αCreERT/+ recombination was induced following 
cerulein treatment animals by oral gavage with 5 mg of tamoxifen (T5648; Millipore-
Sigma, St. Louis, MO) dissolved in corn oil for 5 days.  
Treatment of KrasFSF-G12D/+;Ptf1aFlpO/+;Skn1αCreERT/+ animals harboring the 
ROSA26RDual/+ or ROSA26RtdTomato/+ alleles was performed by once a day 
intraperitoneal injection with 250 µg/kg cerulein (46-1-50; American Peptide Company) 
for 5 days then, following a two week rest, tamoxifen administration by oral gavage for 5 
days before collection 3 days later. Experimental KrasG12D/+;Ptf1aCreERT/+; animals were 
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treated with corn oil dissolved tamoxifen once a day for 5 days by oral gavage then, 
after a 2-day rest post tamoxifen treatment, experimental pancreatitis was induced once 
a day by intraperitoneal injection with 250 µg/kg cerulein (46-1-50; American Peptide 
Company) for 5 days. Pancreata were harvested 6-weeks post cerulein treatment.  
 
Immunohistochemistry 
Pancreata were collected, weighed and fixed in Z-fix (NC9050753; Anatech Ltd., 
Battle Creek, MI) overnight. Processing of tissues was performed using a Leica 
ASP300S tissue processor (Buffalo Grove, IL). Sections (4 µm) of paraffin-embedded 
tissue were stained for target proteins using the Discovery Ultra XT autostainer 
(Ventana Medical Systems Inc., Tucson, AZ). Antibodies were stained as listed in Table 
3.1 followed by Mayer’s hematoxylin (NC9220898; Millipore-Sigma) counterstain. H&E 
staining was done using Mayer’s hematoxylin and eosin Y (HT110116; Fisher, 
Pittsburgh, PA). Picrosirius red staining was performed on sectioned paraffin-embedded 
tissue per manufacturer instructions (Polysciences Inc., Warrington, PA). 
Immunohistochemistry slides were imaged and stitched together by a Pannoramic 
SCAN scanner (Perkin Elmer, Seattle, WA) using a 20x objective lens.  
 
Immunofluorescence 
Immunofluorescence staining was performed on frozen tissue sections, as 
described previously424. In sum, pancreata were collected and fixed in Z-fix for 2-3 
hours, followed by 30% sucrose in phosphate buffered saline (PBS) overnight. 
Pancreata were equilibrated in a 1:1 mixture of 30% sucrose/PBS and optimal cutting 
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temperature embedding medium (OCT) for 30 minutes, embedded in OCT, frozen by 
liquid nitrogen and stored at -80°C. Frozen tissue sections (10 µm) were acquired using 
a Leica CM1860 (Leica Biosystems, Buffalo Grove, IL) cryostat set at -20°C, 
permeabilized in 0.1% Triton X-100 (T9284; Millipore-Sigma) in PBS for 1 hour and 
blocked by using 5% donkey serum/1% bovine serum albumin (BSA) in PBS for 1 hour. 
Incubation with DCLK1, the primary antibody, (listed in Table 3.1) was performed 
overnight at room temperature in 0.1% Triton X-100/1% BSA in PBS, followed by 3 
washes of 0.1% Triton X-100/PBS for a total of 45 minutes. Sections were incubated 
with Alexa Fluor-conjugated anti-rabbit secondary antibodies at 1:500 (Invitrogen, 
Carlsbad, CA) for 1-hour room temperature followed by 3 washes as before. Finally, 
slides were rinsed in deionized water and mounted with Prolong Diamond antifade 
mountant (P36961; Fisher). Images were acquired on a LSM800 confocal microscope 
(Zeiss, Oberkochen, Germany) using a 63x objective or with an Olympus BX53F 
microscope (Olympus, Shinjuku City, Tokyo, Japan) using a 20x objective. Endogenous 
signaling was used for tdTomato imaging (ROSA26RDual and ROSA26RtdTomato). 
 
Table 5.1 Immunostaining Antibodies 
Antibody Company Catalog number Dilution Purpose 
DCLK1 Abcam ab37994 1:2000 IHC, IF 
GFP Rockland 600-406-215 1:100 IHC 
tdTomato Lifespan Bioscience LS‑C340696 1:200 IHC 
 
Organoid Culture 
Acinar cell isolation from fresh pancreas was performed as previously 
described28. Briefly, pancreata from 8- to 10-week old mice were sterilely harvested, 
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washed twice in Hank’s buffered salt solution (HBSS), minced and digested in 0.2 
mg/mL Collagenase P (11249002001; Millipore-Sigma) for 15 minutes at 37°C. Tissue 
was washed 3 times in 5% fetal bovine serum (FBS) in HBSS, centrifuged at 300xg for 
2 minutes, re-suspended in HBSS and filtered through 500 µm and 105 µm 
polypropylene mesh (888-13570 and 888-13597; Spectrum Laboratories, New 
Brunswick, NJ). Cell suspension was slowly added to a gradient consisting of 30% FBS 
in HBSS and centrifuged at 300xg for 2 minutes. Isolated acinar cells were resuspended 
in Pancreatic Progenitor and Tumor Organoid Media (PTOM), made as previously 
described with 100 U/mL Pen Strep (15140122; Invitrogen), 1% B27 supplement 
(17504044; Invitrogen), 50 µg/mL ascorbic acid (A4403; Millipore-Sigma), 0.4% bovine 
pituitary extract (13028-014; Thermo Fisher, Waltham, MA), 10 µg/mL insulin (I2643; 
Millipore-Sigma), 0.5 µg/mL hydrocortisone (H0888; Millipore-Sigma), 5 ng/mL FGF-2 
(F0291; Millipore-Sigma), 10 ng/mL FGF-10 (345-FG; R&D Systems, Minneapolis, MN), 
25 nM retinoic acid (R2625, Millipore-Sigma) and 5 µM Y-27632 (50-175-996; Fisher) in 
DMEM:Glutamax (10564-011; Thermo Fisher).391 Acinar cells were floated in a petri 
dish for 2 hours in PTOM then 10,000 to 12,500 cells were plated in a PTOM 5% 
Matrigel mixture on a bed of 100% Matrigel in a 24-well plate. Media was changed to 
fresh PTOM every 4 days. Live imaging of lineage traced Dclk1CreERT/+; ROSA26RtdTomato 
and Skn1αCreERT/+;ROSA26RtdTomato was performed using an Olympus CKX41 light 
microscope (Olympus).  
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Figures 
Figure 5.1 
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Figure 5.1: Linage tracing shows Dclk1 driven recombinase is not tuft cell specific. (A) Staining of GFP (brown) 
to mark YFP recombined cells in Dclk1Cre/+;ROSA26REYFP pancreas collected at eight weeks of age (left) or treated 
with cerulein for three weeks twice daily and collected seven days post treatment (right). Recombination is found in 
ductal, acinar and stromal cells by YFP expression. Scale bar: 50 µm. (B) GFP stained (brown) YFP positive cells 
from Dclk1Cre/+;ROSA26REYFP intestine, lymph node, spleen and blood vessels/adipose tissues. Scale bar: 50 µm. (C) 
Top: DCLK1 staining (brown) to mark tuft cells or GFP staining (brown) to mark recombined cells from serial sections 
in the bile duct of Dclk1CreERT/+;ROSA26REYFP animals treated with corn oil or tamoxifen collected three days post 
treatment. Bottom: Skn1αCreERT/+;ROSA26RtdTomato tissue collected three days post tamoxifen treatment with serial 
bile duct sections stained for DCLK1 (brown), for tuft cells, or tdTomato (brown), indicating lineage traced cells. Scale 
bar: 50 µm. (D) tdTomato staining (brown) to mark recombined cells in three week twice daily cerulein treated 
pancreata collected three days post treatment, lymph nodes or spleen in corn oil or tamoxifen treated 
Dclk1CreERT/+;ROSA26RtdTomato or Skn1αCreERT/+;ROSA26RtdTomato animals. Scale bar: 50 µm. (E) Ex vivo organoid 
culture of Dclk1CreERT/+;ROSA26RtdTomato or Skn1αCreERT/+;ROSA26RtdTomato acinar cells with or without 
hydroxytamoxifen treatment. tdTomato positive cells (red) were tracked over time with continual hydroxytamoxifen 
administration. Scale bar: Top: 20 µm, left two, 50 µm, middle, 200 µm, right two; Bottom: 20 µm, left, 100 µm, 
second left, 50 µm, middle and second right, 200 µm, right. 
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Figure 5.2 
 
Figure 5.2: Dual reporter allele has low recombination efficiency and alters pancreas transformation. (A) 
Alleles required for the tuft cell specific dual recombinase system where Ptf1aFlpO/+;KrasFSF-G12D (KF) animals promote 
pancreatic transformation while the Skn1αCreERT/+ can be utilized for tuft cell tracking. (B) Lineage tracing reporter 
alleles of the Dual and tdTomato reporters. Both are inserted into the ROSA26R (R26) locus but the Dual reporter 
can be targeted by FLPO to cleave frt sites and CRE to target lox sites. (C) Skn1αCreERT/+ animals treated with 
cerulein for three weeks twice daily, tamoxifen for five days and collected three days post treatment. Analysis of bile 
duct and damaged pancreas for tuft cells, DCLK1 (green), and recombined cells, tdTomato (red), finds clear overlap 
in the tdTomato reporter but no recombination in the dual reporter mice. Nuclei counterstained by DAPI. Scale bar: 20 
µm. (D) Staining of tuft cells by DCLK1 (green) in KF;Skn1αCreERT/+  animals finds nearly 100% overlap with the 
tdTomato reporter but only 10% to 40% with the Dual reporter allele as marked by tdTomato (red). Nuclei 
counterstained by DAPI. Scale bar: 10 µm. (E) H&E of KF;Skn1αCreERT/+  Dual or tdTomato lineage reporter animals 
demonstrating the cystic nature of the Dual reporter (top). Scale bar: 1000 um.  
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Figure 5.3 
 
Figure 5.3: The mTmG reporter allele alters pancreatic transformation. (A) H&E of Ptf1aCreERT/+ pancreata 
harboring the mTmG allele or with no transgene were treated with corn oil or tamoxifen (TMX) followed by two weeks 
of twice daily cerulein (CER) injections and collected one day post treatment. Inset below indicated by black box. 
Scale bar: 1000 µm, top, 50 µm, bottom. (B) H&E of KrasG12D/+;Ptf1aCreERT/+ animals harboring the mTmG allele or no 
transgene treated with tamoxifen (TMX) and treated with or without cerulein (CER) with collection at six weeks post 
treatment. Inset below indicated by black box. Scale bar: 1000 µm, top, 50 µm, bottom. (C) H&E and picrosirius red 
staining of 16 week old KrasG12D/+;Ptf1aCre/+ pancreata with or without the mTmG transgene. Picrosirius red staining 
stains collagen in red. Inset below indicated by black box.  Scale bar: 1000 µm, top, 50 µm, bottom. 
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Chapter 6. Miscellaneous Data, Discussions and Future Directions 
Discussion and Future Directions 
Functional gustatory signaling has a tumor suppressive function in pancreatic 
neoplasia through modulation of CXCL1 and CXCL2 signaling and myeloid-derived 
suppressor cell (MDSC) immunosuppressive phenotypes. However, the exact functional 
mechanism of gustatory signaling in metaplastic tuft cells (MTC) is not completely 
understood. In combination with roles in MDSC directed immunosuppression, MTC 
communication with other cell types in the microenvironment require further analysis as 
to their contribution to tumor progression following gustatory signaling ablation. The 
outstanding questions and experiments outlined below will broaden our knowledge of 
MTC signaling and its role in pancreatic ductal adenocarcinoma (PDA) progression.  
 
6.1. Functional Tuft Cell Signaling  
Gustatory signaling activation in taste cells is coordinate with a calcium response 
that is triggered through binding of compounds to G-protein coupled receptors (GPCRs) 
to induce cation influx and cell depolarization140,143,146. Activation of tuft cells in other 
organs, through bitter or succinate signaling, suggests similar calcium-dependent 
depolarization responses148,510,511 promoting subsequent downstream signal release of 
acetylcholine (ACh)149,432 or interleukin-25 (IL-25)135,147. Pancreatic MTC expression of 
gustatory signaling proteins, including TAS2R4, the GPCR for detection bitter 
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compounds, GNAT3, the G subunit activated following GPCR signaling, and TRPM5, 
the cation channel responsible for cell depolarization94, all indicate a functional pathway 
for sensory detection and response (Figure 3.3A and 6.1A). However, analysis of 
functional MTC gustatory signaling has not been performed. In order to explore sensory 
function, 3D MTC containing organoid culture can be used alongside ablation of GNAT3 
signaling, as a functional model to explore gustatory signaling with activation of 
downstream calcium release as a proxy for determining functional signaling. Analysis of 
MTC-specific calcium release following stimulation by bitter, as MTC express TAS2R4 a 
bitter chemical receptor, sweet, umami or succinate chemicals, as found in other 
organs148,512, can be measured in Trpm5EGFP;KrasG12D/+;Ptf1aCre/+ (KC) organoid culture 
loaded with Fura-Red513, a calcium responsive dye that can detect bound and unbound 
calcium states514. These results can be compared to Trpm5EGFP cultures without mutant 
KRAS or GNAT3-ablated KC animals to analyze drivers for functional MTC calcium 
release. However, these analyses become complicated by the need for detection of 
single MTCs in 3D organoids and the possibility of detection of calcium activated 
responses by surrounding cells.  
Detection of calcium responses can be difficult to measure accurately in 3D 
organoid culture thus requiring the use of alternative models to analyze tuft cell-specific 
activation and signaling. Generation of a novel Ptf1aFlpO recombinase driven animal 
model allows the separation of pancreas-specific mutation of KRAS and subsequent 
alterations in other lineages using CRE recombinase424. Animals with the floxed 
KrasFSF-G12D/+;Ptf1aFlpO/+ (KF) model, which develop pancreatic neoplasia similar to the 
KC model of tumorigenesis80, can be bred to the tuft cell-specific driver Skn1αCreERT, 
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generously shared by Dr. Ichiro Matsumoto at the Monell Chemical Senses Center, 
Trpm5EGFP and a CRE-specific red shifted calcium reporter, CaMPARI2, from the 
ROSA26R locus (ROSA26RLSL-CaMPARI2)515,516 to generate animals where calcium 
specific identifiers are only expressed in MTCs. Isolation of acinar cells from 
KF;Skn1αCreERT;Trpm5EGFP;ROSA26RLSL-CaMPARI2 mice and plating into 3D organoid 
culture allows tracking of MTCs, through EGFP expression, and MTC-specific 
expression of the calcium indicator CaMPARI2 to detect substrate dependent calcium 
release and providing evidence for functional gustatory signaling in pancreatic MTCs. 
Using this model, confounding effects from other cells in the 3D culture will no longer 
have calcium specific responses and allow assessment of MTC function following 
addition of gustatory pathway stimulants.  
 
6.2. Tuft Cell Nerve Signaling 
Sensory nerves play an early role in mediating tumor progression by enhancing 
neuro-immune cell responses155 and mediating tumor spread through perineural 
invasion517,518. Neural activation can promote epithelial paracrine signaling, promoting 
tumor progression by crosstalk with neuroendocrine cells in neoplastic lesions96, but it is 
equally possible that epithelial cells can correspondingly induce neuronal signaling in a 
positive feedback loop. During pancreatic injury or neoplasia there appears a 
heterogeneous population of cell types including neuroendocrine96 and tuft cells94, 
which have been known to communicate directly with neuronal populations in other 
organs146,149,519. Interestingly, with use of a knock-in animal model promoting expression 
of enhanced green fluorescent protein (EGFP) under control of choline 
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acetyltransferase gene regulatory elements (ChATEGFP), an enzyme required for ACh 
synthesis, subsets of both neuroendocrine and MTC are found to have EGFP 
expression, which may be due to patchy expression of the genetic drivers or actual 
expression levels (Figure 6.1B). Further analysis found tuft and neuroendocrine cells in 
close proximity to nerve bundles (Figure 6.1C) and with reaching projections from 
neoplastic lesions toward the surrounding nerves in the stromal compartment (Figure 
6.1D). ACh functions as a tumor-suppressive molecule in PDA, which is mediated by 
neural signaling440, so expression of ChAT in epithelial populations indicates the 
possibility of an epithelial-driven neural activation loop. Furthermore, MTC expression of 
other neuronal signaling molecules, such as ATP release through CALHM1 channels 
(Figure 3.5B), could further play a role in epithelial-directed neural activation. 
 To understand the role of MTC-specific nerve signaling, new experimental 
models need to be generated. Use of the tuft cell-specific Skn1aCreERT recombinase 
system allows ablation of tuft cell-specific ACh release, by breeding with floxed ChAT 
animals520, or directed ablation of tufts cells, through breeding with floxed diptheria toxin 
A animals453, which can be used in both in vivo and ex vivo models. Modification of 
existing nerve cell culture systems which directly co-culture nerves with MTC 
expressing 3D organoids96, would provide a new way of exploring MTC directed nerve 
signaling through loss of gustatory signaling (GNAT3 ablation), loss of tuft cell-specific 
ACh function or complete loss of tuft cells, and measuring organoid growth, survival and 
proximity of nerves to the organoid structures. Further work with this system could also 
measure nerve activation in the spine following tuft cell alteration155, perhaps identifying 
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MTC responsive neural cell subsets and allowing in vivo study of MTC-nerve function 
on PDA progression.  
 
6.3. Immune Subsets 
Analysis of single-cell RNA data in Gnat3-/-;KCERT animals identified differential 
gene expression in the myeloid compartment, specifically in the myeloid-derived 
suppressor cell (MDSC) subset, compared to control mice (Figure 2.5). However, 
further understanding of immune cell function following GNAT3 ablation may shed light 
to the different roles these cells have contributing to the phenotype of increased tumor 
progression and metastasis.  
 
i. T-cells 
T-cell presence in PDA can induce immune suppression or targeted cytotoxicity 
in tumors324,326 to impact survival and treatment325. Alteration of gustatory signaling, 
through ablation of GNAT3, increases the number of myeloid-derived suppressor cells 
(MDSC) present in the neoplastic environment. MDSCs are an immature population of 
immunosuppressive myeloid cells which inhibit T-cell cytotoxicity and promote self-
tolerance. While I found no difference in overall T-cell numbers between tamoxifen- and 
cerulein-treated KCERT and Gnat3-/-;KCERT pancreata (Figure 2.4B), analysis of the 
single-cell RNA sequencing finds the gene expression of T-cell subsets differs and may 
provide a mechanism for accelerated tumorigenesis (Figure 6.2A-C). Isolation of 
identified T-cells from my single-cell RNA sequencing, analyzed by Samantha Kemp, 
shows clustering by distinct gene expression into three populations of T regulatory 
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(Treg), CD8+ and CD4+ T-cells, which were found in both Gnat3-/-;KCERT and KCERT 
samples (Figure 6.2A and B). Comparison of the differentially expressed genes in each 
of the populations found altered gene expression patterns in each group (Figure 6.2C), 
suggesting an alteration in T-cell function. Furthermore, with analyzation help from 
Veerin Sirihorachai, immune regulatory ligand expression patterns were evaluated 
indicating altered ligand production in GNAT3-ablated animals which can interact with 
the receptors found on many other cell compartments altering overall function. A more 
in-depth analysis of T-cell function following ablation of gustatory signaling is required to 
fully understand its role in MTC directed tumor suppression.  
To further expand these T-cell results, experiments analyzing T-cell function and 
location in the tumor microenvironment is required. Isolation of T-cell populations, using 
flow cytometry, will measure immune suppressive protein marker expression such as 
programmed cell death protein 1 (PD-1)328, T cell immunoglobulin and ITIM domain 
(TIGIT)521 or cytotoxic T-lymphocyte-associated protein 4 (CTLA4)334, to find direct 
evidence of an immune suppressive microenvironment. T-cell function can also be 
analyzed by specific ablation of CD4+ or CD8+ T-cells, using targeted antibodies401, to 
explore how the specific function of these cell types contributes to the phenotype of 
GNAT3-ablated mice over time. Further analysis of T-cell function in pancreatic 
neoplasia and progression will facilitate understanding of MTC gustatory signaling on T-
cell function and its role in PDA immunosuppression. 
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ii. Natural Killer Cells 
Natural killer (NK) cells are a tumor suppressive innate immune cell population 
whose decrease in the tumor microenvironment is associated with PDA 
progression522,523. Analysis of tamoxifen- and cerulein-treated KCERT and Gnat3-/-;KCERT 
pancreata through mass cytometry found a non-statistically significant decrease in 
NK1.1 expressing NK cell numbers (Figure 2.4E). Since NK cell loss can accelerate 
tumor progression522,523, I wanted to determine whether this trend in decreased NK cells 
was found systemically in GNAT3-ablated animals. Using flow cytometric analysis on 
spleens collected from wild type and Gnat3-/-;KCERT animals, I found a consistent 
decrease in NK1.1 expressing NK cells compared to control mice (Figure 6.3A). 
However, by use of another NK cell marker, NKp46, I found no difference with GNAT3 
ablation (Figure 6.3A), suggesting a systemic alteration, but not loss, of NK populations 
with alteration of gustatory signaling. These preliminary data indicate alterations in NK 
cell function which may contribute to the rapid development of aggressive PDA found 
with GNAT3 ablation. 
 In order to analyze the effect of NK cell alteration on tumor progression, I 
performed injections with an antibody targeted toward NK1.1 every four days starting 
prior to tamoxifen- and cerulein-treatment in control KCERT animals in order to ablate NK 
cells during neoplastic development. Analysis of NK ablated KCERT spleens by flow 
cytometry found significantly fewer splenic NK cells by both NK1.1 and NKp46 antibody 
targeted assessment and no change in other immune cell populations (Figure 6.3A, 
other immune populations not shown). Analysis of this preliminary data by histology 
(Figure 6.3B) or pancreas-to-body weight ratios (not shown), I found no overall 
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difference between NK ablated pancreata and GNAT3-ablated or control pancreata, 
though some variability in histology suggest NK ablated pancreata may trend toward a 
more damaged phenotype. Continued staining and quantitation of CXCL1 and CXCL2 
expression and flow cytometry of MDSC populations as well as study of functional NK 
ablation in Gnat3-/-;KCERT mice, are still required to determine the role of NK function in 
GNAT3-ablated neoplasia. These future studies could help inform how epithelial 
communication interacts with NK cell function both systemically and during pancreatic 
tumorigenesis.  
 
iii. ILC2s 
Tuft cells in the intestine recruit innate lymphoid cells type 2 (ILC2s) following 
detection of parasitic infection by release of interleukin-25 (IL-25)135,147. Recruited ILC2s 
then promote parasite expulsion through release of interleukin-4 (IL-4) and interleukin-
13 (IL-13) dependent effects on the intestinal epithelium135,147. ILC2 is a tumor 
suppressive cell in PDA however, that function is repressed by expression of PD-1 in 
the immune microenvironment524. It is unknown if MTC in the metaplastic pancreas 
could play a similar role to the intestine in promoting ILC2 recruitment and inducing a 
tumor suppressive immune response that is abrogated following gustatory ablation. 
Recent data, finds IL-25 expression in MTC during pancreatitis175, indicating a potential 
role in ILC2 function and a type-II immune response during disease initiation150, but, in 
the presence of mutant KRAS, IL-25 is no longer found in MTCs153. Mutant KRAS 
signaling seems to alter MTC function through regulation of IL-25 expression and, 
therefore, may not contribute to the ILC2 response. However, other signals, such as 
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interleukin-33 (IL-33), stimulate ILC2 function to induce their tumor specific cytotoxic 
function525, which is worth further study. Analysis of MTC promoted ILC2 function, by 
use of gustatory knockouts and MTC-specific cytokine analysis, may provide a new 
avenue of immunotherapy for treatment of both pancreatitis and PDA. 
 
6.4. Fibroblasts 
Cancer associated fibroblasts (CAFs) are a heterogenous population of 
fibroblasts that promote a desmoplastic, immunosuppressive microenvironment which 
contributes to PDA progression313. Single-cell RNA sequencing experiments and 
staining have revealed at least three subsets of fibroblasts present during PDA 
progression207,208. Inflammatory CAFs (iCAFs) are found in the distal stroma and 
express inflammatory mediators, including interleukin-6 (IL-6), myofibroblastic CAFs 
(myCAFs) express α-smooth muscle actin (αSMA) and are proximal to tumor cells207, 
and antigen presenting CAFs (apCAF) are a novel fibroblast subtype that can activate 
directly activate adaptive immune responses208. Analysis of the single-cell RNA 
sequencing data from tamoxifen- and cerulein-treated KCERT and Gnat3-/-;KCERT 
pancreata, finds a large fibroblast population composed of both iCAF and myCAF 
subsets in both models (Figure 2.5A). While analysis of αSMA staining found no 
difference in fibroblast numbers between KCERT and Gnat3-/-;KCERT animals (Figure 
6.4A), further analysis of my single-cell RNA sequencing of both animal models was 
performed by Samantha Kemp to subset out the fibroblast cells using gene markers 
such as Igfbp7, Col1a1, Pdgfrb and Acta2 to measure gene expression differences. 
Following fibroblast subsetting, iCAFs, myCAFs and apCAFs were all found in KCERT 
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and Gnat3-/-;KCERT samples, along with two unidentified populations of fibroblasts, Fb1 
and Fb2 (Figure 6.4B-D). Analysis of gene expression by Mrs. Kemp did not uncover 
functional genes to identify these two fibroblast populations (Figure 6.4B), which 
provokes questions of the functions of these cells and their potential role in the 
neoplastic pancreas.  
By use of the single-cell RNA sequencing, I wanted to determine differences in 
gene expression between KCERT and Gnat3-/-;KCERT animals, as there was no difference 
in overall numbers of fibroblasts sequenced between the two models (Figure 2.4A and 
6.4A). Analysis of differential gene expression between tamoxifen- and cerulein-treated 
KCERT and Gnat3-/-;KCERT samples identified only two significantly changed genes, 
ubiquitin A-52 (Uba52) and E2F-associated phosphoprotein (Eapp), in myCAF cells 
(Figure 6.4E). However, iCAF differential gene expression finds 12 genes decreased 
and 14 genes increased, including increased Ig-like domain containing receptor 2 
(Ildr2), a receptor inhibiting T-cell responses526, and thymosin beta 10 (Tmsb10), a 
protein associated with worse prognosis in breast cancer527. This suggests gustatory 
signaling plays a role in modulating the immunogenic function of fibroblasts (Figure 
6.4E) with a gene signature that still remains to be explored. Ligand expression and 
interaction analysis of my single-cell RNA sequencing were also analyzed and plotted 
by Veerin Sirihorachai, where I found that fibroblasts can perform crosstalk to many 
compartments and that these interactions are altered with GNAT3 ablation (Figure 
6.4F). These data indicate a difference in gene quality, but not quantity, of fibroblasts 
following MTC gustatory ablation. 
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To further understand the alterations in fibroblast function following GNAT3 
ablation, analysis of fibroblasts can be performed by flow cytometry to assess the 
phenotypic heterogeneity induced by GNAT3 loss in early neoplasia and in 
carcinoma528. Isolated fibroblasts GNAT3 neoplastic pancreata can be used to assess 
roles in tumor growth and proliferation by direct 2D culture, evaluating PDA 
cell/fibroblast proliferation promoting abilities compared to fibroblasts from control 
animals529. 3D MTC containing organoid culture and co-culture also provide a robust 
system to analyze GNAT3 induced fibroblast gene expression differences and cytokine 
alterations, as well as the contribution to organoid growth and survival or to T-cell 
directed immunosuppression530. Continued analysis of fibroblast interactions, by flow 
cytometry, co-culture experiments and staining, are critical to understanding how MTC 
gustatory signaling alters fibroblast roles and their contribution to tumor progression. 
 
6.5. The Microbiome, Sex and Pancreatic Cancer  
Pancreatic cancer initiation and progression is characterized by mutations in 
KRAS, TP53 and the acquisition of an immunosuppressive, desmoplastic stromal 
compartment313, however, novel drivers of PDA progression also play critical roles. 
Recent research found that bacterial invasion into the tumor stroma plays a functional 
role in driving PDA progression through promoting the immunosuppressive tumor 
stroma531. The human microbiome consists of a diverse collection of trillions of 
symbiotic microbes that reside in each individual interacting with environment which 
playing a role in digestion and nutrient balance532. These populations change 
dramatically from person to person, with alteration found prior to disease states which 
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promote disease phenotypes or are altered following disease genesis533. Animal models 
are a useful tool for studying human disease but alterations in microbiome can occur 
easily, through changes in bedding, housing locations, diet and vendor source, among 
others534, which contribute to the lack of reproducibility found in many scientific 
studies535,536.  
During my research here, the Crawford lab moved from North Campus Research 
Center (NCRC) to the Rogel Cancer Center (RCC), with our animal models also 
changing facilities to the Medical Science Building 1 (MS1). Following collection of mice 
at the new housing facility, I found that in both KCERT and Gnat3-/-;KCERT animals had 
consistently more pancreatic neoplasia and damage when collected at NCRC, as 
measured by amylase staining for normal acinar tissue (Figure 6.5A). These differences 
remained consistent and made reproducibility difficult, but collection of all mass 
cytometry and single-cell RNA sequencing data for Chapter 2 was performed with MS1 
housed animals to maintain consistency for in-depth experimental outcomes. 
Differences in neoplastic progression indicate some feature of the microenvironment, 
hypothetically the microbiome, which maintains a tumor promoting function, elevating 
pancreatic damage and the difference between GNAT3-ablated and control animals.  
Further analysis of these data found a striking difference in damage between 
GNAT3-ablated male and female animals. This was most obvious at North Campus 
Research Center (NCRC), where female Gnat3-/-;KCERT mice had little to no normal 
acinar area at the time of analysis, a difference that was not found once animals were 
housed in Medical Science Building 1 (MS1) (Figure 6.5B). This suggests a sex and 
location dependent effect following GNAT3 ablation which I hypothesize could be due to 
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the differences in the microbiome, as tuft cells can induce microbiome elimination135,147. 
For instance, tuft cells in other organs can detect bitter compounds and bacterial 
particles1 149, indicating MTCs could also perform a bacterial sensory role, however 
there is no data on sex dependent roles of tuft cells. Further experiments should be 
performed to analyze pancreatic bacteria influx, immune cell populations and sex 
hormone influences from NCRC and MS1 housed mice, which may uncover novel MTC 
functions contributing to PDA progression.   
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Materials and Methods 
Mice 
All animal procedures and experiments were conducted with approval of the 
Institutional Committee on Use and Care of Animals at the University of Michigan. 
The following mice strains were used: Ptf1aCreERT/+;422 KrasG12D/+ (gift of David 
Tuveson, Cold Spring Harbor Laboratory, NY); Gnat3-/- and Trpm5EGFP (gifts of Robert 
Margolskee, Monell Chemical Senses Center, PA)140,374,375,434 and ChATEGFP (from the 
Jaxson Laboratory). Mice were crossed on a mixed background to generate Gnat3-/-
;KrasG12D/+;Ptf1aCreERT/+, Trpm5EGFP;KrasG12D/+;Ptf1aCre/+, and 
ChATEGFP;KrasG12D/+;Ptf1aCre/+ mice. All analyses were performed using strain-controlled 
animals.  
Acinar specific KrasG12D/+ recombination was induced in 8- to 12-week old 
KrasG12D/+;Ptf1aCreERT/+ mice by oral gavage with 5 mg of tamoxifen (T5648; Millipore-
Sigma, St. Louis, MO) dissolved in corn oil for 5 days. After a 2-day rest post tamoxifen 
treatment, experimental pancreatitis was induced once a day by intraperitoneal injection 
with 250 µg/kg cerulein (46-1-50; American Peptide Company) for 5 days. Pancreata 
were harvested at 6-weeks post cerulein treatment. NK1.1 antibody ablation (BE0036; 
BioXcell, Lebanon, NH, US) was performed by 47 mg intraperitoneal injections of sterile 
PBS diluted antibody every 4 days, which was verified to maintain natural killer cell 
ablation (data not shown), starting one day before tamoxifen treatment and continued 
until collection 8-weeks later. 
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Immunohistochemistry and Quantification 
Pancreata were collected, weighed and fixed in Z-fix (NC9050753; Anatech Ltd., 
Battle Creek, MI) overnight. Processing of tissues was performed using a Leica 
ASP300S tissue processor (Buffalo Grove, IL). Sections (4 µm) of paraffin-embedded 
tissue were stained for target proteins using the Discovery Ultra XT autostainer 
(Ventana Medical Systems Inc., Tucson, AZ). Antibodies were stained as depicted in 
Table 5.1 followed by Mayer’s hematoxylin (NC9220898; Millipore-Sigma) counterstain. 
H&E staining was done using Mayer’s hematoxylin and eosin Y (HT110116; Fisher, 
Pittsburgh, PA). Immunohistochemistry slides were imaged and stitched together by a 
Pannoramic SCAN scanner (Perkin Elmer, Seattle, WA) using a 20x objective lens. 
Scanned images were quantified using Halo software (Indica Labs, Corrales, NM) 
algorithms to identify tissue architecture and separate stroma, neoplasia and acinar 
compartments for analysis. For all quantification, blood vessels, lymph nodes and 
adipose/connective tissue were excluded. 
 
Immunofluorescence  
Immunofluorescence staining was performed on frozen tissue sections, as 
described previously.424 In sum, pancreata were collected and fixed in Z-fix for 2-3 
hours, followed by 30% sucrose in phosphate buffered saline (PBS) overnight. 
Pancreata were equilibrated in a 1:1 mixture of 30% sucrose/PBS and optimal cutting 
temperature embedding medium (OCT) for 30 minutes, embedded in OCT, frozen by 
liquid nitrogen and stored at -80°C. Frozen tissue sections (10 µm) were acquired using 
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a Leica CM1860 (Leica Biosystems, Buffalo Grove, IL) cryostat set at -20°C, 
permeabilized in 0.1% Triton X-100 (T9284; Millipore-Sigma) in PBS for 1 hour and 
blocked by using 5% donkey serum/1% bovine serum albumin (BSA) in PBS for 1 hour. 
Incubation with primary antibody (listed in Table 5.1) was performed overnight at room 
temperature in 0.1% Triton X-100/1% BSA in PBS, followed by 3 washes of 0.1% Triton 
X-100/PBS for a total of 45 minutes. Sections were incubated with Alexa Fluor-
conjugated secondary antibodies at 1:500 and phalloidin at 1:250 (both Invitrogen, 
Carlsbad, CA) for 1-hour room temperature followed by 3 washes as before. Finally, 
slides were rinsed in deionized water and mounted with Prolong Diamond antifade 
mountant (P36961; Fisher). Images were acquired on a LSM800 confocal microscope 
(Zeiss, Oberkochen, Germany) using a 63x objective or with an Olympus BX53F 
microscope (Olympus, Shinjuku City, Tokyo, Japan) using a 20x objective. Endogenous 
signaling was used for all EGFP imaging (Trpm5EGFP and ChATEGFP).  
 
Table 6.1 Immunostaining Antibodies 
Antibody Company Catalog 
number 
Dilution Purpose 
TAS2R4 Abcam Ab65489 1:400 IF 
Synaptophysin Millipore-Sigma 336R-95 1:100 IF 
PGP9.5 Abcam Ab15503 1:100 IF 
αSMA Millipore-Sigma A2547 1:2000 IHC 
Amylase Sigma-Aldrich A8273 1:1000 IHC 
CD45 ThermoFisher MCD4528 1:100 Flow 
NK1.1 BD Biosciences BDB561082 1:100 Flow 
NKp46 R&D Systems AF1850SP 1:100 Flow 
CD3 BD Biosciences 555275 1:100 Flow 
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Flow Cytometry 
 Mouse spleens were collected, washed in PBS then dissociated by mashing on a 
40 µm filters (22-363-547; Fisher) to obtain single cells, as previously described424. 
Single-cell suspension was incubated with fluorescently conjugated antibodies (Table 
5.1) diluted in fluorescence-activated cell sorting buffer consisting of 2% fetal bovine 
serum in Hank’s balanced salt solution. Cell analysis was performed using a Sony 
SH800 Cell Sorter (Sony, Minato City, Tokyo, Japan). 
  
Single-Cell RNA Sequencing 
Single-cell RNA sequencing was performed in duplicate. Each experiment 
included KCERT and Gnat3-/-;KCERT pancreata. To obtain a single cell suspension, 
pancreas tissue was mechanically and chemically digested as detailed above for the 
mass cytometry analysis. Dead cells were excluded using MACS® Dead Cell Removal 
Kit (130-090-101; Miltenyi Biotec Inc., Bergisch Gladbach, Germany). The 10X 
Genomics Platform at the University of Michigan Advanced Genomics Core was used 
for single-cell cDNA library preparation and sequencing. Samples were sequenced 
using paired-end 50 cycle reads on HiSeq 4000 (first two samples) or the NovaSeq 
6000 (second two samples) (Illumina, San Diego, CA) to a depth of 100,000 reads. Raw 
data were then processed, aligned, and filtered using the default setting of Cellranger 
version 3.0 at the University of Michigan Advanced Genomics Core. R package, Seurat 
version 3.0 (http://www.satijalab.org/seurat) was used for analysis.427 Downstream 
analysis was performed as previously described.401 Briefly, data were filtered to include 
cells with at least 100 genes and genes identified in greater than 3 cells. Data were then 
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normalized using the NormalizeData function with a scale factor of 10,000 and the 
LogNormalize normalization method. Variable genes in the data set were identified 
using FindVariableFeatures function then the data were then scaled and centered using 
linear regression on the counts. Principal Component Analysis (PCA) was run using 
RunPCA function on the variable genes identified. Batch correction was performed 
using the R package Harmony (https://github.com/immunogenomics/harmony).428 
FindNeighbors and FindClusters at a resolution of 1.2-2.0 were used to identify cell 
clusters. Cell clusters were visualized using Uniform Manifold Approximation and 
Projection (UMAP) algorithms. To define cell clusters, FindAllMarkers table was 
generated and user-defined criteria were used for final cell population definitions. Circos 
plots were visualized using the free licensed Circos software537. Differentially expressed 
gene heatmaps were manually annotated to remove B-cell and acinar contamination. 
 
Statistics 
All statistics were analyzed using GraphPad Prism 8.4.0 (San Diego, CA). 
Statistics for comparing two groups was done using unbiased t tests corrected for 
multiple comparisons by the Holm-Sidak test and flow cytometry groups was done by 
ordinary one-way ANOVA corrected for multiple comparisons by the Tukey’s test. For all 
single-cell RNA sequencing data statistical significance was determined using the non-
parametric Wilcoxon rank sum test with Bonferroni corrected P values. Kaplan-meier 
curve statistics were calculated by the log-rank (Mantel-Cox) test. P adj. < 0.05 were 
considered statistically significant. P adj. values are listed, with ns = no significance.  
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Figures 
Figure 6.1 
 
Figure 6.1: Pancreatic epithelial acetylcholine signaling to nerves. (A) Tuft cell, marked by phalloidin (white) 
tufts, expression of TAS2R4 (green) from 12-week old KrasG12D/+;Ptf1aCre/+ (KC) pancreas. Counterstained with DAPI 
(blue) to mark nuclei. Scale bar: 20 µm. (B) Staining of a 12-week old ChATEGFP;KC pancreas marking 
neuroendocrine cells, synaptophysin (red), and tuft cells, phalloidin tufts (white), with acetylcholine transferase 
expression (EGFP). DAPI (blue) marks nuclei. Scale bar: 10 µm. (C) Analysis of a 12-week old Trpm5EGFP;KC mouse 
with EGFP (green) marking tuft cells and synaptophysin (red) marking nerves (yellow arrow) and neuroendocrine 
cells. Counterstained with phalloidin (white) to mark filamentous action positive tufts and DAPI (blue) to mark nuclei. 
Scale bar: 5 µm. (D) 3D rendering of a 12-week ChATEGFP;KC pancreas stained for PGP9.5 to mark nerves and 
counterstained by phalloidin (white) to mark tufts and DAPI (blue) to mark nuclei. Yellow line indicates border 
between stroma (top) and neoplastic lesion (bottom). Scale bar: 100 pixels.  
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Figure 6.2 
 
Figure 6.2: T-cell gene expression differs with GNAT3 ablation. Analysis of tamoxifen- and cerulein-treated 
KCERT and Gnat3-/-;KCERT single-cell RNA transcriptomes of T-cells identified from pancreata collected 6-weeks post 
cerulein treatment. (A) Unbiased clustering of T-cell single cells driven by transcriptome differences and visualized by 
UMAP (n = 2; 2). T regulatory cells = Treg. (B) Separation of unbiased clusters identifying KCERT and Gnat3-/-;KCERT 
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populations. (C)  Heatmap of single-cell RNA transcriptomes for CD4+ T-cells, CD8+ T-cells and T regulatory (Treg) 
cells displaying the top 50 statistically significant differentially expressed genes (rows). (D) Circos plots of T-cell 
single-cell RNA analysis of ligand interaction with receptors expressed in the natural killer (NK), dendritic, myeloid, 
epithelial or fibroblast populations. Statistically different Gnat3-/-;KCERT ligand expression in T-cells compared to 
KCERT by expression as indicated by color as increased (blue), decreased (red) and no change (yellow). Significance 
was calculated using Bonferroni adjusted P values from the non-parametric Wilcoxon rank sum test. P adj. < 0.05 
statistically significant. 
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Figure 6.3 
 
Figure 6.3: Natural killer cell alteration following GNAT3 ablation. Analysis of tamoxifen- and cerulein-treated 
KrasG12D/+;Ptf1aCreERT/+ (KCERT), Gnat3-/-;KCERT and KCERT treated with NK1.1 antibody tissues collected 6-weeks post 
cerulein. NK1.1 treatment began at tamoxifen treatment initiation and continued until harvest. (A) Flow cytometry 
analysis of Gnat3-/-;KCERT and NK1.1 antibody treated KCERT spleens compared to control wild type (WT) spleens. 
NK1.1 and NKp46 are both markers for natural killer cells. Percentages are of total immune cells (CD45+). (B) 
Pancreatic histology of KCERT, Gnat3-/-;KCERT and NK1.1 antibody treated KCERT mice. Inset indicated by black box. 
Scale bar: 2000 µm, inset = 100 µm. Significance was calculated using Tukey’s multiple comparisons adjusted P 
values from the ordinary one-way ANOVA test. P adj. < 0.05 statistically significant. 
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Figure 6.4 
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Figure 6.4: Quality, but not quantity, of fibroblasts differs with GNAT3 ablation. (A) α-Smooth muscle actin 
staining and quantification on tamoxifen- and cerulein-treated KrasG12D/+;Ptf1aCreERT/+ (KCERT) and Gnat3-/-;KCERT 
pancreata collected 6-weeks post cerulein treatment. Scale bar: 50 µm. Analysis of tamoxifen- and cerulein-treated 
KCERT and Gnat3-/-;KCERT single-cell RNA cancer associated fibroblast (CAF) transcriptomes from pancreata 
collected 6-weeks post cerulein treatment. (B) Dot plot of gene expression patterns used to identify CAF subsets from 
pooled KCERT and Gnat3-/-;KCERT fibroblast cells. Percent of cells expressing each gene per cluster noted by dot size. 
Average gene expression is represented by color of dot. (C-D) Unbiased clustering of CAF specific single cells driven 
by transcriptome differences and visualized by UMAP (n = 2; 2). (D) CAF single cells separated by KCERT and Gnat3-
/-;KCERT pancreata. Abbreviations: inflammatory CAF (iCAF), myofibroblastic CAF (myCAF), antigen presenting CAF 
(apCAF), Fibroblast subset 1 (Fb1) and Fibroblast subset 2 (Fb2). (E) Heatmap of single-cell RNA transcriptomes for 
myCAFs and iCAFs displaying the statistically significant differentially expressed genes (rows). (F) Circos plots of 
fibroblast (CAF) single-cell RNA analysis of ligand interaction with receptors expressed in the natural killer (NK), 
dendritic, myeloid, epithelial or T-cell populations. Statistically different Gnat3-/-;KCERT ligand expression in T-cells 
compared to KCERT by expression as indicated by color as increased (blue), decreased (red) and no change (yellow). 
Significance was calculated using an unpaired t test or Bonferroni adjusted P values from the non-parametric 
Wilcoxon rank sum test. P < 0.05 or P adj. < 0.05 statistically significant. 
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Figure 6.5 
 
Figure 6.5: Pancreatic progression rate is influenced by location and sex. Analysis of tamoxifen- and cerulein-
treated KrasG12D/+;Ptf1aCreERT/+ (KCERT) and Gnat3-/-;KCERT pancreata collected after 6-weeks. (A) H&E and amylase 
staining of female animals raised in the North Campus Research Center (NCRC) or in the Medical Science Research 
Building 1 (MS1) animal housing facilities. Quantification of amylase positive staining for male and female animals 
comparing NCRC and MS1 housing facilities. Scale bar: 1000 µm. (B) Amylase staining of representative male and 
female Gnat3-/-: KCERT tissues raised in the NCRC housing facility. Quantification of amylase staining of male or 
female animals raised in either NCRC or MS1 animal housing facilities. Scale bar: 1000 µm. Significance was 
calculated using an unpaired t test with Holm-Sidak adjusted P values. P adj. < 0.05 statistically significant. 
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Chapter 7. Targeting Tuft Cells in the Pancreaticobiliary Tract 
Pancreatic ductal adenocarcinoma (PDA) is the third most common cause of 
cancer death with only a 10% 5-year survival rate1, making diagnosis of this disease a 
near death sentence. In nearly 90% of patients diagnoses occurs at a late stage of 
disease after metastatic spread6. Current chemotherapies are mostly ineffective at 
treating late stage disease prolonging survival for only a few months16. Current research 
is focused on understanding the molecular features of PDA initiation and progression 
and has identified the critical role of the immune microenvironment315,317. However, 
clinical trials with novel immunotherapies have shown little to no success in PDA 
survival538, suggesting a more complicated interplay in the cancer milieu. The research 
presented in this thesis could aid the development of novel therapies by taking 
advantage of tuft cell mediated signaling mechanisms.  
 
7.1. Activation of Tuft Cell Signaling 
Metaplastic tuft cell (MTC) gustatory signaling slows the advancement of PDA 
progression through regulation of CXCL1 and CXCL2 release and MDSC recruitment to 
the tumor. MTCs are present early in disease initiation and become less prevalent 
during disease progression, with presence only detected in PanIN lesions surrounding 
the carcinoma area. However, targeting MTC may still function to alter the immune 
microenvironment through modifying recruitment patterns of immunosuppressive cells, 
such as MDSCs, regulating tumor progression. My research shows that MTC activation 
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may be directly regulated through gustatory signaling responses, providing a novel 
target for immunotherapy. 
Gustatory signaling responses can be activated by chemicals evoking a bitter, 
sweet or umami responses in the taste bud and throughout the body139. MTCs also 
express components of the gustatory pathway, including TAS2R4, a bitter sensing G-
protein coupled receptor, GNAT3, TRPM5 and CALHM194 (Figure 1.5), suggesting 
these cells can sense and respond to gustatory signals. MTC gustatory signaling was 
found in this thesis to help to restrain tumor progression therefore, activation of this 
signaling pathway may provide a novel supplement to conventional immunotherapeutic 
approaches. Activation of gustatory response pathways to alter MDSC recruitment to 
the pancreas may function to act in concert with checkpoint inhibitors539 to reduce the 
immunosuppressive cells in the pancreas and activate immune cell mediated 
cytotoxicity, respectively. The function of these two processes hold potential to boost 
tumor mediated immunity and create more durable tumor treatment responses.  
Further work is still required to elucidate the response profile of MTC gustatory 
signaling to mediate these immune responses. However, once the chemical nature of 
MTC activating ligands is determined, drugs can be synthesized to target the gustatory 
pathway. This avenue of treatment is a non-cytotoxic therapy, which results in better 
quality of life540, and also relies on cells which are found directly in the tumor 
microenvironment, promoting therapeutic responses in lieu of immune cell exclusion541. 
Stimulation of the gustatory pathway may provide a novel, tumor directed response to 
restrain tumor cell mediated immunosuppression. However, these responses still need 
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to be studied more thoroughly, especially in the context of TP53 mutations where 
gustatory signaling ablation demonstrated less clear tumor promoting results,. 
Targeting gustatory signaling of MTCs may also be a strategy in pancreatitis, 
providing a multifaceted treatment in different disease contexts. Chronic pancreatitis is a 
persistent disease with no curative options and few palliative remedies, begging the 
need for novel treatments163,164. Interestingly, MTCs are found in both experimental 
models of chronic pancreatitis and in patients with pancreatitis175 indicating a possible a 
role in disease function. Further studies are required to elucidate a clear role of MTCs in 
pancreatitis but activation of the gustatory pathway may function to alter pancreatic 
recruitment of immune cells, as identified in PDA models, promoting a directed therapy 
to alter the chronic inflammatory responses. With additional research to elucidate the 
role of MTC in pancreatitis, MTC targeting may form a viable strategy to mediate 
pancreatic damage and immune responses.  
 
7.2. Targeting CXCL-CXCR axis 
 The CXCL1-CXCR2 axis is known to promote PDA progression through the 
immunosuppressive function of MDSC populations altering immune cell targeted 
cytotoxicity386,388,389,395. Analysis of tumor cells finds a direct release of CXCL1386, which 
is corroborated in my findings by ex vivo culture and in vivo immunofluorescent staining. 
Additionally, gustatory ablated animals have higher overall levels of CXCL1 indicating a 
mechanism of gustatory signaling in MTC mediated control of immunosuppression. 
However, the exact signals from the microenvironment controlling the production of 
CXCL1 in tumor cells are unknown542.  
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In this dissertation, my analysis finds MTCs as possible direct contributors to the 
CXCL1 pool by immunofluorescent staining marking MTCs and CXCL1 (Figure 3.5E). 
But, more strikingly, there was an overall increase in CXCL1 staining in the GNAT3 
ablated neoplastic lesions (Figure 3.5E). These data suggest MTC directed signaling 
promotes CXCL1 expression in neoplastic lesions in the pancreas. Analysis of 
molecules released by MTCs may uncover the ligand(s) responsible for promoting the 
CXCL1 response in the pancreas which can be studied for drug inhibition. As CXCL1 is 
known to promote immunosuppression through CXCR2 signaling, upstream blockade of 
this pathway could contribute to durable immunotherapeutic responses in PDA. 
Additionally, understanding the mechanism of gustatory signaling mediated CXCL1 
increase may provide an overarching treatment for early and late stage PDA therapy as 
this signaling pathway may be more ubiquitous than tuft cell presence itself.  
 
7.3. Tuft cells in biliary disease 
The pilot data presented in this thesis finds tuft cell gustatory function, in the 
context of KRAS mutations, to maintain biliary homeostasis and promote bile flow. 
Though GNAT3 ablation does not show progression to cholangiocarcinoma, clinically 
the phenotype presents similar to choledochal cysts487, a rare cystic dilatation of the 
biliary tree, of which known complications are pancreatitis, biliary cirrhosis and 
cholangiocarcinoma543. This disease currently has no known etiology or treatment 
beyond surgery488, marking a need for novel treatments. My analysis in Chapter 4 finds 
a dramatic dilation of the biliary tree in animal models following gustatory signaling 
ablation in the context of oncogenic KRAS mutations which is further accelerated by 
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loss-of-function mutations in TP53, mimicking clinical features of choledochal cysts543. 
However, further analysis of the clinical presentation of choledochal cysts is needed to 
evaluate presence of genetic mutations, function of tuft cells and influx of immune 
populations in the biliary tract following disease presence to compare and characterize 
this GEMM system. Utilization of a novel model for choledochal cysts may provide new 
avenues for research into tuft cell function in the bile duct during disease states and 
lead to discovery of clinical targets to maintain biliary homeostasis.  
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Concluding Remarks 
Metaplastic tuft cells (MTCs) are a unique cell type found in the neoplastic 
pancreas that express immune cell modifying properties which slow tumor progression. 
Tuft cells outside the taste system were only recently found to have a role in 
homeostasis by modifying the immune influx in various organs throughout the body. My 
dissertation aims at uncovering the functional role of metaplastic tuft cells in the 
neoplastic pancreas. The data presented in Chapter 2 and 3 find that gustatory 
signaling plays a tumor suppressive role in pancreatic cancer. These analyses suggest 
MTCs perform this role by regulation of CXCL1 and CXCL2 signaling and modification 
of myeloid-derived suppressor cell (MDSC) recruitment and gene expression. 
Preliminary data presented in Chapter 3 also suggest the use of the canonical gustatory 
signaling pathway and the release of multiple signaling molecules to modify the tumor 
microenvironment, such as ATP, acetylcholine and CXCL1, with future work presented 
for this project in Chapter 6. In Chapter 4, I explored the functional role of mutant KRAS 
modified tuft cell biliary function. These preliminary data indicate tuft cell gustatory 
signaling regulates bile production and secretion or immune cell communication to 
maintain organ homeostasis. Additionally, critical evaluation of novel model systems, 
presented in Chapter 5, showcase the necessity for properly controlled experiments. In 
total these projects only hint at MTC function and further research is required to fully 
understand the role of tuft cells in diseases of the pancreaticobiliary tract.  
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Pancreatic cancer is a rapid and deadly diagnosis with few effective treatment 
options to extend survival. Activation of the immune system to induce cancer cell 
cytotoxicity through immunotherapy has performed underwhelmingly in clinical trials. 
Though MTC are single cells found in neoplastic lesions during tumor genesis and only 
surround the carcinoma mass, MTC signaling plays an important role in tumor 
progression. Understanding the mechanisms of this interaction may uncover unique 
immunotherapeutic treatments by promoting MTC function, using activation of gustatory 
signaling, to induce a tumor suppressive microenvironment. Understanding how 
pancreatic cancer progresses, and the role of MTC in this process, can uncover novel 
therapeutic targets providing hope for those with this deadly diagnosis. 
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